Biological characterisation of morphological alterations of the cornea following collagen cross-linking (CXL) treatment by Subasinghe, Sandeepani Kanchana
Biological characterisation of morphological 
alterations of the cornea following collagen cross-
linking (CXL) treatment 
 
Sandeepani Kanchana Subasinghe 
 
 thesis submitted in partial fulfilment 
of the requirements for the degree of 
 
Doctor of Philosophy 
 






Introduction: Keratoconus (KC) is a disease included in a broader range of 
conditions called corneal ectasia which leads to spontaneous, non-inflammatory, 
self-limiting ectasia of the cornea that results in localized corneal thinning with 
protrusion of the thinned cornea. In recent years, corneal crosslinking (CXL) 
treatment with ultraviolet light (UVA) and riboflavin has been introduced as a 
minimally invasive treatment option to arrest the progression of keratectasia and it 
has revolutionized the treatment of KC. Several animal models, including rabbits, 
have been used to study the morphological alterations of the cornea following CXL 
treatment. Few studies have investigated the corneal morphological alterations 
following CXL treatment in porcine and rabbit corneas due to their structural 
similarity to the human cornea. Currently, no studies that have compared the 
normal corneal collagen fibrillar (CF) diameter, interfibrillar distance and 
interlamellar distance between human and these animal models. In addition, none 
have compared the morphological alterations of collagen fibrils (CFs) in both 
porcine and rabbit corneas with human, to identify an animal model that reacts in 
a similar manner to the human cornea, following CXL treatment.  
 
Aims: In the present study, we have compared the normal morphology of CF’s in 
porcine and rabbits to find an animal model comparable to human. These models 
(rabbit and porcine) were also investigated to find the optimal animal model that 
mimics reactions similar to human, to CXL treatment. Finally, we have investigated 
the effects of crosslinked corneas maintained in vitro for two weeks. We have also 
explored the possibility of extending the time a crosslinked cornea that can be kept 
in vitro beyond 2 weeks.  
 
Study 1: 
Materials and methods: The normal morphology of porcine (n=5), rabbit (n=5) and 
human (n=5) corneas were analysed using light and Transmission Electron 
microscopy (TEM).  
Results & conclusion: Histologically, all five layers (epithelium, Bowman's layer, 
stroma, Descemet membrane and endothelium) of the cornea were visible in all the 
three species. The CF diameter, interfibrillar distance and interlamellar distance 
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were compared between porcine, rabbit and human corneas for any statistically 
significant difference. It was evident that the CF diameter and interfibrillar distance 
of porcine and rabbit corneas were significantly different (p<0.001) from the human 
corneal values, but not from each other. While neither of animal models were 
structurally identical to the human cornea, they are both relatively similar to being 
used as models to study the biomechanical effects of external insults/treatments to 
be extrapolated to the human cornea. 
 
Study 2: 
Materials & methods:  Porcine (n=10), rabbit (n=10) and human (n=10) corneas were 
treated with CXL treatment. The central corneal thickness (CCT) was measured 
before and after CXL treatment. Each treated and control corneas were bisected, and 
one half was used for histological examination; the other half imaged by 
Transmission Electron Microscope (TEM) to investigate the morphological changes 
of corneal CF’s. These parameters were compared to identify the optimal animal 
model that mimics reactions of human following CXL treatment.  
Results & conclusion: The CXL treatment leads to an increase in CF diameter, a 
decrease in the interfibrillar distance, and a decrease in interlamellar distance. The 
effect of the CXL treatment was greatest in the anterior region of the corneal stroma, 
followed by the intermediate region, followed by the posterior region. All the 
species showed statistically significant keratocyte apoptosis and a significant 
reduction in the CCT following CXL treatment. When the magnitude of the change 
post-CXL treatment is taken into consideration, it was evident that porcine corneas 
were more suitable as an animal model to study reactions of CXL treatment.  
 
Study 3: 
Materials & methods: The effects/changes to the morphology of the CF’s in 
crosslinked corneas in vitro for two weeks were investigated, by maintaining 15 
human corneas in a culture medium.  
Results & conclusion: The results revealed that the effect of crosslinking (increase 
in collagen fibre diameter, decrease in interfibrillar and interlamellar distance) does 
not significantly change during the 2 week post-treatment. In the next part of the in 
vitro study, porcine (n=12) and human (n=3) corneas were investigated for the 
possibility of extending the viability of the crosslinked cornea in vitro beyond 2 
weeks. However, we were unable to maintain the crosslinked corneas for more than 
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two weeks, and we postulate that epithelial damage due to de-epithelialization 
before crosslinking treatment has an adverse effect on maintaining a healthy 
endothelium in vitro, hindering the de-epithelialized cornea from being maintained 
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Keratoconus (KC) is a spontaneous, non-inflammatory, self-limiting ectasia of the 
cornea with an incidence of 1 in 2000, generally affecting young patients (Romero-
Jiménez, Santodomingo-Rubido, & Wolffsohn, 2010). This condition impairs vision 
by causing irregular astigmatism of the cornea, and in more advanced cases, cause 
corneal scarring. The treatment of choice is the refractive correction. This correction 
is initially achieved with spectacles, but often rigid gas permeable lenses are often 
used to correct irregular astigmatism (Ozkurt, Atakan, Gencaga, & Akkaya, 2012). 
In advanced KC, when refractive correction is no longer possible due to severe 
irregular astigmatism or corneal scarring, the treatment for is penetrating 
keratoplasty (PK). Other treatment options available for mild to severe forms of KC 
are deep anterior lamellar keratoplasty (DALK), anterior lamellar keratoplasty (ALKP), 
and intrastromal corneal ring segments (Boimer, Lee, Sharpen, Mashour, & Slomovic, 
2011; Busin, Scorcia, Zambianchi, & Ponzin, 2012). In recent years, corneal 
crosslinking (CXL) treatment has been introduced as a minimally invasive 
treatment option to stop the progression of keratectasia, and it has revolutionised 
the treatment of KC. 
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Crosslinking is a process of forming chemical bridges between proteins and other 
molecules (Raiskup & Spoerl, 2013). Improving the mechanical properties of a 
material by crosslinking is not novel in biological sciences. Crosslinking can be 
initiated by different factors, including chemical catalysts; heat; pressure; and 
radiation with beta or gamma rays, or both (Gehring, 2000). Ultraviolet light (UV) 
mediated crosslinking to polymerise composite filling materials is used in dentistry 
(Ruyter, 1988). UV light is also widely used in the curing of adhesives by 
polymerisation in the polymer industry (Hudis & Prescott, 1972; Moszner, 
Gianasmidis, Klapdohr, Fischer, & Rheinberger, 2008). Chemically mediated 
crosslinking of type I collagen with glutaraldehyde has been used to stabilise 
prosthetic heart valves (Dahl, Spotts, & Truong, 2012; Golomb et al., 1987). 
Crosslinking occurs naturally within corneas during the ageing process, where the 
collagen fibrillar diameter increases by 4.5 per cent over a person’s lifetime due to 
age-related glycosylated crosslinking (Bailey, 1987; Daxer, Misof, Grabner, Ettl, & 
Fratzl, 1998). 
 
The strengthening of corneal collagen by crosslinking was described in the 1990s 
when researchers at the Technical University of Dresden, Germany observed that 
diabetic patients were rarely affected with keratoconus due to a glycosylation-
mediated crosslinking process that occurs within the corneal collagen fibres. Based 
on this observation, they developed a technique, which induced similar 
crosslinking effects on keratoconic subjects (Dahl et al., 2012). After extensive 
investigations, corneal collagen crosslinking (CXL) with riboflavin and Ultraviolet 
A (UVA) light was introduced as an effective treatment mode for keratoconus 
(Spoerl, Huhle, & Seiler, 1998; Wollensak, Spoerl, & Seiler, 2003a). 
 
Currently, CXL treatment is the only minimally invasive surgical procedure that 
has been proposed to halt the progression of keratoconus. It is considered the “gold 
standard” procedure to halt the progression of keratoconus (Jouve et al., 2017; 
Labate, De Santo, Lombardo, & Lombardo, 2015). According to the Global consensus 
of keratoconus and ectatic diseases (2015), 83.3 per cent of ophthalmic clinicians who	
are	experienced	in	the	management	of	keratoconus	and	ectatic	diseases	perform CXL 
as a treatment modality for keratoconus. Those who do not currently have access to 
this technique have indicated their willingness to use this procedure once it 
becomes available (Gomes et al., 2015).  
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Different animal models have been used to study corneal pathologies and their 
associated complications. Most of these studies were performed using the rabbit 
model (Cameron, Flaxman, & Yanoff, 1974; Helena, Baerveldt, Kim, & Wilson, 1998). 
Some in vivo investigations have been performed on the mouse and human corneas 
(Mencucci et al., 2010; Wilson et al., 1996). Besides, other studies have used rat and 
bovine corneas to evaluate the corneal wound-healing (Kamma-Lorger et al., 2009; 
Reid, Song, McCaig, & Zhao, 2005). The porcine model has been used as an ex-vivo 
model for other areas of vision-related research due to its morphological similarity 
to the human eye (Fernandez-Bueno, Pastor, Gayoso, Alcalde, & Garcia, 2008; 
Sanchez, Martin, Ussa, & Fernandez-Bueno, 2011). 
 
The rabbit eye model has been used in several investigations to study the 
morphological alterations of the cornea following CXL treatment (Wollensak, 
Spoerl, Wilsch, & Seiler, 2004)(Wollensak, Iomdina, Dittert, & Herbst, 2007). Human 
corneas have also been used in very few studies (Mencucci et al., 2010). But none 
have investigated the collagen fibre morphological alterations in porcine corneas 
following crosslinking treatment, despite their striking similarity to that of the 
human. Furthermore, no studies have compared the structural similarity of porcine 
and rabbit corneas to the human corneas, in an attempt to select the optimal animal 
model. Furthermore, alterations of the collagen fibre morphology over time in 
vitro following crosslinking treatment has not been investigated. 
 
1.1 Aims  
 
1. Compare the morphology and collagen fibre arrangement of the healthy rabbit, 
porcine, and human corneas with and without CXL treatment (Conventional 
Dresden treatment). 
2. Evaluate the short-term and long-term (three months) alterations in the collagen 
fibre architecture following the CXL procedure in vitro.  
 
The study consists of three main components:  
1) Compare the normal morphology of corneal collagen fibres in healthy 
porcine, rabbit and human corneas.  
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2) Based on the above results, choose the animal model that has 
morphological characteristics closer to human, to study the effects of crosslinking 
treatment. 
3) Evaluate the in vitro short- and long-term collagen fibre alterations 
following CXL treatment  
 
1.2 Thesis Format 
 
This thesis is divided into six chapters based on the objectives mentioned above.  
 
Chapter	1:	Introduces	the	topic	and	the	use	of	crosslinking	treatment	as	a	treatment	
modality	 for	 keratoconus.	 It	 also	 highlights	 the	 main	 objectives	 of	 the	 study	 and	
provides	an	overview	of	the	remaining	chapters. 
 
Chapter 2: This section is a comprehensive literature review on the various ways 
the corneal collagen treatment is applied to the eye. Additionally, the chapter also 
describes the general anatomical and histological features of porcine, rabbit, and 
human corneas, currently using other crosslinking techniques and a general 
understanding of the corneal storage techniques and corneal culturing.  
 
Chapter 3:  This section describes the normal morphology of corneal collagen fibres 
in healthy porcine, rabbit and human cornea without any external interventions to 
find an animal model similar to humans.  
 
Chapter 4:  This chapter details the process of choosing an ideal animal model that 
mimics the reactions of the human cornea following crosslinking treatment.  
 
Chapter 5: The chapter 5 explains the technique of in vitro evaluation of crosslinked 
corneas to evaluate the short- and long-term collagen fibre alterations following 
CXL treatment.  
 
Each chapter commences with a brief introduction, followed by the methodology 
and results. A discussion is included at the end of each chapter.  
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Part of this chapter has been published in 2018 (Appendix 1) as:  
“Subasinghe SK, Ogbuehi KC, Dias GJ (2018) Current perspectives on corneal 
collagen crosslinking (CXL). Graefes Arch Clin Exp Ophthalmol 256 (8):1363-1384. 
doi:10.1007/s00417-018-3966-0” 
  
2.1 Anatomy of the human eye 
 
The human eye is an almost spherical structure located within the bony orbital 
cavity. The diameters of the eyeball generally range from 23-25mm 
anteroposteriorly and around 24mm transversely. The eye consists of three main 
layers: the sclera, the choroid, and the retina (Garhart & Lakshminarayanan, 2012). 
The sclera is the outermost layer of the eye, which an opening on the anterior surface 
for the cornea. The limbus borders the cornea and sclera. The uveal tract is made up 
of the ciliary body, choroid, and iris. Pupil lies in the centre of the iris and posterior 
to the iris lies the lens. Finally, the retina is a layer of neural tissue lining the 
posterior two-thirds of the orbit. This is the photosensitive layer where light 
impulse will be directed toward the optic nerve (Parver, 1999). The space between 
the back of the cornea and front of the iris is the anterior chamber and space between 
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posterior iris and lens is the posterior chamber. Space between the back of the lens 
and front of the retina forms the vitreous chamber (Ansari & Nadeem, 2016) (Figure 
2.1). The cornea lies in the anterior segment of the eye with aqueous humour, 
forming the main refractive element of the eye. The vitreous humour is a clear 
gelatinous substance that fills the chamber behind the lens (Figure 2.1). 
 
2.2 Structural characteristics of the human cornea  
 
The cornea is a transparent avascular structure of the anterior surface of the eye, 
which acts as the primary structural barrier, particularly against infections. It 
occupies the anterior one-fourteenth of the fibrous outer tunic of the eye (Freegard, 
1997). Together with the overlying tear film, it also provides a proper anterior 
refractive surface for the eye. The cornea is an oval-shaped structure with 
approximately 12.6mm horizontal diameter and 11.7mm vertical diameter. The 
thickness of the cornea gradually increases from the centre to the periphery. It is 
roughly 0.5-0.6mm in thickness at its centre and about 0.8mm in the periphery 
(Freegard, 1997; Garhart & Lakshminarayanan, 2016; Kiely, Smith, & Carney, 1982; 
Skalicky, 2016b). Corneal shape and curvature are maintained by the intrinsic 
biomechanical structures and extrinsic environment. The human corneas consist of 
five layers, including three cellular layers (epithelium, stroma and endothelium) 
and two membranes (Bowman’s and Descemet’s membranes). The corneal stroma 
constitutes 90 per cent of the thickness of the  entire cornea (Freegard, 1997). 
 
2.2.1 Epithelium  
 
The epithelium is a highly organised and stable structure. It is the outermost layer 
of the cornea, and it is derived from the surface developing ectoderm (Jacob & 
Naveen, 2016). Also, it creates the first barrier to the outside environment. The 
corneal epithelium is comprises a stratified, non-keratinizing squamous layer which 
is characterised by extreme uniformity from limbus to limbus (Delmonte & Kim, 
2011). The epithelium is five to seven layers (squamous cells) deep ( measuring 40 - 
50µm thick) increasing in thickness towards the peripheral limbus (Ehlers et al., 
2010). It has three cell types, superficial, wing or suprabasal, and basal cells from 




Figure 2.1 – Anatomy of the human eye 
Atlas of human anatomy, Frank H. Netter (Frank Henry), 1906-1991, Carlos A. G. 
Machado; John T. Hansen; Brion Benninger; Jennifer K. Brueckner 1970-; Todd M. 





Superficial cells form three to four layers of the cornea. These cells are terminally 
differentiated cells that degenerate and slough off from the surface. Superficial cells 
have apical surface microvilli that express adherent glycocalyx that anchors the tear 
film. The next is the wing cell layer, named because of the typical wing shaped cells. 
These wing cells form the intermediate one to three layers of the epithelium. These 
cells are less flat than the superficial cell layer and are in an intermediate state of 
differentiation (Jacob & Naveen, 2016). The basal cell layer is the deepest of the 
epithelial cell layers, which is composed of a single layer of cuboidal cells that rest 
on the basement membrane of type IV collagen. Laminin is secreted by the basal 
cells of the epithelium (Alvarado, Murphy, & Juster, 1983). It is the only layer where 
the cells have mitotic activity and differentiate into the wing and superficial cells 
(Jacob & Naveen, 2016; Masters & Thaer, 1994). The basal layer is attached to the 
basement membrane (0.05µm thickness) through a tight hemidesmosomal system 
that prevents the epithelium from separating from the underlining corneal layers. 
The epithelium regenerates every 7 to 14 days. The epithelial stem cells play an 
important role in the formation of new corneal epithelium. These stem cells are in 
the limbal basal epithelium. During, cell division, the daughter cells move toward 
the corneal surface and begin to differentiate. Each basal cell divides into two wing 
cells that subsequently differentiate into superficial cells.  
 
2.2.2 Bowman’s Layer/ Bowman’s membrane/Anterior limiting lamina 
  
This layer is not considered to be a true membrane, but rather a cellular 
condensation of the most anterior portion of the stroma (Figure 2.2). Bowman’s 
layer is composed of type I and type III collagen fibres and is devoid of keratocytes. 
This layer is 8µm -15µm in thickness. It is believed that this layer helps the cornea 
to maintain its shape (Delmonte & Kim, 2011; Freegard, 1997; Krachmer, Mannis, & 
Holland, 2005). Unlike the epithelium, however, the Bowman’s membrane does not 
regenerate. Therefore, when damaged, it can result in the formation of a fibrous scar 










Figure 2.2 - Microstructural view of the human cornea 
Light micrograph of different layers of the cornea (A - x10 magnification, a & b - x40 
magnification) 
B & C - Electron micrograph showing the B- epithelium and Bowman membrane and C – 
stroma, Descemet membrane and endothelium (B & C – magnification x 6000)  
(Gray’s Anatomy: the Anatomical basis of clinical practice, Susan Standring et al. 41st ed. Elsevier 




The stroma forms the major part of the cornea constituting 80-90 per cent of its full 
thickness, providing the bulk of its structural framework. Embryologically, the 
stroma is developed as a result of the second wave of neural crest migration at the 
seventh week of gestation, following the establishment of the primitive 
endothelium (Delmonte & Kim, 2011). It is mainly composed of type I collagen in a 
heterodimeric complex along with type V collagen (Fini & Stramer, 2005). The 
presence of smaller amounts of collagen type III and VI was also described in the 
literature (Jacob & Naveen, 2016). Corneal fibroblasts/ keratocytes are responsible 
in the synthesis of collagen fibres within the corneal stroma. The collagen molecules 
secreted by the keratocytes are composed of sulpherhelix of polypeptide chains 
(alpha chains). The composition of these sulpherhelix determined the type of 
collagen formed. These procollagen molecules assemble as triple helix (coiled coils) 
and several of these triple helix tropocollagen molecules ultimately form a collagen 
fibril (CF). Several collagen fibrils (CFs) aggregate together to form a collagen fibre/ 
collagen lamellar. These collagen lamellae are arranged in parallel bundles within 
the human corneal stroma (Figure 2.3)  
 
These colinear collagen fibres are 9-20um long with 2.0um of thickness (Meek & 
Boote, 2004; Ojeda, Ventosa, & Piedra, 2001). In the central part of the cornea, these 
collagen fibrils are 31nm in diameter. The distance between these CFs is generally 
57nm (Skalicky, 2016a). The corneal stroma is composed of 200-250 highly 
organised lamella. Each layer arranged at a right angle relative to fibres in the 
adjacent lamellae. It was also noted that the collagen fibre arrangement is more 
strictly organised in the deeper layers than in the superficial layers. The fibres also 
change their direction, becoming circumferential around the limbus at the corneal 
sulcus. This circumferential arrangement of collagen fibres at the limbus assists in 
withstanding the increased tension around the limbal area. Additionally, this 
arrangement is also required to maintain the different curvatures of the cornea and 






Figure 2.3 – Structure of a collagen fibre/ lamellar 
(Modified from Functional Histology, Jeffrey B Kerr, 2nd Edition, ELSEVIER)  
 
 
The collagen fibre complexes are arranged in a proteoglycan matrix consisting of 
keratan sulphate, chondroitin sulphate or dermatan sulphate.  Keratan sulphate is 
the most abundant proteoglycan (Ihanamäki, Pelliniemi, & Vuorio, 
2004). Keratocytes / stromal fibroblasts are the main types of cells within the 
corneal stroma. These cells have high metabolic activity and can synthesise collagen 
and proteoglycans of the stroma. In case of a corneal injury, keratocytes get 
activated and differentiate into myofibroblasts during wound healing (Fini, 1999). 
Furthermore, there are structural differences between the anterior one third and 












Table 1 – Structural differences between the anterior one third and posterior two thirds of 




Anterior one third of the corneal stroma 
 
Posterior two thirds of the corneal stroma 
 
  
Collagen fibril arrangement less 
organized 
Collagen fibril are more strictly organized 
 
Lamella arrangement is oblique to each 
other and interlacing providing more 
strength  
Lamella arrangement is parallel to each 
other which facilitates less strength 
 
Less water More water 
 
Less glucose More glucose 
 
More dermatan sulphate Less dermatan sulphate 
 
Less keratan sulphate More keratan sulphate 
 
Strong interlamellar connections Poor interlamellar connections 
 
High tensile strength  Low tensile strength  
 

















2.2.4 Pre-Descemet’ layer or Dua’s layer 
  
The pre-Descemet’s layer is a well-defined acellular layer situated between the 
posterior stroma and the Descemet’s membrane. It comprised of between five and 
eight thin lamellae of tightly packed collagen fibrillar bundles which run in 
longitudinal, transverse and oblique directions (Dua, Faraj, Said, Gray, & Lowe, 
2013; McKee et al., 2014). Due’s layer seems to have thinner collagen fibres than the 
corneal stroma. One of the characteristic features of this layer is it’s cellularity. For 
instance, According to a immunohistochemical study, it was noted that CD34 was 
absent in Dua’s layer. This shows that this layer is lacking keratocytes unlike the 




2.2.5 Descemet’s membrane/ Posterior limiting lamina 
  
The formation of Descemet’s membrane occurs during the eighth week of gestation 
by endothelial cells. The thickness of this membrane varies from 8 to 10µm and it is 
predominantly composed of type IV collagen, laminin and fibronectin (Grant & 
Leblond, 1988; Skalicky, 2016a). The presence of type VIII collagen fibres within the 
Descemet’s membrane was also noted (Jacob & Naveen, 2016). It is a tough 
membrane that resists enzymatic degradation, and it can remain intact even when 
the overlying stroma is  destroyed (Twining, Davis, & Hyndiuk, 1986).  
 
2.2.6 Endothelium  
 
The endothelium is composed of a single layer of mostly cuboidal cells, of which 
70-80 per cent are hexagonal cells (Jacob & Naveen, 2016). The cell density of the 
endothelium decreases gradually throughout the life from about 23,000 cells/mm2 
at birth to about 2000 cells/mm2 in old age (Price, 2015). The minimum cell density 
required for normal corneal function is 400-700cells/mm2 (Skalicky, 2016a). The 
activity of the endothelial cells maintains the stroma in a relatively hydrated state 
(78 per cent water content) where fluid egresses from the corneal stroma down an 
osmotic gradient from a relatively hypo-osmotic stroma towards a relatively 
hypertonic aqueous humour (Watsky, McDermott, & Edelhauser, 1989). 
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2.3 Structural characteristics of porcine and rabbit corneas 
 
The structural characteristics of both porcine and rabbit corneas are similar to 
humans in different aspects. As a result, these animal models have been used 
extensively as experimental models for many laboratory studies.  
 
2.3.1 Porcine cornea 
 
The thickness of the porcine cornea varies in different regions. The central corneal 
thickness (CCT) is 0.98mm, which increases to a 1.19mm at the limbus 
(Bartholomew, Pang, Sam, & Cavender, 1997; Reichard et al., 2010). It is also noted 
that in general the pig corneal epithelium thickness could vary from 25µm up to 
80µm. The stromal thickness is 900µm, which is twice as thick as in human (Jay et 
al., 2008). Furthermore, the porcine cornea has a larger corneal radius and greater 
corneal astigmatism than in human (Sanchez et al., 2011).  
 
The corneal epithelium is composed of around five stratified cellular layers in which 
superficial, wing cells, and basal cells are lined up from superficial to deep. The 
architecture of these cells differs from each other, the superficial cells are flatter, and 
intermediate wing cells are rounder in shape. The deep basal cells are larger and 
elongated, with their long axis oriented perpendicular to the stromal surface (Jay et 
al., 2008).  
 
There is disagreement regarding the existence of a Bowman’s layer in porcine 
corneas. A Confocal microscopy study described the Bowman’s layer, which is 
composed of amorphous tissue with a less regular organisation of collagen fibres 
and being absent at the limbus (Cafaro et al., 2009). Bartholomew et al. (1997) and 
Jay et al. (2008) stated that the Bowman’s layer is absent in porcine corneas 
(Bartholomew et al., 1997; Jay et al., 2008). Nautscher (2016) noted that the 
Bowman’s layer not developed in pigs to a similar dimension as in humans 
(Nautscher, Bauer, Steffl, & Amselgruber, 2016). 
 
The corneal stroma is the thickest corneal layer constituting 75-80 per cent of the 
total corneal thickness. The stroma is mainly composed of a uniform collagen fibril 
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matrix along with glycosaminoglycans. The collagen fibrils (CFs) are arranged 
parallel to each other and to the cornea surface. Keratocytes are distributed between 
collagen fibrillar bundles/ lamellar within the stroma (Jay et al., 2008; Nautscher et 
al., 2016). The collagen fibre within the stroma was arranged parallel to each other 
and to the corneal surface. Most of the collagen fibres within the stroma are of 
collagen type 1 (Jay et al., 2008). Posterior to the corneal stroma is the Descemet’s 
membrane with a thickness of 18.2 ± 2.7µm, and it is covered by a single-layered 
corneal endothelium.  
 
2.3.2 Rabbit cornea  
 
Morphologically, the rabbit orbit is considered to be more complete than many 
other lower mammals. The thickness of the rabbit corneas varies in different areas, 
with greater thickness at the limbus 0.45 mm and 0.37 mm at the centre of the cornea. 
(Davis, 1929; Hayes et al., 2007). The cornea of a rabbit is composed of the following 
structures: 1) epithelium, 2) stroma, 3) Descemet’s membrane, and 4) endothelium. 
In rabbit cornea, there was no evidence of a Bowman’s membrane which makes the 
epithelium directly in contact with the corneal stroma.  
 
The corneal epithelium is made up of six layers of stratified squamous cells; the 
deepest layer consists of cylindrical cells (Davis, 1929). The stroma is 
morphologically similar to that of the human cornea with a much thicker 
Descemet’s membrane, which can be seen in older animals (Davis, 1929). Stromal 
lamellar collagen is more tightly packed than human corneal lamellae and is 
arranged parallel to the corneal surface with a uniform thickness and variable width. 
Keratocytes lie within the corneal stroma, parallel to the corneal surface with a 
greater density of keratocytes dispersed in the anterior region of the corneal stroma 
than in the posterior stroma (Ojeda et al., 2001). 
 
2.4 Corneal collagen fibrillar distribution and arrangement 
 
Approximately 90 per cent of the dry weight of human corneas consists of collagen. 
The transparency of the cornea is maintained by the regular arrangement of these 
collagen fibres within the corneal stroma. Both rabbit and porcine corneal CFs are 
arranged predominantly in a circumferential pattern compared to human corneal 
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CFs which are arranged in an orthogonal pattern, except at the periphery where 
they are arranged circumferentially (Hayes et al., 2007). These CFs that are arranged 
in orthogonal pattern facilitate additional support in withstanding pressure during 
eye movement. Additionally, it also contributes to maintaining the shape of the 
cornea, preventing distortion of the cornea during the eye movement (Daxer & 
Fratzl, 1997).  
 
Most of the mammalian corneal collagen is composed of type I collagen. The 
presence of type II, III and V has been reported. The presence of type III collagen 
can vary from not having any to comprising 20% of the human corneal stroma 
(Bailey, 1987). Another study on rabbits illustrated the presence of type II and III 
fibres in the embryo. It is believed that these types of collagen tend to disappear 
after maturity in adult animals. In contrast, type V collagen fibres have an increment 
of 5-10% following maturation (Lee & Davison, 1981). Type V collagen is thought 
to be important in maintaining the precise diameter of collagen fibres in the corneal 
stroma. Sometimes these type V collagen fibres seem to be incorporated with the 
collagen type I fibres (Birk, Fitch, & Linsenmayer, 1986; Fitch, Gross, Mayne, 
Johnson-Wint, & Linsenmayer, 1984). An indirect immunofluorescence study has 
identified collagen type VI within the human corneal stroma. These collagens were 
filamentous collagen of the cornea. Their function is not well understood 
(Zimmermann, Trüeb, Winterhalter, Witmer, & Fischer, 1986). Unlike collagen type 
V, type VI fibres are not incorporated into striated collagen fibrils of the cornea but 
present mainly in the inter-fibrillary matrix (Marshall, Konstas, & Lee, 1991). Apart 
from the corneal stroma, both type V and type VI fibrils are also distributed within 
the Descemet’s membrane and in areas immediately between the Descemet’s 
membrane and stroma (Bailey, 1987; Marshall et al., 1991). 
 
Although there are many studies illustrating the biomechanical properties of 
porcine and rabbit corneas (Kampmeier, Radt, Birngruber, & Brinkmann, 2000; 
Zeng, Yang, Huang, Lee, & Lee, 2001), there is a paucity of studies describing the 
arrangement of the CFs within the corneal stroma, and none of these studies have 
described the stromal collagen fibrillar arrangement in-depth following corneal 
crosslinking (CXL) treatment. 
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2.5 Porcine and Rabbit Eyes as Experimental Models in 
vision sciences 
 
The pig and rabbit corneas have commonly been used in vision science research due 
to their morphological similarities to the human cornea (Abraham et al., 2003; 
Acosta, Vazquez, & Castillo, 2009; Brunette et al., 2011; Evinger, Shaw, Peck, 
Manning, & Baker, 1984; Fernandez-Bueno et al., 2008; Wong, Koopmans, Terwee, 
& Kooijman, 2007). These animal models have been used extensively to study 
different parts of the eye, including the ciliary epithelium, trabecular meshwork, 
aqueous outflow, neuroretinal and retinal vascularisation. There are many studies 
in the literature in which these animal models have been used to develop new 
imaging techniques (Rosolen, Saint-Macary, Gautier, & Le Gargasson, 2002; Rosolen, 
Saint-Macary, Gautier, & LeGargasson, 2001). Furthermore, porcine and rabbit 
experimental models have been used to investigate different pathologies like 
glaucoma (Ruiz-Ederra et al., 2005; Sheppard & Shanklin, 1968) and cataract (Nishi, 
Nishi, Nishi, & Chang, 2008; Sugiura et al., 1999; Watsky et al., 1989). Experiments 
with different surgical techniques on retinas, vitreous humour and cataracts were 
undertaken using the porcine eyes (Ghosh & Arnér, 2002). In some studies, rabbit 
corneas were used to test different topical medications. For instance, it has been 
used as an animal model to test ophthalmic drug delivery systems (Oh et al., 2007; 
Stratford, Yang, Redell, & Lee, 1983; Xiong et al., 2008) and to evaluate the effects of 
ultraviolet light on the ocular structures (Čejková & Lojda, 1995). Rabbit eyes have 
also been used to study dry eye syndromes that can occur due to some chronic 
diseases, and as a model to study the effects of different diseases such as 
tuberculosis (Bunn & Dortbeck, 1952; Fujihara, Nangano, Nakamura, & Shirasawa, 
1995). 
 
 There are several studies on the anatomy, pathophysiology, biomechanics and 
immunology of cornea based on porcine models (Fernandez-Bueno et al., 2008; 
Majo, Rochat, Nicolas, Jaoudé, & Barrandon, 2008). Porcine corneas have also been 
used in developing an effective culture media to store corneal flaps in eye banks 
and also as an experimental model for different studies in tissue engineering (Proulx 
et al., 2007) and pharmacology (Scholz et al., 2002; Vijayasekaran et al., 2011). The 
possibility of obtaining porcine cornea as a potential alternative to human corneas 
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have also been discussed in the literature. It was noted that graft survival in the 
absence of prolonged immunosuppressive therapy could be achieved by producing 
pigs with multiple genetic modifications (Ekser et al., 2012; Hara & Cooper, 2010). 
Although there are many studies conducted using porcine and rabbit corneas as 
experimental models, none have compared the morphological features of these pigs 
with the humans to choose an ideal animal model to investigate the collagen fibrillar 






Keratoconus is a disease included in a wider range of diseases called corneal 
ectasias. Corneal ectasia is a progressive, non-inflammatory thinning of the cornea 
resulting in irregular astigmatism and vision loss. Pellucid marginal degeneration 
(PMD), keratoglobus, and post-laser ectasia are some of the other conditions that 
are considered in this broad group of corneal thinning disorders. The first detailed 
description of keratoconus was undertaken 150 years ago by Dr. John Nottingham, 
and investigated further by his contemporary Sir William Bowman (Rosen, 2012). 
Initially, keratoconus was referred to as hyperkeratosis; ochlodes; sugar-loaf 
disease; cornea conica; and staphyloma pellucidum (Grzybowski & McGhee, 2013). 
A review that was published in 1984 by Krachmer on keratoconus is considered to 
be one of the most comprehensive clinical descriptions on this condition at that time 
(Krachmer, Feder, & Belin, 1984). There has since been much research built on the 
foundation of Krachmer’s study, exploring treatment options, complications, and 
new improvements followed by several review articles (Yaron S. Rabinowitz, 1998; 
Romero-Jiménez et al., 2010; Sinha, Gupta, Sharma, Gupta, & Titiyal, 2010; Spadea, 
Salvatore, & Vingolo, 2013; Yanoff, Duker, & Augsburger, 2009).   
 
Keratoconus is a spontaneous, non-inflammatory, self-limiting ectasia of the cornea, 
and the name has derived from the Greek words Kerato (cornea) and Konos (cone) 
(Lembach, 1991; Mahadevan, Arumugam, Arunachalam, & Kumaresan, 2009; 
Romero-Jiménez et al., 2010). The corneal degeneration results in localised corneal 
thinning, which leads to protrusion of the thinned cornea (Figure 2.4). Usually, the 
corneal thinning occurs at the central or inferior temporal aspects of the cornea 
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(Auffarth, Wang, & Völcker, 2000). However, superior localisation of corneal 
thinning has also been reported (Prisant, Legeais, & Renard, 1997; Weed, McGhee, 





Figure 2.4 – Normal and keratoconic cornea 
A,C – Normal cornea, B, D – Keratoconic cornea 






The incidence of keratoconus in early studies is estimated to be between 50 and 230 
per 100,000 population annually, approximately 1-4 per 2000 (or 0.5-2 per 1,000), 
with a prevalence of 54.5 per 100,000 (Rabinowitz, 1998). However, recent 
developments in advanced diagnostic modalities have allowed early detection of 
corneal changes, enabling faster diagnosis and treatment of the disease at sub-
clinical stages. The incidence of keratoconus also varies in different ethnic groups. 
For example, in Maharashtra, India, keratoconus prevalence is 2,240 per 100,000 
people (Barbara, Turnbull, Hossain, Anderson, & Barbara, 2017), while the 
incidence in Saudi Arabia is 20 per 100,000 per year (Assiri, Yousuf, Quantock, & 
Murphy, 2005). The incidence of keratoconus ranges from 0.3 per 100,000 in Russia, 
1.3 per 100,000 per year in Denmark and 19.9 per 100,000 people per year in Britain 
(Barbara et al., 2017; Nielsen, Hjortdal, Aagaard Nohr, & Ehlers, 2007). More recent 
data suggest a 2-3 fold increase in the incidence of keratoconus in Denmark, which 
have tributed to the recent developments of new diagnostic techniques of 
keratoconus (Bak-Nielsen, Ramlau-Hansen, Ivarsen, Plana-Ripoll, & Hjortdal, 2019).  
Significant lower prevalence of keratoconus has been reported in Israel at 2.34 per 
100,000 per year (Millodot, Shneor, Albou, Atlani, & Gordon-Shaag, 2011), and the 
United States, where the prevalence was as low as 0.09 (Kennedy, Bourne, & Dyer, 
1986; Nielsen et al., 2007). Japanese are considered to have a low keratoconus 
prevalence compared to Caucasians (Barbara et al., 2017).  
 
In New Zealand, a high incidence of keratoconus has been observed for more than 
30 years (Patel & McGhee, 2013; Sabiston, 1978). One practitioner-based survey 
revealed that most of the people who suffer from this condition in New Zealand are 
of European descent, with 20 per cent of the cohort from those of Māori or Pacific 
descent. The reason for having lower cases of Maori or Pacific descent being not 
requesting medical care and preliminary testing to diagnose keratoconus (Owens & 
Gamble, 2003). Furthermore, a study conducted on keratoconic patients at the 
Department of Ophthalmology at the Auckland District Health Board revealed that 
keratoconus is largely associated with the ethological risk factors and involvement 
of Maori  and Pacific island ethnicities were over represented in this population.  
(Jordan et al., 2011). Another study describes that Māori and Pacifika ethnicities 
seem to be related with more severe forms of the disease and a younger mean age 
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at diagnosis than among Caucasian and Asian populations (Niederer, Perumal, 
Sherwin, & McGhee, 2008). A study which was conducted to screen New Zealand 
school children for topographic anomalies, reported that 19 per cent of the screened 
cohort had suggestive signs of early keratoconus. It was also noted that the odds of 
Māori/Polynesian populations exhibiting corneal anomalies were twice (26.9%) 
that of non- Māori/Polynesian (12.9%) populations (Owens & Gamble, 2003). 
 
The onset of this condition generally happens at puberty, and it progresses until the 
third or fourth decade of life. It is believed that after the third or fourth decade, the 
progression of the disease is usually arrested (Albert & Jakobiec's principles and 
practice of ophthalmology, 2008; Yanoff et al., 2009). Keratoconus appears to affect both 
males and females, but it is unclear whether significant differences between these 
genders exist. Some studies have noticed no significant differences between genders 
(Kennedy et al., 1986; Li, Rabinowitz, Rasheed, & Yang, 2004). In contrast, other 
investigators have found males to be more prone to keratoconus than females 
(Owens & Gamble, 2003; Pearson, Soneji, Sarvananthan, & Sandford-Smith, 2000; 
Wagner, Barr, & Zadnik, 2007; Weed & McGhee, 1998) while, and others have found 
higher prevalence in females (Krachmer et al., 1984; Stein, 2006).  
 
2.6.3 Aetiology and pathogenesis 
 
It is a well-known fact that keratoconus is caused by a multifarious interplay of 
environmental, genetic, biomechanical and biochemical disorders. However, the 
effects of these factors on the development of this condition are unclear (Barbara et 
al., 2017; Romero-Jiménez et al., 2010). The complexity of this condition was 
described by Pickford in 1844: “there is probably no disease to which the eye is subject, 
hitherto so rebellious to medicine, so intractable in its nature, and at the same time, so fatal 
to vision, as conical cornea; and not one, the pathology and treatment of which are so little 
understood” (McGhee, Kim, & Wilson, 2015).  
 
Many studies have suggested a genetic predisposition to this condition. It is 
believed that 50 per cent of subjects with keratoconus have at least one close relative 
affected by the disease (Gonzalez & McDonnell, 1992). Another study estimated that 
in comparison to normal subjects, relatives of keratoconic patients have a 15-67 per 
cent higher risk of acquiring this condition (Wang, Rabinowitz, Rotter, & Yang, 
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2000). However, few studies have explained the development of keratoconus as a 
result of adverse effects of different mutations of genes (Bisceglia et al., 2005; Hon 
et al., 2002). In contrast, recent studies by Aldave et al. (2006) and Liskova et al. 
(2007) highlighted that there is no relationship between having genes with 
mutations and acquiring keratoconus (Aldave et al., 2006; Liskova et al., 2007).  
 
Association of keratoconus development to obstructive sleep apnoea (OSA) and 
floppy eye syndrome has been mentioned in the literature (Pellegrini et al., 2020). It 
was noted that 1 of 44 (2.3%) of OSA patients had a diagnosis of keratoconus(Mojon 
et al., 1999). Gupta et al., 2012, reported a prevalence of 18% of OSA among patients 
with KC (Gupta et al., 2012) which is much higher than the previously published 
data where the prevalence ranges from 1-5% . It was noted that patients with KC 
1.8 times as likely to have OSA (Pellegrini et al., 2020). Another study by Nadran et 
al. (2015), stated that patient with KC has a higher risk of developing OSA and KC 
patients with a higher risk of developing OSA are associated with more sever forms 
of KC (Ferrari and Rama, 2020; Woodward et al., 2016). The association of increase 
levels of proteolytic enzymes and  increase in the reactive oxygen species, which are 
common features of OSA and keratoconus, seems to be the factors linking these 
conditions with regard to their pathogenesis (Pellegrini et al., 2020). 
 
Several biomechanical and biochemical theories have been put forward to support 
the hypothesis that keratoconus occur as a result of alterations of corneal structural 
components. Alterations in the composition of different types of collagen (types XII, 
XV and XVII) and increased levels of protease and other catabolic enzymes seemed 
to affect on the development of keratoconus (Fukuchi, Yue, Sugar, & Lam, 1994; 
Määttä et al., 2006). Fukuchi et al. (1994), found a four folds increase of Interleukin-
1 receptors in keratocytes of keratoconic corneas, where Interleukin-1 has been 
postulated to be a modulator of keratocytes proliferation, differentiation and death 
(Bureau, Fabre, Hecquet, Pouliquen, & Lorans, 1993; Wilson et al., 1996). It is 
believed that the lower number of stromal lamellae might have been a contributing 
factor in thinning of the cornea and reducing its rigidity in keratoconic patients 
(Klintworth & Damms, 1995). There were conflicting findings in the literature 
regarding whether or not atrophy of the cornea is associated with keratoconus 
(Copeman, 1965; Georgiou, Funnell, Cassels-Brown, & Conor, 2004; Lowell & 
Carroll, 1970).   
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Rigid contact lens use has been associated with the disease progression (Gasset, 
Houde, & Garcia-Bengochea, 1978). However, whether it can trigger the 
development of keratoconus is still unclear (Rabinowitz, 1998). Although 
keratoconus is a disease that occurs as an isolated condition, it also has been 
associated with many syndromes and diseases. For instance, there is a high 
incidence of developing keratoconus in patients with Down syndrome – some 0.5-
15 per cent (Cullen & Butler, 1963; J. H. Krachmer et al., 1984) and Leber’s congenital 
amaurosis, up to 30 per cent of patients (Elder, 1994). There is evidence suggesting 
an association of keratoconus with different connective tissue disorders such as 
Ehlers-Danlos syndrome subtype VI (Emine Kalkan et al., 2014; Kuming & Joffe, 
1977), osteogenesis imperfecta (Beckh, Schönherr, & Naumann, 1995), joint 
hypermobility and mitral valve prolapse (Lichter et al., 2000; Sharif, Casey, & 
Coltart, 1992). 
 
2.6.4 Clinical features 
 
The clinical features of keratoconus vary according to the severity of the disease. In 
subclinical forms, it might be asymptomatic and thus go unnoticed by the patient 
and doctor. This is one of the main reasons for the late detection of this disease. 
(Arntz, Duran, & Pijoan, 2003; de Sanctis, Aragno, Dalmasso, Brusasco, & Grignolo, 
2013). In recent years, Ozgurhan et al. (2013) have suggested in vivo confocal 
microscopy as a suitable method to detect early microstructural variations 
occurring in healthy corneas (Ozgurhan et al., 2013). However, the practical 
implication of this technique as a regular eye investigation might be difficult in all 
cases. When keratoconus progresses, visual acuity will deteriorate continuously to 
an extent where it cannot be compensated with spectacles. In other words, the 
patent cannot be refracted to a clear 20/20 correct vision. The visual acuity may be 
reduced due to irregular astigmatism, high myopia and corneal scarring (Johnson 
& Harissi-Dagher, 2017). Fortunately, these patients never become completely blind 
from this condition. In the initial stages of the disease, usually, one eye may be 
affected. However, as the disease progresses, however, bilateral involvement is 
common (Lee, Hirst, & Readshaw, 1995; Rabinowitz, Nesburn, McDonnell, Ben-
Meir, & Bahrl, 1993). In keratoconus, the cornea thins, with the thinnest part located 
outside the visual axis. The stromal thinning is mostly noted centrally or 
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paracentrally, most commonly inferiorly or inferiomedially. This results ultimately 
in conical protrusion of the cornea (Krachmer et al., 1984) 
 
In moderate to advanced cases of keratoconus, the tear film deposits iron into the 
cornea (Fleischer’s ring) changing the corneal curvatures (Mannis, 1983). The 
appearance of fine vertical lines in the deep parts of the corneal stroma, and 
Descemet’s membrane which disappear when digital pressure is applied (Vogt’s 
striae) is another characteristic sign in keratoconus (Albert & Jakobiec's principles and 
practice of ophthalmology, 2008). Other accompanying signs that might occur in a 
keratocnic eyes are: 1) superficial and deep corneal opacities, 2) increased visibility 
of corneal nerves, 3) apical thinning, 4) anterior stromal clearing lines, 5) 
subepithelial fibrillary lines and 6) central or eccentric corneal protrusion (Khaled 
et al., 2017; Li et al., 2004). In advanced stages of the disease, when a person’s eyes 
are positioned inferiorly, a V-shaped deformation of the lower eyelid can be noted 
(Rizzuti’s sign). Breaks in Descemet’s membrane results in acute stromal oedema 
(Hydrops), sudden loss of vision, and significant pain can also occur in more 
advanced cases of keratoconus (Thota, Miller, & Bergmanson, 2006).   
 
2.6.5 Management of keratoconus 
 
The management of keratoconus transformed in the past decade. A burgeoning 
clinical literature describes new surgical and conservative techniques to improve 
the clinical outcomes of this condition. Management options of keratoconus can be 
subdivided broadly into two main groups; nonsurgical management and surgical 
management.  
 
A. Nonsurgical management 
  
The nonsurgical management is focused on achieving two main goals, whereas 
firstly to halt the progression of the disease, and the next goal is to attain visual 
rehabilitation. Constant eye rubbing has been regarded as one of the potential risk 
factors for developing this condition. Consequently, keratoconic patients were 
advised to refrain from constant rubbing their eyes. In patients suffering from 
allergies, the allergic component was identified, and they were treated with topical 
anti-allergic medications and lubricants. Furthermore, keratoconus associated with 
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atrophy or a history of eye rubbing can also be treated with tropical multi-action 
anti-allergic medications like antihistamines, mast cell stabiliser and anti-
inflammatory drugs (McGhee et al., 2015). Many experts in the field of keratoconus 
have agreed that even though there were no definitive connections between eye 
rubbing and keratoconus, used of eye drops without preservatives is preferable in 
patients with this condition (Gomes et al., 2015). Refractive errors and optical 
corrections can be achieved by the use of spectacle or contact lenses. At present, 
there are many types of rigid and flexible contact lenses that are in use for 
keratoconus (Mandell, 1997). Spectacles are usually indicated for mild stages of the 
disease. However, in more advanced stages of the disease, rigid gas permeable 
contact lenses or scleral lenses are superior to spectacles in the management of 
keratoconus. As the disease, progresses further, contact lenses may no longer be 
optimal for managing the visual symptoms (Rabinowitz, 1998).  
 
The use of contact lenses for mild to moderate cases of keratoconus was first 
introduced by Adolf Fick, in 1988. Since then, many types and models of contact 
lenses have been introduced in clinical practice (Romero-Jiménez et al., 2010). 
However, the management of keratoconus through contact lenses was a highly 
debatable topic with many of the experts in these files. For instance, a study by Lass 
et al. (1990), stated that contact lens use is a major therapeutic modality in treating 
keratoconus irrelevant of which stage of the disease (Lass et al., 1990) while Dana et 
al. (1992), suggested that it can be used to manage even advanced cases of 
keratoconus. However, using contact lenses for advanced stages of this condition 
have resulted in contact lens failure, and ultimately the patients had to undergo 
surgical interventions (Dana, Putz, Viana, Sugar, & McMahon, 1992). Furthermore, 
the use of hard contact lenses and their association in developing keratoconus also 
have been discussed in the literature (Rabinowitz, 1998).  
 
B. Surgical management 
  
Once the keratoconus cannot be managed by conservative treatments, the next steps 
of management include different interventional procedures including deep anterior 
lamellar keratoplasty (DALK), intraocular refractive lenses, intrastromal corneal 
ring segment (ICRS), and corneal crosslinking (CXL). If any of these techniques 
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become ineffective, the final treatment option is corneal transplantation 
(penetrating keratoplasty -PK).   
 
a) Penetrating keratoplasty (PK)  
 
Penetrating keratoplasty (PK) was first performed by a Spanish ophthalmologist 
Castroviejo in 1936. According to his findings, this procedure improved vision by 
between 75% and 90% in patients with keratoconus (Castroviejo, 1948; Coster, Lowe, 
Keane, Williams, & Contributors, 2014). The procedure involved in removing the 
entire thickness of the cornea and replacing it with a donor cornea. This treatment 
was recommended for severe cases of keratoconus (Rabinowitz, 1998; Sray, Cohen, 
Rapuano, & Laibson, 2002). Although PK has been used as the best and most 
successful surgical option for patients with moderate to severe cases of keratoconus 
in the past decade (Anseth & Palm, 1971; Keates & Falkenstein, 1972), recent studies 
have suggested less use of PK for the treatment of keratoconus. In the United States, 
according to Eye Bank Association data from the year 1990-2004, there was a 
gradual increase in the use of PK for keratoconus and an overall decrease in the use 
of PK for all the other corneal diseases (Darlington, Adrean, & Schwab, 2006). In 
contrast, a recent study performed by Sarezky et al. (2017) found a drop in the rate 
of PK performed for keratoconus between the years 2001 and 2012, with a 
significant drop between the years of 2009 and 2012 (Sarezky, Orlin, Pan, & 
Vanderbeek, 2017). A study in which keratoconic patients were followed up for 48 
years, reported that less than 20 per cent of them required PK intervention (Gordon 
et al., 2006). Although this technique is less frequently used in many countries, it is 
considered the preferable method to treat advanced cases of keratoconus 
(Jabbehdari et al., 2017). Additionally, there are certain conditions which increase 
the likelihood of having the PK procedure performed on patients with keratoconus, 
such as the presence of corneal scarring, visual acuity worse than 6/12 (20/40) with 
contact lens correction, corneal keratometry steeper than 55D, development of 
keratoconus at an early age, corneal astigmatism > 10D, and poor contact lens 
tolerance (Gordon et al., 2006; Reeves, Stinnett, Adelman, & Afshari, 2005; Tuft, 





b) Deep anterior lamellar keratoplasty (DALK) 
  
Arthur von Hippel described the lamellar keratoplasty technique before PK, in 1888 
(Alió, 2017). However, this technique was abandoned for PK and was re-introduced 
in the 1940’s. The application of this technique for deep lamellar keratoplasty was 
introduced more recently. In one of the studies performed in the 1970’s, the DALK 
procedure had a good post-surgical outcome 80 per cent of the time (Gasset, 1979). 
This procedure can be broadly classified into two groups, Pre-Descemetic DALK 
where a small amount of posterior stroma (in the recipient) is left intact along with 
the Descemet’s membrane and endothelium, and Descemetic DALK in which  the 
entire anterior stroma of the recipient is removed leaving only the Descemet’s 
membrane and endothelium (Henein & Nanavaty, 2017). Once the stroma has been 
removed, it was replaced with healthy donor tissue.  
 
The dissection of corneal stroma is achieved using different techniques including: 
the bubble technique (Anwar & Teichmann, 2002; Smadja et al., 2012); using hydro-
dissection (Amayem, Hamdi, & Hamdi, 2013); visco-dissection (Melles, Remeijer, 
Geerards, & Beekhuis, 2000), manual dissection (Melles et al., 1999); and dissection 
using a Femtosecond laser (Baradaran-Rafii & Eslani, 2013). Although PK has been 
the ideal solution for the management of advanced keratoconus, DALK has gained 
popularity in the past 15 years due the supposed reduction of endothelial cell loss 
and fewer allogeneic endothelial rejections compared with a rapid decrease in 
donor corneal endothelial cell density after PK surgery (Vabres, Bosnjakowski, 
Bekri, Weber, & Pechereau, 2006; Watson, Ramsay, Dart, Bunce, & Craig, 2004). 
There are other advantages of DALK over PK surgery including: DALK is an 
extraocular procedure; less prolonged used of immune-suppressive treatments 
post-surgery; and the ability to remove sutures earlier than with PK surgery. Due 
to these advantages, there has been an increase in DALK procedures performed for 
keratoconus between 1996 and 2012 (Reinhart et al., 2011).  
 
c) Intracorneal ring segment (ICRS) 
  
This technique was initially used to correct early myopia in keratoconus and was 
described by Fleming et al. (Fleming et al., 1987). ICRS are implants that are 
introduced into the corneal stroma by creating an incision. The incision is generally 
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made either by a femtosecond laser or by a mechanical tunnelling technique, in the 
superficial part of the cornea (Bao, Geraghty, Wang, & Elsheikh, 2017). These ICRS 
are designed as a way to improve refractive outcomes through flattening the corneal 
curvatures while maintaining the optical zone (Assil, Barrett, Fouraker, & Schanzlin, 
1995; Nose, Neves, Burris, Schanzlin, & Belfort Junior, 1996). Later it was used as a 
treatment option for keratoconic patients suffering from severe forms of corneal 
astigmatism and patients who were intolerant to contact lenses (Rabinowitz, 2007). 
The first implantation of ICRS for keratoconus was performed in 1997 by Colin et 
al. (Colin, Cochener, Savary, & Malet, 2000) and since then many follow up studies 
have been performed to investigate the effectiveness of this technique in treating 
keratoconus (Colin, Cochener, Savary, Malet, & Holmes-Higgin, 2001; Kymionis, 
Siganos, et al., 2007).   
 
There are many controversies regarding when ICRS can be used in keratoconus 
(Wilde, Naylor, Varga, Morrell, & Ball, 2017). Some authors believe that this 
treatment option should be used only in severe forms of keratoconus as a last resort 
before a patient undergo corneal transplant (Gore, Shortt, & Allan, 2013). However, 
according to Wilde et al. (2017), the best results with this technique are achieved in 
mild cases of keratoconus while only 63.6 per cent of severe cases has a significant 
improvement in best-corrected distance visual acuity (BCVA) following the 
procedure (Wilde et al., 2017). Supporting these findings, Alfonso et al. (2011) and 
Miraftab et al. (2016), stated that the ICRS technique is an effective treatment option 
for mild to moderate cases of keratoconus (Alfonso, Lisa, Fernandez-Vega, Madrid-
Costa, & Montes-Mico, 2011; Miraftab, Hashemi, Hafezi, & Asgari, 2017) 
Furthermore, it is believed that the controversies regarding conflicting results of 
ICRS outcomes for different severities of the disease are mainly due to fundamental 
differences either in the type  of ICRS or in the manner in which the ICRS was 
implanted (mechanically or with the help of a femtosecond laser) (Wilde et al., 
2017).  
 
Some of the complications of this technique include: Epithelial defects at the 
keratotomy site; anterior and posterior perforations; uneven placement of the ICRS; 
introduction of epithelial cells into the corneal tunnel; stromal thinning; and corneal 
stromal oedema (Pinero et al., 2009). Sometimes, post-operative complications such 
as segment extrusion, corneal neovascularisation, corneal haze, segment migration, 
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corneal melting and infectious keratitis were also noted (Vega-Estrada & Alio, 2016). 
In some patients, white deposits around the segment and inside the channel were 
evident. However, these deposits do not interfere with the visual function 
(Ruckhofer, Twa, & Schanzlin, 2000). Unlike corneal crosslinking treatment which 
will be discussed later, ICRS does not stop the progression of keratoconus but rather 
delay the time for corneal transplantation (Jhanji, Sharma, & Vajpayee, 2011). 
Although some investigators believe that this technique could be used as a 
replacement for PK, still there are not enough data to support this idea (Siganos et 
al., 2003). 
 
d) Phakic intraocular lenses (PIOL) 
 
The use of PIOL for correction of astigmatism and spherical errors that occur in 
keratoconus has been reported in the literature (Budo, Bartels, & van Rij, 2005; 
Leccisotti, 2006). Sometimes, the implantation of intraocular lenses is performed in 
combination with another refractive surgery such as intracorneal rings or 
keratoplasty (Romero-Jiménez et al., 2010). Efficient and stable ametropia correction, 
preservation of accommodation, centred and rotational stability of the lenses not 
dependent on corneal morphology, retinal image magnification in patients 
suffering from high myopia and the ability to reverse the surgery in the event of 
failure, are some of the noted advantages of PIOLs. Some of the disadvantages of 
PIOLs include accelerated endothelial cell loss, cataract formation, pupil ovalization, 
lens rotation or decentration, and photic phenomena. In some isolated cases, the 
patient also had a retinal detachment (Díez, Estrada, & Alió, 2017).  
 
e) Corneal collagen crosslinking (CXL) 
 




In general, the term “crosslinking” is used to describe the process of formation of 
chemical bridges after chemical reactions between proteins and other molecules 
(Raiskup & Spoerl, 2013a). Improving the mechanical properties of a material with 
crosslinking is not novel in the biological sciences. Crosslinking can be initiated by 
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different factors, including chemical catalysts, heat, pressure, and radiation (beta 
and/or gamma) (Gehring, 2000). Dentists use ultraviolet light (UV)-mediated 
crosslinking to polymerise composite filling materials (Moszner et al., 2008; Ruyter, 
1988). In the polymer industry, UV light is widely used to cure adhesives by 
polymerisation (Hudis & Prescott, 1972; Moszner et al., 2008). Chemically mediated 
crosslinking of type I collagen with glutaraldehyde has been used to stabilise 
prosthetic heart valves (Dahl et al., 2012; Golomb et al., 1987). Crosslinking occurs 
naturally within corneas during the ageing process, after which the collagen fibrillar 
diameter increases by 4.5 per cent over a person’s lifetime due to age-related 
glycosylated crosslinking (Bailey, 1987; Daxer et al., 1998).   
 
Strengthening of corneal collagen by crosslinking was initially described in the 
1990s when researchers at the Technical University of Dresden, Germany, 
discovered that diabetic patients were rarely diagnosed with keratoconus due to a 
glycosylation-mediated crosslinking process that occurs within the corneal collagen 
fibres. They set about to develop a technique which induced similar crosslinking 
effects on keratoconic subjects (Dahl et al., 2012). After extensive investigations, 
corneal collagen crosslinking (CXL) with riboflavin and Ultraviolet A (UVA) light 
was introduced as an effective treatment mode for keratoconus (Spoerl et al., 1998; 
Wollensak, Spoerl, & Seiler, 2003a). It has recently been highlighted that CXL 
treatment with UVA and riboflavin is the only treatment that can halt the 
progression of keratoconus (Jouve et al., 2017; Labate et al., 2015). Abbondanza et 
al. (2017), reported that CXL treatment is now the “gold standard” procedure for 
the treatment of keratoconus (Abbondanza, Abbondanza, & Felice, 2017). 
According to global consensus for treatment of keratoconus and ectatic diseases, 
published in 2015, 83.3 per cent of ophthalmologists perform CXL as a treatment 
modality for keratoconus and the ophthalmologists who do not currently have 
access to this technique were willing to use it once it becomes available (Gomes et 
al., 2015). Although CXL is widely used in many countries, it has only gained 
traction  in the United States since about 2016 (Johnson & Harissi-Dagher, 2017).   
 
2.7.2 Development and principles of CXL 
 
The mechanical stability of the cornea is mainly associated with its collagen fibres 
and their orientation within the corneal stroma. It is believed that the mechanical 
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stability of cornea is affected mainly by its long collagen fibrils that extend from one 
limbus to the other. During the crosslinking process, the collagen fibrils are 
stabilised at the curved part of the cornea and prevented from sliding away from 
each other. However, the physiological characteristics of the degree of crosslinks 
had to be regulated closely for optimal results. If the degree of crosslinking is not 
controlled, pathological changes could occur. For example, in pathological 
conditions such as diabetes mellitus leads to an increase in protein glycosylation 
and formation of advanced glycosylation end products. These advanced 
glycosylation end products influence in changing the structure of the cornea by 
increasing the collagen crosslinks within the corneal stroma (Ramm, Herber, Spoerl, 
Pillunat, & Terai, 2019).  In physiological conditions, the collagen fibrils attain their 
natural strength, firmness and the elasticity due to the enzymatic crosslinking that 
happen with the help of enzyme lysyl oxidase.  It is known that this enzyme 
transforms the amino groups of certain amino acids into aldehyde groups, and that 
these aldehyde groups can function in one of the two ways: 
 1) The aldehyde groups can react spontaneously with their neighbouring aldehyde 
group in an aldol condensation reaction or; 
 2) The aldehyde group can react with amino groups of amino acids to form covalent, 
aldimine crosslinks (Cartwright, Tyrer, & Marshall, 2011; Elsheikh et al., 2007; 
Kagan & Trackman, 1991). 
 
There are several proposed mechanisms that seek to explain the development of 
keratoconus. One possible mechanism is the presence of lysyl oxidase gene defects 
in keratoconic patients (Bykhovskaya et al., 2012; Li et al., 2006), while another is 
that increased pH levels in the tear film, observed in keratoconic patients, may 
interfered with the lysyl oxidase activity in the cornea (Avetisov, Mamikonian, & 
Novikov, 2010). It has also been noted that in keloids and scars, the activity of lysyl 
oxidase is enhanced (Uzawa et al., 1998). Similar effects can be achieved using 
chemical agents such as riboflavin to achieve photo-oxidative crosslinking using 
ultraviolet (UVA).   
 
There are several reasons for choosing photo-oxidative CXL treatment for 
keratoconus. For instance, this procedure induces a localised effect on the treated 
area. The procedure allows for a short period of therapy which is sufficient to get 
an optimal result while the transparency of the cornea remains unaltered following 
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the treatment. Initially, Spoerl and Seiler (1999) suggested that  riboflavin and 
glutaraldehyde in low concentrations could be used to stabilise corneas during CXL 
treatment (Spoerl & Seiler, 1999). The following years with many investigations into 
this filed, the use of glutaraldehyde in the treatment of CXL was discontinued due 
to a high incidence of corneal scarring and haze formation. Furthermore, several 
identified technical drawbacks such as prolonged treatment time and some 
application problems made glutaraldehyde use to fall out of favour (Wollensak et 
al., 2003b). Consequently, riboflavin is commonly being used as the photosensitiser 
in the CXL treatment for keratoconus.  
 
Riboflavin (vitamin B12) is used as a special photosensitiser – that is, to increase the 
effectiveness of the photochemical reaction with UVA. Riboflavin is a non-toxic 
material, which is commonly used in food industries, and it is also bioavailable as 
a medication. The CXL treatment with riboflavin and UVA is a complex 
photochemical process that consists of an aerobic phase (Type II photochemical 
kinetic mechanism) and an anaerobic phase (Type I photochemical kinetic 
mechanism). During the aerobic phase, riboflavin molecules absorb UVA and get 
excited to form an excited singlet (excited singlet riboflavin, lifetime 10-8) or reactive 
triplet riboflavin state (lifetime 10-2). The excited triplet riboflavin interacts with the 
triplet oxygen species in the atmosphere to form active singlet oxygen. These singlet 
oxygens interact with carbonyl groups of collagens to form crosslinks (Figure 2.5). 
During the anaerobic phase, oxygen depletion cause triplet riboflavin to form 
riboflavin radicals that interact with corneal stroma creating crosslinks between 
collagen molecules (Figure 2.5) (Huang, Choe, & Min, 2004; Malik et al., 1992; 
Kamaev, Friedman, Sherr, & Muller, 2012). 
 
This complex photochemical process ultimately results in creating covalent 
connections between the amino acids such as histidine, hydroxyproline, 
hydroxylysine, tyrosine and threonine, thus creating so- called cross linkages. Intra- 
and inter-molecular linkages between collagen and tyrosine-derived dityrisine has 
also been reported in the literature (Balasubramanian & Kanwar, 2002; Kato, Uchida, 
& Kawakishi, 1994; Marcovich et al., 2012; McCall et al., 2010). Zhang et al. (2001), 
stated that the UVA/riboflavin crosslinking technique forms crosslinks between 
proteoglycan core proteins and thus it does not increase bonds between collagen 
lamellae. However, the possibility of the interfibrillar bond has been discussed 
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(Wollensak, Spörl, Mazzotta, Kalinski, & Sel, 2011; Y. Zhang, Conrad, & Conrad, 
2011).   
 
The first law of photochemistry states that light must be absorbed by a substance in 
order for a photochemical reaction to occur (Raiskup & Spoerl, 2013a). Therefore, in 
CXL treatment, the crosslinking effect is confined to the anterior region of the 
corneal stroma where the majority of UV light is absorbed. Over recent years, 
several UV delivery systems have been introduced into clinical practice with 
wavelengths varying from 360-430nm. However, it was evident that the wavelength 
of 365nm achieved a more significant CXL effect due to its high-energy content 
along with a high potency to absorb riboflavin into the corneal stroma. It was 
evident that this specific wavelength was able to attain 90 per cent absorption of UV 
light in 400µm thick de-epithelialised corneas (Raiskup & E. Spoerl, 2013a). Most of 
the existing UV radiation systems consist of UV emission diodes that produce a 
homogeneous irradiation strength of 3mW/cm2 for an 8mm diameter on the corneal 
tissue. The effect of which was only confined to the central cornea. A fixed diameter 
was used for the radiation diode to prevent the possibility of limbus, corneas and 
goblet cells being exposed to radiation. However, at present varying number of 
diodes, focusing systems, working distances, beam diameters and beam 
uniformities are been used to treat keratoconus using CXL treatment (Raiskup & 





Figure 2.5 – Mechanism of formation of crosslinks in crosslinking treatment with 
riboflavin and UVA 
Aerobic and anaerobic pathways of formation of crosslinks within collagen fibres 
following crosslinking treatment 
(Subasinghe, S.K., Ogbuehi, K.C., Dias, G.J. (2018). Current perspectives on corneal collagen crosslinking 





A study to characterise UVA crosslinked collagen hydrogels, suggested that the 
optimal UVA exposure time to increase the elastic modulus of the hydrogel was 
between 30-45 minutes. The majority of crosslinking occurs within the first 30-45 
minutes with no further crosslinking taking place beyond 45 minutes. A statistically 
significant increase was also evident after 15 minutes of UV exposure. However, 
there was no further stiffening effect even after 60 minutes of exposure to UVA 
(Ahearne, Yang, Then, & Liu, 2008; Lanchares, Buey, Cristóbal, Lavilla, & Calvo, 
2011). Moreover, when CXL treatment was performed repetitively for several days, 
there was no additive effect on corneal stiffness (Tabibian, Kling, Hammer, Richoz, 
& Hafezi, 2017). Another study illustrated the dependence of increases in corneal 
stiffness, on illumination intensity while keeping a constant irradiation dose 
5.4J/cm2 with an exposure time of two minutes (Wernli, Schumacher, Spoerl, & 
Mrochen, 2013).  
 
The maintenance of the concentration of riboflavin is a vital component to obtain 
optimal crosslinking. Initiation of the chemical reaction by the UVA 
(photopolymerisation, which is discussed earlier) occurred only where riboflavin is 
activated by UV light. However, it seemed that the concentration of riboflavin not 
only absorb UVA to promote photochemical crosslinking reaction, but it absorbs 
most of the UVA to prevent it from reaching the deeper layers of the stroma and 
beyond where it might cause damage to the endothelium and other intraocular 
structures (Huang et al., 2004). In contrast, inadequate riboflavin exposure will fail 
to generate sufficient crosslinks to provide the needed therapeutic effect (Snibson, 
2010b). Sufficient concentration of riboflavin in the cornea is attained using different 
methods;  
1) Standard method (diffusion in the de-epithelialised cornea); 
2) Transepithelial method (diffusion, through an intact epithelium, into the stroma); 
3) Direct introduction of riboflavin into the stroma (pocket technique, ring 
technique, needle technique); 
4) Iontophoresis (enhance riboflavin penetration using a small electric current). 
 
In some studies, chemicals such as benzalkonium chloride, gentamicin and 
ethylenediaminetetraacetic acid (EDTA) were added to the riboflavin solution to 
increase its penetration through corneal tight junctions (Acar, Utine, Ozturk, Acar, 
& Ciftci, 2014; Cha, Lee, Oum, & Kim, 2004; Chang, Chi, Wu, & Su, 2000; Saettone, 
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Chetoni, Cerbai, Mazzanti, & Braghiroli, 1996). In the pocket and ring technique, the 
riboflavin solution is applied directly into cornea by making a pocket in the stroma 
(Daxer, Mahmoud, & Venkateswaran, 2010). This method can be used in the 
implantation of intracorneal rings where the canal is filled with riboflavin and 
followed by CXL treatment (Coskunseven et al., 2009; Ertan, Karacal, & 
Kamburoglu, 2009). More recently, the delivery of riboflavin through a whole 
micro-needle array which is inserted through the epithelium into anterior stroma 
has been described. However, its application in current clinical practise needs 
further investigation (Daugimont et al., 2010). Iontophoresis is a technique used to 
increase riboflavin penetration without making any changes, or causing any 
damage, to the epithelium in which a weak electric current is used to enhance 
riboflavin absorption into the corneal stroma. Another added benefit of this 
technique is the shorter pre-treatment time compared to other crosslinking 
techniques (Vinciguerra, Spoerl, Romano, Rosetta, & Vinciguerra, 2012).   
 
In current practice 0.1 per cent riboflavin is used for CXL treatment of corneas with 
a minimum corneal thickness of 400µm (Wollensak et al., 2003a). A study to 
examine the distribution of different concentrations of riboflavin on human and 
porcine corneas reported that absorbed riboflavin is primarily located in the 
anterior 200µm of stroma in both humans and pig corneas with human corneas 
having a higher riboflavin uptake than porcine corneas (Søndergaard, Hjortdal, 
Breitenbach, & Ivarsen, 2010; Spörl, Schreiber, Hellmund, Seiler, & Knuschke, 2000). 
A concentration of 1 per cent seems to be the most effective concentration to 
produce a large absorption coefficient (Iseli, Popp, Seiler, Spoerl, & Mrochen, 2011; 
Spörl et al., 2000; Wollensak, Aurich, Wirbelauer, & Sel, 2010) which in turn allows 
90 per cent of UV radiation to absorbed by the stroma (for the maximum treatment 
effect) while preventing significant amount of UV radiation from reaching the 
corneal endothelium, crystalline lens, and retina.   
 
 2.7.3 Indications for CXL   
 
There are no strict indications to implement CXL treatment in current practice. The 
decision depends on the severity of the disease, physician preferences, patients’ 
wishes and available resources. In general, CXL treatment can be recommended for 
patients with a mild to moderate disease (Raiskup & Spoerl, 2013b). When assessing 
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the progression of the disease, changes in the refraction, uncorrected visual acuity 
(UCVA), best-corrected visual acuity (BCVA), and topographical parameters are 
considered. However, when analysing a patient with keratoconus the parameters 
of progression vary between studies.  For instance, in one study, an increase in 
Kmax (steepest keratometry) at the apex of keratoconus of one diopter (D) in one 
year, deterioration of visual acuity or change of contact lenses more than once 
within two years were considered as parameters that determined significant 
progression of keratoconus (Raiskup-Wolf, Hoyer, Spoerl, & Pillunat, 2008). 
Another study used  mean central K-reading increase of more than 1.5D on three 
consecutive topographies within six months period or, a mean central corneal 
thickness (CCT) decrease of >5 per cent on three consecutive topographies 
performed within 6 months as indices of significant progression (Hersh, Greenstein, 
& Fry, 2011). Johnson and Harrissi-Dagher suggested that it was also reasonable to 
carry out CXL treatment in young patients (less than 20 years) without any 




The CXL procedure is relatively contraindicated in patients with prior hepatic 
infections, severe corneal scarring, a history of poor wound-healing, patients 
suffering from systemic collagen vascular diseases and immune disorders 
(Mastropasqua, 2015). These conditions should be addressed case by case 
depending on personal preference. For instance,	In a patient with severe corneal 
scarring even after preforming CXL there will not be much improvement in the 
vision due to prior existing corneal scaring. Patients with subclinical infective 
process like in hepatic infections leads to prolonged healing process and prolonged 
epithelialisation. These patients seems to have high risk of procedure failure 
(Raiskup and Spoerl, 2013). Furthermore, patients with prior incisional refractive 
surgeries, such as radical keratotomy or astigmatic keratotomy are contraindicated. 
This is because changes to the cornea that occur after CXL treatment can cause 
keratotomy incisions to rupture (Abad & Panesso, 2008). The conditions that might 
affect the re-epithelialisation of the cornea, including central corneal opacities and 
severe dry eyes are also considered contraindicated (Spoerl, Mrochen, Sliney, 
Trokel, & Seiler, 2007). Pregnant and breastfeeding women are advised to avoid 
CXL treatment to avoid postoperative complications such as infections and melting 
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of the cornea. Despite initial CXL treatment, pregnant women experienced a high 
incidence of progression of the diseases in subsequent pregnancies due to hormonal 
changes that occur during the pregnancy (Hafezi & Iseli, 2008). To undergo CXL 
treatment, the person should have a minimum corneal thickness of 400µm, which 
reduces the risk of endothelial damage during the procedure. However, more recent 
investigations have introduced the use of hypo-osmolar riboflavin for thinner 
corneas. The hypo-osmolar riboflavin induces corneal swelling that prevents the 
toxic effect of photosensitisation of the endothelium (Hafezi, Mrochen, Iseli, & Seiler, 
2009). Another study suggested the use of lower irradiation doses that correspond 
to the thickness of the cornea as a means of minimising the effects of UV light on 




Debridement of the corneal epithelium theoretically exposes the cornea to infective 
organisms, and ultimately resulting in postoperative infections or ulcer formation. 
In a case study reported by Pollhammer and Cursiefen (2009), E. coli infection was 
noted in a patient after three days of CXL treatment (Pollhammer & Cursiefen, 2009). 
The reactivation of herpes simplex virus (HSV) due to stress, trauma, and laser 
surgery has been recorded in the past (Hou, Chen, Wang, & Hu, 2004). Kymionis et 
al. (2007) documented a case in which a reactivated HSV infection followed CXL 
treatment resulting in herpes keratitis and iritis. Therefore, it was apparent that 
UVA light could be a potent stimulus to trigger or induce reactivation of latent HSV 
infection, even in a patient with no clinical history of HSV ocular infections 
(Kymionis, Siganos, et al., 2007). Kymionis et al. (2007) also reported a case where 
diffuse lamellar keratitis was observed following CXL in a patient with post-
laser in-situ keratomileuses corneal ectasia (Kymionis, Bouzoukis, et al., 2007). By 
contrast, in a case report by Igal et al. (2017), CXL treatment was used successfully 
to treat a patient with fungal keratitis with abscess. This technique was used as a 
means of preventing corneal melting due to fungal keratitis (Igal, Pikkel Igal, & 
Pikkel, 2017). 
 
Corneal haze is another complication observed following the CXL procedure. The 
exact mechanism of development of corneal haze is not clearly understood (Kim, 
Jordan, McGhee, & Patel, 2016), and is  thought to be associated with loss of 
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keratocytes and increase in extracellular spaces (Adel & Pei-Rong, 2015; Greenstein, 
Shah, Fry, & Hersh, 2011). There is an association between cytokines (Kuo, Lee, & 
Hwang, 2004,) and alterations in the collagen fibre arrangements, with the 
formation of corneal haze (Greenstein et al., 2011). Höllhumer et al. (2017) identified 
a connection between the development of corneal haze and the combination of 
riboflavin and dextran solution used for the CXL treatment (Höllhumer, Watson, & 
Beckingsale, 2017). However, the corneal haze that occurs following CXL treatment 
appears to be a temporary process that can be resolved within several months with 
the administration of corticosteroid therapy (Herrmann, Hammer, & Duncker, 
2008). Corneal haze was also noted in CXL postoperative patients who suffered 
from advanced stages of keratoconus without significant visual impairment 
(Mazzotta, Balestrazzi, Baiocchi, Traversi, & Caporossi, 2007). It was evident that in 
advanced stages of keratoconus with low corneal thickness and high corneal 
curvatures, there is a high risk of developing permanent corneal haze and scar 
formation (Raiskup, Hoyer, & Spoerl, 2009).      
 
Another complication of CXL treatment is endothelial cell density loss, which was 
commonly noted in thin corneas. In a study by Kymionis et al. (2012), the 
cytotoxicity of the photosensitisers using in CXL treatment has induced a toxic effect 
on the endothelium leading to endothelial cell density loss in patients with thin 
corneas (Kymionis et al., 2012). Another study stated that the endothelial thickness 
decreased temporarily before stabilising 12 months after  CXL treatment (X. Zhang 
et al., 2016). There are cases of the endothelial and limbal cell damage associated 
with CXL treatment. This can be caused by exposure to UV radiation, or it may be 
due to free radical formation during the crosslinking process (Abad & Panesso, 
2008; Snibson, 2010a). Several studies described incidences of corneal melting 
following the corneal CXL procedure (Chiu, Sade, & Chew, 2017). Impairment of 
wound healing, a neurotrophic effect resulting from the analgesic properties of the 
drugs used after the CXL treatment (diclofenac sodium and proparacaine), and the 
activation of matrix metalloproteinases, are the suggested mechanisms for the 
development of corneal melt following CXL treatment (Gokhale & Vemuganti, 
2010). Apart from these complications, cases of sterile infiltrates (Angunawela, 
Arnalich-Montiel, & Allan, 2009; Çerman, Özcan, & Toker, 2016; Mangioris et al., 
2010) and recurrent corneal erosions syndrome (Romppainen et al., 2007) were also 
identified. 
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2.7.6 Popular surgical techniques used for CXL 
 
Conventional Dresden Crosslinking(C-CXL) technique is the commonest 
crosslinking technique used in current practice. Since its introduction, several other 
methods have been developed in the past decade to treat keratoconus. The corneal 
epithelium-off accelerated corneal crosslinking, corneal epithelium–on/ 
transepithelial techniques using chemical enhancers, and iontophoresis 
crosslinking techniques are some of the commonly used and currently investigated 
procedures in clinical practice.   
 
The present project investigates the effects of using C-CXL treatment and therefore, 
in the following sections, we will be describing the laboratory and clinical studies 
performed to investigate the effects of C-CXL treatment in detail, followed by 
general description of other commonly used methods of CXL treatment.    
   
A) Conventional Dresden protocol (C-CXL) 
 
The Dresden protocol was introduced by Wollensak et al. in 2003 as a treatment 
option for keratoconus (Wollensak et al., 2003a). The technique involves the 
removal of corneal epithelium followed by application of riboflavin solution (0.1 
per cent riboflavin in 20 per cent dextran solution) to the de-epithelialised cornea 30 
minutes before the cornea is irradiated with UVA. Then the cornea is UVA 
irradiated (wavelength -370nm and power – 3mW/cm2 or 5.4J/cm2) for another 30 
minutes (Wollensak et al., 2003a). The riboflavin solution is applied every three to 
five minutes during the irradiation process. Usually, an 8 mm area of the central 
cornea is irradiated. Currently, this technique is considered as the standard 
treatment to stop the progression of keratoconus in adults and is frequently used in 
an outpatient setting, (Padmanabhan et al., 2016). The corneal epithelium is 
removed prior CXL treatment to ensure adequate penetration of riboflavin into the 
stroma (Samaras et al., 20009; Mooren et al., 2016). The riboflavin facilitates 
absorption of UVA and also prevents UVA damage to the endothelium (Wollensak 
et al., 2010). The area of the epithelial removal may vary from 5mm to 9mm in 
diameter (Arbelaez et al., 2009; Uçakhan et al., 2017; Wollensak et al., 2004). The 
corneal epithelium can be removed manually using a self-constructed triple-blade 
scalpel (Leccisotti & Islam, 2010), blunt hockey knife (Wollensak et al., 2004), blunt 
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spatula (Caporossi et al., 2006) or by simply wiping off the epithelium with or 
without the use of alcohol (Choi et al., 2017) or using a 213-nm solid-state laser 
system (Kymionis et al., 2010). The effectiveness of C-CXL treatment in halting the 
progression of keratoconus has been investigated in both laboratory, and in clinical 
settings, and the key findings of these studies are summarised in Table 2 and Table 
3.   
a) Laboratory studies 
 
Parameters: Spoerl et al. (1998) first described crosslinking of the cornea using 
ultraviolet light with a wavelength of 254 nm and 0.5 per cent riboflavin in 20 per 
cent dextran (Spoerl et al., 1998). Several laboratory studies have since tried to prove 
the effectiveness of the CXL as a treatment option for keratoconus. When evaluating 
the effectiveness of this technique, the parameters of the C-CXL protocol need to be 
maintained throughout. For instance, an increase in the exposure time of UVA light 
has led to structural weakness in the porcine cornea. The resultant weakness was 
believed to be due to either the destruction of collagen crosslinks or due to tissue 
damage caused by excessively long UVA exposure (Lanchares, Buey, Cristobal, 
Lavilla & Calvo, 2011). Wernli et al. (2013) indicated that UVA intensity of 40 to 45 
mW/cm2 could be used to achieve increase corneal stiffness in porcine corneas 
when applied for two minutes (Wernli, Schumacher, Sporel & Mrochen, 2013). 
However, no significant increase in corneal stiffness could be achieved when the 
intensity was increased to a range of 50 to 90 mW/cm2 (Wernli et al., 2015). The 
osmolality of the riboflavin solution is another factor to be considered for optimal 
results. For example, a decrease in the corneal thickness by 54 per cent of its original 
thickness due to hyperosmolality of the riboflavin solution was reported in the 
literature (Kling, Remon, Pérez-Escudero, Merayo-Lloves, & Marcos, 2010). In 
contrast, hypo-osmolar riboflavin solutions are used in current practice to increase 
the thickness of thin corneas before CXL treatment (Hafezi, Mrochen, Iseli, Seiler, 
2009). The degree of the riboflavin penetration, into the stroma, controls the extent 
of the crosslinking effect by confining the energy of the UVA light to the riboflavin 
absorbed areas of the cornea. However, it was also noted that the concentration and 
changes in exposure time of the riboflavin had minimal effect on the penetration 
quality of the riboflavin solution in porcine, rabbit and human corneas (Wollensak 
et al. 2004; Søndergaard et al. 2010).   
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Stiffening effect: Many biomechanical studies have proven the stiffening effect of C-
CXL treatment and the factors contributing to it (Seifert et al., 2014; Dias et al., 2013). 
Most biomechanical studies that investigated the stiffening effect of C-CXL 
treatment were performed on porcine models (Matteoli, Virga, Paladini, Mencucci 
& Corvi, 2016; Scarcelli, Kling, Quijano, Pineda, Marcos, & Yun, 2013; Seiler et al., 
2014). A few studies have been conducted on bovine, (Hatami-Marbini & Rahimi, 
2015) rabbit, (Wollensak et al., 2009) and human corneas (Kohlhaas et al., 2006). The 
C-CXL effect is more pronounced at the anterior half of the corneal stroma while it 
gradually decreases towards the posterior surface (Beshtawi et al., 2016; Kohlhaas 
et al., 2006; Matteoli et al., 2016;  Scarcelli et al., 2013). More precisely, the crosslinks 
are more confined to the anterior 242 µm of the cornea with the next 107 µm 
(intermediate zone/ region) with a smaller degree of crosslinking in bovine cornea 
(Wollensak et al., 2007). The difference in the degree of crosslinking is caused by the 
rapid loss of UVA irradiance across the cornea due to riboflavin-enhanced UVA 
absorption. Tabibian et al. (2017) stated that the repeated crosslinking of the same 
cornea within a short time does not provide any additional biomechanical stiffness 
(cumulative stiffening effect) on the treated mouse cornea (Tabibian et al., 2017) . 
Another study described a decrease in the viscosity along with an increase in 
elasticity in the human anterior stroma at a nano-particle level(Labate et al., 2015). 
The stiffening effect following CXL treatment and its association with the hydration 
properties of the cornea were investigated in bovine models. It is evident from these 
studies that when the corneal hydration decreases, there is a high possibility of an 
increase in Young’s modulus (YM) - an increase in the stiffening effect (Hatami-
Marbini et al., 2016; Hatami-Marbini et al.,2015). The degree of the corneal stiffening 
effect varies in different species with porcine corneas having a 30 per cent increase 
in stiffening and human corneas having a 3.9 per cent increase in stiffening (Seifert 
et al., 2014; Tabibian et al., 2017). Additionally, across the entire depth of the cornea, 
a mean stiffening factor of 1.7 (Seifert et al., 2014) and 1.8 (Seifert et al., 2014; 
Wollensak & Iomdina, 2009) was documented in porcine models. The mean 
stiffening factor is determined by the division of YM of each sample in the region of 
interest by the YM of the posterior 100 µm of the cornea. Increase of YM by 78.4-
87.3 per cent in rabbits (Wollensal et al., 2009) and by 42 per cent in the human 
cornea (Matteoli et al., 2016) has also been reported. 
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Collagen fibrils: C-CXL treatment results in increased diameter of the crosslinked 
type I CFs Akhtar et al., 2013). A pronounced increase in the anterior stromal CF 
diameter was evident when compared to posterior stromal CFs. For instance, 
studies conducted on rabbit corneas have shown a 12.2 per cent (3.96nm) increment 
in corneal CF diameter in the anterior corneal stroma and 4.6 per cent (1.63nm) 
increment in the posterior corneal stroma. The average increase in diameter was 9.3 
per cent (3.1nm) (Wollensak et al., 2004). Furthermore, a 103 per cent increase in CF 
diameter and a 107 per cent increase in the corneal thickness following CXL 
treatment in human corneas in the ex-vivo model was also noted (Choi et al., 2013). 
Increase in fibrillary diameter has been illustrated in both human (Akhtar, 
Almubrad, Paladini, & Mencucci, 2013) and rabbit (Wollensak et al., 2004) corneas, 
although there have been no studies to date on the effect of C-CXL on CF diameter 
in porcine corneas. Crosslinking of corneal CFs at an intra-fibrillary and inter-
fibrillary level has been reported by Wollensak and Redl in 2008 in a pig eye. 
However, it was quoted that in this study, no crosslinking was evident in between 
the adjacent collagen lamellae (Wollensak et al., 2008). According to the study by 
Akhtar et al. (2013), the mean diameter of a normal CF of human was 23.8 ±4.5nm 
while in keratoconic corneas’ mean diameter was 21.3 ±2.5nm. Following 
crosslinking treatment the diameter was increased to 22.4 ±3.1nm. Therefore, it was 
evident that the corneal CF diameter becomes almost similar to normal diameter 
following crosslinking treatment in keratoconic subjects (Akhtar et al., 2013). In 
contrast, another study has suggested that no direct inter-fibrillary crosslinking 
takes place following CXL treatment on porcine, sheep and rabbit corneas (Hayes 
et al., 2013). Some studies suggest that the crosslinking effects are not limited to 
collagen molecules but also affect the protein network surrounding the collagen 
(Hayes et al., 2013; Bottós et al., 2008). Thus, it is evident that the C-CXL treatment 
results in increased stromal CF diameter of the crosslinked corneas with visible 
intra-fibrillary crosslinks. However, the presence of interfibrillar crosslinks and 
crosslinking within the adjacent lamellae needs to be investigated further.   
 
Keratocytes: Research has shown that immediately following CXL treatment, there 
is marked damage to the corneal keratocytes - cell shrinkage, chromatin 
condensation and apoptotic bodies in the anterior and the intermediate zone of the 
corneal stroma, reaching a corneal tissue depth of 250-300µm (Mencucci et al., 2010; 
Dhaliwal et al., 2009). However, after the initial keratocyte apoptosis, within the 
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next few months following the treatment, the keratocytes are gradually repopulated 
(Mazzotta et al., 2007). In rabbit corneas, the initial apoptosis was completed by 
three days, and gradual repopulation of keratocytes could be observed from day 7, 
reaching completion by six weeks post-treatment. While in human corneas, 
keratocytes repopulation was complete by six months of post-CXL treatment 
(Mencucci et al., 2010; Wollensak et al., 2007). This highlights the fact that the 
crosslinking procedure can stimulate a distinct biological response that can induce 
both apoptosis and cell proliferation. The degree of keratocyte apoptosis depends 
on the radiation dose used for the crosslinking procedure. For instance, it was stated 
that cytotoxic levels of UVA irradiance for keratocytes could be achieved at an 
irradiation dose of 0.5-0.7mW/cm2 in a rabbit model in vivo (Wollensak et al., 2004).  
 
Enzymatic degradation of collagen: Collagen degradation due to the action of 
enzymes (human trypsin-2, cathepsin K) within the tear film contributes to the 
thinning effect of the cornea in keratoconus (Mackiewicz et al., 2006) . The corneas 
treated with CXL treatment have a higher resistance to enzymatic digestion, which 
in turn results in lengthening of the turnover time of collagen fibres (Schilde et al., 
2005; Spoerl et al., 2004).  
 
In general, there are limited laboratory studies on the ultrastructural alterations of 
the crosslinked corneas with a majority of studies focusing on the biomechanical 
properties following C-CXL treatment. This highlights the importance of detailed 
investigation into the fine morphological changes that occur following CXL, to 







Table 2 - Laboratory studies on Conventional Crosslinking treatment 
 
CXL- Crosslinking, YM- Young’s modulus, OCT- Optical coherence tomography, SAM – Scanning acoustic microscopy, AFM- Atomic force 
microscopy, TEM – Transmission electron microscopy, UVA – Ultraviolet A, PG- Proteoglycan, CFs – Collagen fibrils, CF- Collagen fibril, BM- 
Basement membrane, H&E – Haematoxylin and eosin, PAS – Periodic Acid-Schiff, NZ – New Zealand, IOP – Intraocular pressure, TUNEL – 
TdT-mediated dUTP Nick-End Labeling, AS- Anterior corneal stroma, PS- Posterior corneal stroma, MSF – Mean stiffening factor, MSE- Mean 

























ex vivo Bovine 
 
25 Post CXL - Increase equilibrium stress, maximum stress, and tangent 
modulus (p < 0.01). 
Increasing the hydration – decrease in equilibrium stress, maximum 
stress, and tangent modulus (p < 0.01)  
 




ex vivo Porcine 24 Reduction of CT (34%) immediately after CXL treatment  





SAM ex vivo Human 6 Speed of sound measurement increase (square foot of thickness) by a 
factor of 1.039× in CXL cornea  
AS and PS increased by factor of 1.019x 
 
(Labate et al., 
2015) 
AFM ex vivo Human 7  YM increased at AS (1.1-1.5x), Mean hysteresis decrease- 0.9x- 1.5x  
(Seifert et al., 
2014) 
AFM ex vivo Porcine 16  YM maximum at the corneal surface and decreased within next 
200µm 
Maximum CS higher (p<0.01) than posterior 100µm  
MSF at the corneal surface 8.1, MSE - 1.7x 
 






ex vivo Porcine 
Sheep 
Rabbit 
117  CT decrease after riboflavin application and UVA exposure 
CXL treatment induces cross-links within collagen molecules and/or 
between collagen fibrils and the proteoglycan 
CXL do not effect on hydrodynamic behaviour of cornea 
CXL increase enzymatic digestion 
 
(Dias et al., 
2013) 
AFM ex vivo Human 24  CXL increase AS stiffness 1.9 times than the control corneas 
PS not significantly affected    
 
Akhtar et al. 
(2013) 
TEM 
in vivo Human  9 Diameter of CXL treated corneas increased  
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CXL treatment has no effect on hemidesmosomes, BM, Bowman's 
layers                                                                                                                         
CFs diameter smaller than normal but larger than KC                 
Interfibrillar distance increased 





testing / Uniaxila 
tensile testing 
ex vivo Porcine 17  30-min UVA CXL with riboflavin increased stiffness  









ex vivo Porcine 72 CXL mainly occur at intra- and interfibrillar CF, Absent interlamellar 
CXL 
Crosslinking effect on interlamellar cohesion, upheld by interlacing 
collagen lamellae and PG 






ex vivo Porcine  38  Immediate decrease in CT following riboflavin installation 
CXL effective in preventing an increase in anterior corneal radius in 
the horizontal than in the vertical meridian  
1.54 reduction in corneal thinning, 2.8 reduction in corneal apical 
rise,  











in vivo Human 15  CXL stimulates keratocyte apoptosis and repopulation  
CF diameter increased by 22.6% compared to control, 16.1% 




testing in vivo Rabbits 9 
Increase YM by 78.4-87.4%, ultimate stress by 69.7-106.0%  












Human  5 
Keratocyte apoptotic changes a depth of 300#m with demarcation 
line 
Spherical structures evident until the depth of 300#m 
 





ex vivo Porcine 25 Maximum CXL of CF in anterior stroma 
CXL effect is more in de-epithelialized than corneas with epithelium 
intact 




Pepsin Extraction of 
Collagen type I ex vivo Porcine 40 
CFs has a very strong chemical stability following CXL treatment 














ex vivo Porcine 25  Swelling pattern – intense in AS (242µm), for next 238 µm (hydration 
factor 2.2), non-crosslinked posterior 135 µm (hydration factor 2.7) 
Sensitivity of swelling response is in relation with degree of CXL  











Significant stiffening in AS (200#m). 75-70% of UVA irradiation 









ex vivo Porcine 20  Resistance to enzymatic digestion is high in CXL corneas  
CXL of the CFs extends pass the first anterior 200µm to next 200µm 
of cornea     
65% of riboflavin absorbed in anterior 200µm and 25-30% absorbed 









ex vivo Porcine 30 Shrinkage temperature – AS (75 ±1.2 °C) than PS (70±0.8C)  
(Wollensak, 
Spoerl, Wilsch, 








38 Keratocyte apoptosis present at anterior 50µm 4 hours post treatment 
Cytotoxic UVA irradiation range from 0.5-0.7mW/cm2 
 
(Wollensak, 










CF diameter increased 12.2% (3.96 nm) in AS and 4.6% (1.63nm) in PS   








ex vivo Porcine 80 CXL treatment significantly increases resistance to collagenase, 











Increased in YM by factor 1.8 in porcine and 4.5 in human corneas 
Mean CT - 850#m ± 70 (SD) in porcine, 550 ± 40#m in human corneas 






b) Clinical studies 
 
Wollensak et al. (2003a) performed the first clinical study of C-CXL in 2003 
(Wollensak et al., 2003a). Subsequently, many clinical studies have been 
performed to investigate the effectiveness of this technique and the summary 
of the results from studies carried out between 2010 and 2017 are depicted in 
Table 2. The effectiveness of the C-CXL technique in halting the progression of 
keratoconus has been discussed in literature through both prospective and 
retrospective studies (Giacomin et al., 2016; Poli et al., 2015; Rechichi et al., 
2013) . Most of these published clinical studies introduce C-CXL treatment as 
an effective mode of halting the progression of keratoconus with only a few 
subjects requiring a second treatment (2 patients out of 241 eyes) (Raiskup-Wolf 
et al., 2008).   
 
In recent years many studies have investigated the effects of CLX treatment for 
long periods.  According to FDA approval, crosslinking treatment seems to be 
initially worsening the BSCVA, pachymetry, and keratometry values. However, 
after 24 months post treatment improvements in Kmax values and stability in 
the visual acuity were observed (Ansah et al., 2020). Similar results were also 
observed by Abbondanza et al., 2019 in a 5 year follow-up study (Abbondanza 
et al., 2019). In addition, improvement in Uncorrected visual acuity and 
corrected visual acuity and KC stability was maintained for 10 years post CXL 
treatment in  paediatric patients. (Mazzotta et al., 2018). It was also noted that 
the outcome of the KC following CXL treatment is associated with blood group, 
rubbing of eyes, place of birth, corneal asphericity (Peyman et al., 2020). When 
compared to A-CXL C-CXL seem to be more effective in offering better anterior 
corneal flattening in the centre and periphery of the cornea after 4 years post 
CXL treatment (Hashemi et al., 2020). According to Grišević et al., 2020, corneal 
CXL should be considered as a procedure not just for corneal stiffening and 
stabilization, but also for visual acuity improvement in keratoconus 
patients(Grišević et al., 2020). 
 
Corneal responses to crosslinking; C-CXL improves corneal curvature 
parameters such as keratometric values along with visual and topographic 
parameters (Braun, Kanellopoulos & Jankov, 2005; O'Brart et al., 2013; O'Brart 
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et al., 2011; Sedaghat et al., 2015). The extent of visual acuity improvement 
following CXL treatment is directly correlated with the stabilization of the 
topographic parameters of the cornea (Ghanem et al., 2016). It was apparent 
that the C-CXL technique resulted in improving uncorrected distance visual 
acuity (UCDVA) and best-corrected visual acuity (BCVA) in keratoconic eyes 
without causing any changes to the anterior chamber volume (ACV), corneal 
volume (CV) and anterior chamber depth (ACD) (Caporossi et al., 2010; De 
Bernardo et al., 2015; Sedaghat et al., 2015). There have been some cases in 
which a slight decrease in UCDVA and BCVA was noted 4-5 years of post-CXL 
treatment (Khan et al., 2015; Heshemin et al., 2013). In some cases, 
improvements in visual acuity were observed without any associated change 
in keratometry values. In most of these cases, the visual acuity was improved 
due to a reduction of irregular astigmatism (Vinciguerra et al., 2009; Agrawal 
et al., 2009).  
 
When evaluating the anterior corneal elevation changes with the Orbscan II, it 
is apparent that the changes in the collagen distribution influenced the shape 
of the cornea following CXL treatment (Tu & Aslanides, 2009). Following C-
CXL treatment, different degrees of improvement in keratometric values 
(including steepest keratometry values - Kmax) have been recorded. Decreases 
in Kmax by -2.24D (Lang et al., 2015), -2.57D (Kosekahya et al., 2017), -2D 
(Kymionis et al., 2013) -1.16D (Parissi et al., 2016), -1.68D (Kumar, Kodavoor, 
Arsiwala & Ramamurthy, 2014), -0.74D (Steinberg et al., 2014) have been 
reported in the literature. The improvements of Kmax were not associated with 
the age or gender of the patients (Steinberg et al., 2014). A clinical study to 
evaluate biomechanical corneal properties (such as corneal hysteresis - CH and 
corneal resistance factor - CRF), before and after CXL, revealed no significant 
changes (Sedaghat et al., 2014). The absence of significant changes in CH and 
CRF was also noted in other studies conducted six months after CXL treatment 
(Ghanem, Santhiago, Berti, Netto, & Ghanem, 2014; Goldich et al., 2014). 
However, another study noted that the biomechanical properties of CXL - 
treated corneas were significantly different from those of the healthy corneas 
(Spoerl et al., 2011).  
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The flattening effect of the crosslinking treatment on the anterior corneal 
surface has been well documented (Kránitz et al., 2012). A significant increase 
in the posterior “astigmatism” and posterior elevation values (despite a 
flattened anterior corneal surface), 12 months following CXL treatment, has 
been reported in the literature (Kosekahya et al., 2017). These findings are 
similar to the study of Steinberg et al. 2014, suggesting an ongoing posterior 
ectasia despite a stabilised anterior corneal surface following CXL treatment 
(Steinberg et al., 2014). When these values are compared with the untreated 
keratoconic eyes, the increment in posterior elevation values and posterior 
astigmatism values following CXL treatment are not statistically significant 
(Piñero et al., 2010). In contrast, another study described a flattening effect on 
both anterior and posterior corneal surfaces with a significant decrease in the 
posterior elevation values (Kránitz et al., 2012). Supporting the above study, 
Hashemi et al. (2013), also reported decrease in posterior elevation values even 
after 5years post-CXL treatment (Hashemi, Seyedian, Miraftab, Fotouhi, & 
Asgari, 2013).  
 
CXL causes thinning of the cornea, an effect of which starts at the 
commencement of the procedure and continues until 1-3 months following 
treatment (Kelkar et al., 2017; Kymionis et al., 2009). However, recovery of the 
corneal thickness starts from 3 months and reaches the baseline thickness 
(thickness of the cornea before CXL treatment) by one year (Greenstein et al., 
2011; Hersh et al., 2011). In some cases, the thinning effect immediately 
following CXL treatment is significant enough to result in endothelial damage 
(Pang et al., 2012). In contrast, in other cases, no significant thinning effect was 
noted after the procedure (Lagare et al., 2013; Viswanathan et al., 2013). There 
is a variety of opinions in the published literature about the post-CXL effect on 
the corneal thickness in vivo. For instance, it was noted that the average corneal 
thickness increase within 12 months post-CXL treatment was 20µm from three-
month baseline values (Greenstein et al., 2013). Kim et al. (2016b) stated that 
even after five years, there was a statistically significant decrease in the corneal 
thickness in comparison with the baseline values before crosslinking treatment 
(Kim et al., 2016b). According to Polat et al. (2017), the first six months to 1-year 
period is considered as the optimal healing and remodelling stage of the cornea. 
During this period, the maximum re-thickening effect of cornea post-CXL 
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treatment can be observed. In the aforementioned study, the corneal thickness 
pre-CXL treatment was 436.20 ± 32.15µm, and after one year following CXL 
treatment, the value was increased to 454.10 ± 45.70µm (Pollat et al., 2017).  
 
Corneal innervation and tear film: The C-CXL technique does not damage the 
limbal stem cells, and epithelial regrowth completes within several days of 
treatment (Mazzotta et al., 2008). The corneal subepithelial nerve fibres (Figure 
2.6) start to regenerate at an early stage (one month after CXL treatment) 
whereas anterior-mid-stromal nerve fibres regenerate from the deep stromal 
nerve plexus between 2-3 months postoperatively. Six months post-treatment, 
the corneal sensitivity is fully restored with complete regeneration of nerve 
fibres within the corneal stroma (Mazzotta et al., 2008) (Figure 2.5). However, 
another study has described a progression of abnormal nerve migration as late 
as after five years post-CXL treatment. Even then the corneal sub-basal nerves 
did not regenerate to reach the level of a healthy cornea following C-CXL 
treatment (Parissi et al., 2011). Therefore, given the widespread use of this 
treatment for the management of keratoconus, abnormal nerve migration post-
CXL treatment should be recognised and further investigated. 
 
Corneal denervation leads to dry eye, which is one of the most recognised 
complications of corneal refractive surgeries (Kontadakis et al., 2013) . The tear 
film plays a significant role in preventing evaporation and prevent eyes from 
drying. Patients suffering from keratoconus have disturbed tear film function 
with reduced Goblet cells within the conjunctival epithelium and significantly 
lower values of tear film break-up time (TFBUT) as a result (Dogru et al., 2003). 
One positive result of the CXL treatment is that it does not appear to have any 
adverse effects on the tear film parameters including TFBUT, osmolality, ocular 





Figure 2.6 - Innervation to the corneas with sub-basal nerve plexus and subepithelial 
nerve plexus  
A – Epithelium, B- Basal lamina, C- Stroma, D – Terminal nerve endings within the 
epithelium, E- Sub-basal nerves, F- Sub-epithelial nerve plexus within the corneal 
stroma 
(Subasinghe, S.K., Ogbuehi, K.C., Dias, G.J. (2018). Current perspectives on corneal collagen 
crosslinking (CXL). Graefes Arch Clin Exp Ophthalmol, 256(8), 1363-1384) 
 
Riboflavin: The effect of riboflavin on the crosslinking process has been 
discussed in the literature. This includes factors such as the concentration and 
time of exposure of riboflavin to corneal tissue that needs to be considered for 
a better outcome ( Baiocchi et al., 2009; Iseli, Thiel, Hafezi, Kampmeier, & Seiler, 
2008; Schumacher et al., 2012). The corneal tissue strongly absorbs the UV light, 
and the absorbed light converts into heat dissipate into the corneal tissue 
causing thermal damage. Therefore, the cooling effect of riboflavin on the 
corneal surface is an added benefit in preventing thermal injury to the cornea 
(Mencucci et al., 2007). The use of a Dextran solution is a vital component in 
the CXL treatment. For instance, the substitution of dextran (T-500) with 
dextran sulphate in riboflavin solutions has resulted in the loss of vision and 
permanent corneal opacity in some cases (Höllhumer et al., 2017). The main 
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purpose of adding dextran is to increase the viscosity of the riboflavin drops 
and to create an isotonic solution from a hypo-osmolar riboflavin solution 
which prevent excessive swelling of the corneal stroma (Mark et al., 2013). In 
some cases, hypo-osmolar solutions of riboflavin have been used to induce 
swelling of the thin corneas to make them suitable for C-CXL treatment (Hafezi 
et al., 2009).  
  
CXL for younger age groups: The effectiveness of the C-CXL treatment on 
younger age groups has given variable outcomes. While some studies have 
shown an improvement of keratometric values with a reduction in the 
progression of the disease within the age group of 9-18 years (Arora et al., 2012; 
Kumar et al., 2014; Parissi et al., 2016; Seiler, Fischinger, Senfft, Schmidinger, & 
Seiler, 2014; Viswanathan et al., 2014), others illustrate adverse outcomes such 
as worsening of topographic and pachymetric values long term in the same age 
group ( Chatzis et al., 2012; Caporossi et al., 2012; Wollensak, Spoerl, et al., 2004) 
In general, determining the effectiveness of crosslinking treatment on younger 
patients has been difficult due to the effect of continuous growth and 
development. Vinciguerra et al. (2013), stated that the effectiveness of the C-
CXL treatment is optimal in patients within the age group of 18-30 years 
(Vinciguerra et al., 2013), while Deepa et al. (2014) illustrated promising results 
in patients in a much younger age group (8-17 years). In general, performing 
C-CXL at an early stage of keratoconus seems to have produced useful results 
compared to advanced stages of keratoconus in paediatric and adolescent 
groups (Deepa et al., 2014).   
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Table 3 – Clinical outcomes following Conventional Dresden Protocol in literature  
 
Spectacle-corrected distance visual acuity (SCDVA), keratoconus (KC), Conventional corneal collagen crosslinking (C-CXL), Best-corrected visual 
acuity (BCVA), Best spectacle-corrected visual acuity (BSCVA), Corrected distance visual acuity (CDVA) , Central corneal thickness (CCT ), 
Corneal volume (CV), Anterior chamber volume (ACV), Anterior chamber depth (ACD), Axial length (AL), Uncorrected visual acuity (UCVA), 
Apical gradient curvature (AGC), Best fit sphere (BFS), Endothelial cell density (ECD), Thinnest point in corneal thickness (TPCT), Best corrected 
distance visual acuity  (BDVA), Uncorrected distance visual acuity (UDVA), Corneal higher order aberrations (HOA), Corneal hysteresis (CH), 
Corneal resistance factor (CRF), Contrast sensitivity (CS), Central-Kmax (C-Kmax), Intraocular pressure (IOP), Surface asymmetry index (SAI), 
Thinnest corneal thickness (TCT), Corneal thinnest point (CTP), steepest keratometry (Kmax), Stimulated keratometry (Sim K), spherical equivalent 
(SE) 
 






(Recalde et al., 
2017) 
12 months Prospective  24 Tear film function not altered  
(Tiveron Jr et al., 
2017) 
12 months Retrospective  
 
100 SCDVA- improved 33%, stable 62% patients. 
82% stabilized or improved apex value 
improved keratometric values and SCDVA  
(Höllhumer et al., 
2017) 
- Case report 6 Substitution of dextran (T-500) with dextran results in loss of vision from 
permanent corneal opacity 
(Polat et al.,2017) 1 year Retrospective  45 Improved K values, Corneal curvature, anterior chamber parameters  
TCT decrease, CV increased 
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(Kelkar et al., 2017) 2 years Prospective  47 Improved BCVA, K vales decreased, IOP increased 
Patchymetry reduced with reduced corneal thickness 
(Kosekahya et al., 
2017) 
12 months Prospective  93 Decreased Kmax, anterior elevation, anterior astigmatism, thinnest corneal  
Increased posterior astigmatism and posterior elevation values  
(Toprak et al., 2017) 2 years Prospective  29 Improve CDVA, Kmax, visual acuity and topographic indices 




Sub-basal nerves not regenerate to healthy level  
Abnormal nerve migration  
(Pang et al., 2016) Before & 
after CXL 
Prospective  26 No changes in the endothelial cell density,  
CCT decrease  
(Kim, Kim, Han, & 
Jin, 2016) 
60 months Retrospective  9 BCVA improved with mean keratometry increased   
Decrease TCT, Kmax, corneal astigmatism  
(Giacomin et al., 
2016a) 
4 year Retrospective  40 Stable topography, visual acuity, Reduced apical keratometry  
Reduced CT   
(Lang et al., 2015) 36 months Prospective  29 Decreased corneal refractive power, Kmax, CCT,  
No changes in visual acuity 
(Poli et al., 2015) 6 years Prospective 
 
36 In bilateral keratoconus results of one eye almost similar to the outcome of 
the remaining eye 
CDVA, UDVA improved, Reduced CCT, Increased IOP 
(Malta et al., 2015) 1 month Retrospective  59 Mean depth of demarcation line greater centrally than nasally and temporally 
No correlation between the demarcation line and corneal pachymetry  
(De Bernardo et al., 
2015) 
24 months Prospective 
 
57 Stable ACV, ACD, CH, CHF 
Improvement in BCVA, decrease of the Kmax, CV, CTP, Increased AL  
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(Sedaghat et al., 
2015) 
1 year Prospective 
 
97 Improved UCVA and BCVA  
Decreased average keratometry, astigmatism, CT, CV in anterior and  
Increased posterior elevation, average progressive index, CH. CRF  
Anterior BFS and elevation without change, Posterior BFS and elevation 
increased  
(Khan et al.,2015) 3 years Prospective  
 
71 Improved UCVA 31%, BCVA 56.3% 
Decreased spherical equivalent, Kmax, CCT 
Decreased K max in 60.6% 
(Viswanathan et al., 
2014) 
20 months Prospective  25 Visual acuity, astigmatism, keratometry value improve  
Reduce corneal curvature 




Prospective  25 UCVA, BSCVA, visual acuity, keratometry improved 
No change ECD, CCT  
(Kodavoor et al., 
2014) 
12 months Retrospective  35 Improved BCVA, decrease in Kmax  
Decrease cylindrical and spherical equivalent 
(Steinberg et al., 
2014) 
2 years Retrospective  20 Reduction flat and steep meridian of topographic asymmetry parameters 
Kmax not statistically reduced  
Decreased TPCT and CT at apex 
(Goldich et al., 
2014) 
36 moths Prospective  
 
17 Reduced Kmax  
BSCVA, UCVA, visual acuity, corneal thickness stable  
No change ECD, CH, CRF, fovea thickness 
(Kránitz et al., 2014) 25 months Prospective  50 Decreased TCT  
Improved keratoconic indices, keratomeric values 
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(Ghanem et al., 
2014) 
24 months Prospective  42 Improved UDVA, CDVA, Spherical equivalent, HOA 
Keratometric values decreased 
Changes in HOA do not correlated with improvement of visual acuity  
(Wittig-Silva et al., 
2014) 
36 months Prospective  100 Improved Kmax, UCVA, and BSCVA 
Decrease CT 
(O'Brart et al., 2013) 6 years Prospective  29 Increased mean spherical equivalent error 
Improved CDVA, astigmatism 
Reduced corneal wave form values 
Improve visual and topographic parameters with time 
(Legare et al., 2013) 24 months Retrospective  30 Reduced TCT 
Increased keratoconus indices 
Stable Kmax, refractive measurements  
Improved UDVA not significant difference in mean UDVA  
(Vinciguerra et al., 
2013) 
 Retrospective  400 Keratoconus stabilized in all paediatric groups  
Better functional and morphological results in 18-30 years of age with better 
pachymetric and aberrometric results 
(Rechichi et al., 
2013) 
1 year Prospective   
28 
Improved CDVA, UDVA, keratoconus indices 
Decreased mean spherical equivalent, CT 
Endothelial cell count stable 
Corneal demarcation line at 250.41±21.89µm centrally 




Prospective  40 Improved CS, BSCVA, UCVA, Kmax 
No significant change in keratometric values 
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Decrease anterior elevation, posterior elevation 
Refraction decreased within first year and remain stable  
(Lamy, Netto, et al., 
2013) 
2 year Prospective  68 Improved CS, BSCVA 
Decrease in C-Kmax C-Kmax  
(Ivarsen & 
Hjortdal, 2013) 
1 year Retrospective  28 Decreased Kmax, CT initially decreased, CDVA unchanged 




24 months Prospective  51 Improve visual acuity, Kmax, logMAR BSCVA 
No statistical difference central CT, spherical equivalent, cylindrical power 
(Poli et al., 2013) 36 months Prospective  55 Improved UCVA, BSCVA 
Keratomeric vales were improved but not significant 
IOP and endothelial densities were not changed 




Prospective  14 Improved UDVA, CDVA 
Reduced mean keratometry, endothelial density 
(Chatzis & Hafezi, 
2012) 
36 months Prospective  52 Reduced Kmax, after 36 months K max has a tendency to progress  
CDVA takes longer time to improve 
Children, the effect of CXL does not last longer as in adults 
(Kránitz et al., 2012) 1 year Prospective  40 Improved manifest sphere, UDVA, CDVA 
Decrease TCT, posterior elevation, keratometric values 
Corneal flattening evident on anterior and posterior surfaces 
(Arora et al., 2012) 12 months Prospective  15 Improved in UDVA, CDVA, Apical K, Kmax 
No significant changes flat K, Steep K  
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(Caporossi et al., 
2012) 
36 months Prospective  77 Improved UCVA, BSCVA, SAI, K values 
Worsening of topographic and pachymetric values 
Faster functional recovery in thinner corneas (<450µm) than thicker corneas  
(Greenstein et al., 
2011) 
12 months Prospective  82 Decrease in thinnest pachymetry 
Statistically insignificant changes in apical, pupil-center pachymetry 




71 Improved UDVA, CDVA 
Increase Kmax (1 month), Decrease Kmax (1-3months), no change from 6-12 
months 
Visual acuity and corneal steepness worsen at 1month, resolute to baseline 
from 3 months  
(Spoerl et al. (2011) 12 months Prospective  50 No significant differences in CH and CCT  
(O'Brart et al., 2011) 18 months Prospective  24 Improve keratometric topographic parameters  
No change in patchymetry values, UCVA, BSCVA, refractive cylinder 
correction, spherical equivalent refractive error 
Improved BSCVA  
(Caporossi et al., 
2010) 
48 months Prospective  363 
Reduced Mean K, coma aberration 
Improved corneal symmetry, UCVA, BCVA 
(Sinha et al., 2010) Immediate
ly after 
CXL  
Prospective  16 Elastic modulus increment 110.8±48.1% 
The corneal shape varied to different patients 
(Sedaghat et al., 
2010) 





6 months Prospective  31 No change in the endothelium following C-CXL treatment 
(Ansah et al., 2020) 3 years Prospective 125 Initial worsening of BSCVA, pachymetry, and keratometry  
Improvements in K max and stability in visual acuity over 24 months 
 
(Abbondanza et al., 
2019) 
5 years Retrospective 15 Best spectacle-corrected visual acuity improved for all patients, from 0.46 ± 
0.69 
Mean pachymetry increased in 93% of patients 
Mean keratometry improved in 87% of patients 
 
(Bamahfouz et al., 
2020) 
18 months Prospective 
cohort study 
45 K max significantly declined (P = 0.05)  
Spherical equivalent refractive status changed from median −1.5D to −2.27D 
(P = 0.002).  
Central corneal thickness significantly reduced (P = 0.001). 
 
(Iqbal et al., 2020) 24 months Prospective 
study 
271 C-CXL was more effective for managing KC and it can achieved greater 
stability than either ACXL or TCXL 
(Peyman et al,. 
2020) 
12 months Prospective 
study 
106 Blood group, rubbing of eye, place of birth, corneal asphericity, pre-treatment 
BCVA, CKI, KI, and CCT statistically associated with the outcome of KC 
following CXL. 
(Takahashi et al., 
2018) 
12 months Prospective 
study 
20  Sim K and TCRP was decreased by approximately 1 D after CXL 
 
(Abdel-Radi et al., 
2020) 
12 months Prospective 
study 
74 Although A-CXL create a deeper demarcation line, the effect of both C- CXL 
and A-CXL is the same 
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(Shajari et al., 2019)  Meta-
analysis 
1158 UDVA improved in C-CXL  
CDVA improved in both A-CXL and C-CXL 
A-CXL provide less corneal flattening than C-CXL 
CH and CRF better in C-CXL than A-CXL 
Corneal stabilisation better in C-CXL than A-CXL 
(Mazzotta et al., 
2018) 
10 years Prospective 
study 
62 eyes Uncorrected visual acuity and corrected visual acuity improved from 0.45 to 
0.23. KC stability 
(Hashemi et al,. 
2019) 
4 years Randomized 
clinical trial 
31 At 4 years – C-CXL offered better anterior corneal flattening in the centre 
and periphery than A-CXL 
At 18mothns – No significant difference between C-CXL and A-CXL 
 
(Yousef et al., 2020) 6 months Randomized, 
controlled-
trial study  
 
30 Improvements in Sim K, K min, spherical power, cylinder power, SE, UCVA, 
BCVA  
(Grišević et al., 
2020) 
12 months Prospective 
study 
34 Visual acuity improved significantly post CXL 
K max was changed significantly for12 months post cross linking, but not in 




6 months Prospective  31 No change in the endothelium following C-CXL treatment 
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B. Protocol variations 
 
Although the Dresden protocol is commonly used in clinical practice, 
alternative protocols have been introduced to overcome some of its drawbacks. 
The complications related to C-CXL were mostly associated with the significant 
epithelial defects that occur during epithelial removal before treatment. 
Complications associated with epithelial removal before C-CXL may vary from 
minor effects such as delayed epithelial closure to more advanced 
complications such as corneal scarring, infectious keratitis and corneal 
perforation (Pollhammer & Cursiefen, 2009; Pérez-Santonja, Artola, Javaloy, 
Alió, & Abad, 2009; Sharma, Maharana, Singh & Titiyal, 2010; Zamora & Males, 
2009). Prolonged treatment time is also another drawback that has to be 
addressed when modifying the existing C-CXL protocol. In an attempt to 
improve the visual and topographical outcomes of C-CXL, various 
modifications such as Accelerated crosslinking and Transepithelial 
crosslinking methods have been introduced in clinical practice. 
 
a) Accelerated CXL (A-CXL) 
 
A-CXL treatment is based on “Bunsen-Roscoe law of photochemical reciprocity” 
where the same photochemical effect can be achieved by reducing the 
irradiation interval but keeping the total energy level constant by a 
corresponding increase in the irradiation intensity. Therefore, the cumulative 
dose has to be maintained while applying a higher irradiation dose for a shorter 
time (Mastropasqua et al., 2015; Yildirim et al., 2017). The main advantage of 
this protocol in comparison with C-CXL is the reduced treatment time. 
Theoretically, the infection risk might also be reduced as the de-epithelialised 
cornea is exposed for a shorter period (Kymionis et al., 2017). Several different 
accelerated protocols with a cumulative dose of 5.4 J/cm2 have been described. 
However, experimental and clinical studies have shown conflicting outcomes.  
 
A study that used stress-strain measurements of porcine corneas reported that 
A-CXL produced equivalent corneal stiffening effects (compared to C-CXL) 
with a radiation dose of 10mW/cm2 for nine minutes (Schumacher et al., 2011). 
In contrast, Hammer et al. (2014) stated that the biochemical effect of CXL 
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decreases with high irradiance or a short irradiation time (Hammer et al., 2014). 
There are also reported cases of stiffer anterior cornea resulting from the C-CXL 
than from the A-CXL treatment (Dai, Chu, Zhou, Chen, Qu & Wang, 2006). 
 
A few clinical studies, using different intensities and exposure times, have 
illustrated contradictory results concerning the efficacy of A-CXL compared to 
C-CXL. Favourable outcomes with improved visual acuity and keratometric 
values/ K values were noted in a 12-months follow-up study following A-CXL 
(Artola et al., 2017; Aixinjueluo et al., 2017). Improved visual acuity and 
decrease in keratometric values were observed in A-CXL than in C-CXL in one 
of the studies which used irradiation of 10mW/cm2 for nine minutes (Çınar et 
al., 2014). Another study with the same irradiation dose did not note a 
significant difference in visual, keratometric and aberrometric results between 
the A-CXL and C-CXL protocols (Kontadakis, Kymionis, Kankariya, & 
Pallikaris, 2013). Similar results were observed in A-CXL treatment under 
30mW/cm2 exposure for three minutes (Razmjoo, Peyman, Rahimi, & Modrek, 
2017; Tomita, Mita & Huseynova, 2014). In one of the studies, one-year post-
CXL keratometry value (Kmax) reduction was statistically significantly greater 
in A-CXL compared with C-CXL (Brittingham et al., 2014; Tomita, Mita & 
Huseynova, 2014), while in other cases the reduction of keratometry values was 
more significant in C-CXL-treated corneas than in A-CXL-treated corneas 
(Brittingham et al., 2014; Choi et al., 2009; Chow et al., 2015). A study by 
Razmjoo et al. (2017), reported no significant difference in improving visual 
acuity and refractive errors in the A-CXL procedure in comparison to C-CXL, 
in a six-month follow-up study (Razmjoo, Peyman, Rahimi, & Modrek, (2017). 
In some cases, non-significant changes in the keratometric values were 
observed with A-CXL treatment, whereas the K values were always 
significantly decreased with C-CXL treatment (Chow et al., 2015; Hashemi et 
al., 2015). 
 
When evaluating the safety and the efficacy of CXL treatment, accurate 
measurement of the depth of the CXL effect is essential. The cytotoxicity of the 
CXL treatment and non-regenerative nature of the corneal endothelial cells 
should also be taken into consideration when choosing an effective therapeutic 
procedure. Therefore, various methods have been suggested to measure the 
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depth of CXL treatment. Measurement of the crosslinked depth with the 
corneal demarcation line was first described by Seilar and Hafezi using the slit-
lamp biomicroscope (Mark, Ngounou, Tamon, Marx-Gross, & Preussner, 2014). 
It has been investigated more recently using confocal microscopy, optical 
coherence tomography and Scheimpflug imaging (Thorsrud, Sandvik, Hagem, 
& Drolsum, 2017). When investigating the corneal stromal demarcation line 
depths of C-CXL and A-CXL protocol, both have been shown to preserve the 
corneal limbal stem cells (Kymionis et al., 2016; Uçakhan et al., 2017). 
Furthermore, topographic studies have revealed that the effect of corneal 
flattening was less in A-CXL than in the C-CXL with a deeper corneal 
demarcation line visible with the former technique (Choi et al., 2017; Chow et 
al., 2014). Another study suggested a lack of demarcation line depth, where the 
demarcation line was not evident in A-CXL (Bozkurt et al., 2017). The epithelial 
thickness decreased immediately following A-CXL procedure and was 
gradually recovered and achieved the pre-operative thickness one month after 
treatment (Zhang, Chen, Tian & Zhou, 2016). The temperature increment due 
to both C-CXL and A-CXL techniques were below the threshold for thermal 
injury (50°C) to corneal collagen fibrils (Mencucci et al., 2015). 
 
Despite the results of several clinical and laboratory studies, a number of 
studies have suggested that the A-CXL procedure is an effective method to 
stabilise the progression of keratoconus both in adults (Kurt et al., 2016, Pahuja 
et al., 2016) and in children (Badawi, 2017). In general, it seems likely that A-
CXL has a lower therapeutic effect when compared to C-CXL despite 
associated reduced treatment time. 
 
b) Epithelium-on/ Transepithelial technique (T-CXL) 
 
The principal clinical drawbacks of the C-CXL, such as a painful recovery 
process and prolonged visual recovery due to the large epithelial defect, has 
encouraged clinicians to look for a method of crosslinking without epithelial 
debridement. Therefore, T-CXL was developed where the corneal epithelium 
is left intact prior to the CXL treatment. Preservation of the epithelial layer 
conserves corneal morphology and makes the procedure more comfortable for 
patients (Filippello, Stagni, & O’Brart, 2012; Hayes et al., 2016; Mencucci et al., 
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2013). According to current published data, this technique has significantly 
improved the best-corrected visual acuity (BCVA), manifest refraction, 
refractive and corneal astigmatism and maximum K values in mild to moderate 
cases of keratoconic patients after a year post-CXL treatment (Ameen, 
Mehboob, & Ali, 2016; Heikal, Soliman, Fayed, & Hamed, 2017). The collagen 
fibre arrangement became similar to normal corneas after three months of post-
treatment (Spadea et al., 2012). However, studies to compare riboflavin 
penetration into the corneal stroma with and without removal of the 
epithelium illustrated that the time-dependent riboflavin penetration was 
maximal only after the removal of the epithelium (Baiocchi	et	al.,	2009;	Bottós 
et al., 2008;  Wollensak & Iomdina, 2009). The corneal epithelial cells are 
connected by tight junctions, which play a vital role in the barrier function of 
the epithelium (Kimura et al., 2010), and these tight corneal junctions limit the 
diffusion of riboflavin into the stroma during the T-CXL procedure 
(Mannermaa, Vellonen, & Urtti, 2006; Mencucci et al., 2007) .  
 
Different techniques have been proposed in the literature, to increase the 
riboflavin penetration into the cornea without epithelial debridement. Some of 
the strategies used are: changing the physiochemical properties of the  
riboflavin molecule with the use of chemical enhancers; (Torricelli et al., 2014) 
performing mechanical disruption of the corneal epithelium; (Rechichi et al., 
2013) increasing the application time of riboflavin; (Arora et al., 2013) 
iontophoresis; (Mastropasqua et al., 2014) ultrasound enhanced penetration of 
riboflavin; (Lamy et al., 2013; Lafond, Aptel, Mestas & Lafon, 2017) the use of 
intrastromal channels to introduce riboflavin to bypass the corneal epithelium; 
(Cruzat et al. 2017; Kanellopoulos, 2009; Seiler et al., 2013) transepithelial 
delivery of riboflavin with microneedles; (Jiang et al. 2007) and 
nanotechnology-based transepithelial crosslinking (Labate, Lombardo, 
Lombardo & Santo, 2017). Although these techniques have overcome some of 
the immediate postoperative complications of C-CXL, their effectiveness seems 
to be less than that of conventional CXL; thus, their utility is still a matter of 
debate (Aldahlawi et al., 2016; Badawi, 2016; Eraslan, Toker, Cerman, & 
Ozarslan, 2017; Gatzioufas et al. 2016; Yousef, 2016). Two of the more 
commonly investigated techniques (the use of chemical enhancers, and 
iontophoresis) are discussed in the following paragraphs.   
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Use of chemical enhancers to increase the riboflavin penetration: One of the 
main aspects of achieving adequate penetration of riboflavin is to use different 
chemical enhancers. However, most parts of these chemical agents are toxic to 
the epithelium. Some of the commonly investigated chemicals were 
benzalkonium chloride (BAC), ethylenediamine tetraacetic acid (EDTA), d-
alpha-tocopheryl polyethylene-glycol 1000 succinate, tetracaine, proparacaine, 
ethanol and gentamicin (Chang et al., 2000; Cha et al., 2004, Caruso et al., 2016; 
Nakamura et al., 2007; Saettone et al., 1996; Uematsu et al. 2007). The use of a 
combination of these enhancers seemed to have an improved effect with topical 
hydrophilic drugs achieving a better intraocular penetration (Mohanty et al., 
2013; Rathore et al., 2006). For instance, in conjunction with proparacaine, 
gentamicin and BAC have shown promising improvements in visual acuity 
and refractive indexes following T-CXL (Stojanovic et al., 2012). A study 
performed on rabbit corneas suggested BAC as an effective enhancer that 
allows microscopically evident crosslinking at the anterior cornea (Pinelli & El-
Shawaf, 2009). However, when compared, the percentage of increase in corneal 
rigidity in rabbit cornea following T-CXL using BAC, was significantly lower 
in comparison to the C-CXL technique (Wollensak & Iomdina, 2009). A clinical 
study by Leccisott and Islam (2010) using 51 patients suffering from 
keratoconus suggested a favourable effect of T-CXL with an absence of any 
notable complications. However, in this study, the corneal curvature was not 
improved with the T-CXL procedure (Leccisott & Islam, 2010). Besides, the 
absence of any significant improvement in corrected distance visual acuity 
value (CDAV) and topographical parameters following T-CXL has also been 
reported in a study conducted with 61 keratoconic eyes (Mannermaa, Vellonen, 
& Urtti, 2006). In contrast, a different study illustrated a significant 
improvement of maximum K values and CDVA at six months follow up in T-
CXL treatment (Lesniak & Hersh, 2014).  
 
Iontophoresis CXL (I-CXL) : Iontophoresis is a technique which results in 
enhancing penetration of different solutions using a small electric current. This 
technique is in many fields of medicine (Dubinsky et al., 2004; Gomez, Szabo, 
Pap, Pap, Boda & Szekanecz, 2012; Prasad & Koul, 2012), including drug 
delivery to intraocular compartments (Fruchit-Pery, Raiskup, Mechoulam, 
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Shapiro et al., 2006; Gaudana, Ananthula, Parenky & Mitra, 2010; Vinciguerra 
et al., 2016). However, more recently this technique has been tested in corneal 
crosslinking in order to increase the penetration of riboflavin through the tight 
junctions of the intact corneal epithelium (Manetti, Favuzza, Sgambati, 
Mencucci & Marini, 2017). However, the absorption of riboflavin into the 
stroma is reduced by half in I-CXL compared with C-CXL (Bikbova & 
Bokbov,2016; Cassagne et al., 2016). From the total riboflavin absorbed, 15-20 
per cent of riboflavin is absorbed by the corneal epithelium (Bouheraoua et al., 
2014). Therefore, the C-CXL technique seems to have greater and deeper 
riboflavin saturation when compared to I-CXL technique (Mastropasqua et al., 
2014). A study to investigate modifications in human corneas following I-CXL 
and C-CXL methods, suggested that the I-CXL induced less tissue damage and 
better stromal remodelling compared to C-CXL treatment (Mastropasqua et al., 
2014).  
 
I-CXL increases the mechanical rigidity of the corneas when compared to T-
CXL treatment with Tromethamine (Vinciguerra et al., 2012). Biomechanical 
resistance acquired by I-CXL treated corneas was greater than the 
biomechanical resistance induced by C-CXL treatment (Mencucci et al., 2015). 
Lambardo et al. (2017) noted that biomechanical strengthening of the cornea is 
more pronounced with the C-CXL treatment than with the I-CXL treatment, 12 
months following the crosslinking procedure (Lambardo et al., 2017). I-CXL 
induced quicker improvement of visual acuity compared to C-CXL with a 
significant improvement in the CDVA values within three months compared 
to C-CXL treatment (Vinciguerra et al., 2016). A few studies have stated that 
both the techniques have almost similar therapeutic effects on crosslinking 
(Cassagne et al., 2016; Cantemir, Alexa, Anton & Ciuntu et al., 2017; Manetti et 
al., 2017;). In contrast, many studies that compared the long-term effects of I-
CXL and C-CXL stated that the I-CXL was less effective in arresting the disease 
progression of keratoconus compared to C-CXL treatment (Jouve et al., 2017). 
The Kmax value of I-CXL treated corneas seemed to stabilise at two years, 
whereas it decreased significantly one to two years after C-CXL treatment 
(Bikbova & Bikbov, 2016; Jouve et al., 2017; Lombardo et al., 2017). In contrast, 
another study noted a reduction in the Kmax values in both I-CXL and C-CXL 
treatment groups (Bikbova & Bikbov, 2016). However, according to this study 
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Kmax reduction (-1.05 ± 1.51 D) following the C-CXL treatment is statistically 
greater compared with the I-CXL treatment (-0.31 ± 1.87 D). This suggests that 
in general, the C-CXL treatment is more effective than the I-CXL treatment for 
the treatment of keratoconus (Vinciguerra et al., 2016). Although the I-CXL 
technique has been researched for years, long term follow-up studies with large 
number of participants have not yet been carried out, hence should be 
conducted to assess the effectiveness of this technique when compared to the 
C-CXL technique. 
 
C) Recent advances in the treatment protocol 
 
More recently, pulsed light accelerated crosslinking with 8 min of UVA 
exposure at 30 mW/cm2 with an energy dose of 7.2 J/cm2 was introduced as 
an effective mode of treating KC (Mazzotta et al., 2017).  A clinical study with 
a 1-year follow-up stated that the functional outcome of the pulsed light A-CXL 
is better than the continuous light A-CXL  with a capability of penetrating 
deeper into the corneal stroma when compared with continuous light A-CXL 
treatment (Mazzotta et al., 2014).  Oxygen supplemented A-CXL is another 
modification introduced into the existing protocol (Hill et al., 2020). According 
to a more recent study by Aydin et al. 2021, oxygen supplemented A-CXL 
treatment seems to increase the corneal topographic parameters 12 months 
after the treatment.(Aydın and Aslan, 2021). 
 
High-intensity corneal crosslinking was introduced in the literature where 
irradiation does of 9 mW/cm2 for duration of 10 minutes was applied for 
crosslinking keratoconic corneas. It seems to be an effective mode of treatment 
with minimal post-operative complications. (Kymionis et al., 2014). The main 
advantage over the C-CXL protocol is the reduced treatment time and 
homogeneity of UVA irradiation (Kissner et al., 2012). However, another 
investigators argue that high doses of irradiation will be less effective in the 
treatment due to the rapid depletion of oxygen (Chan, 2020). Another approach 
in the CXL treatment of Keratocnus without epithelial abrasion is dietary intake 
of riboflavin followed by sunlight exposure. The initial study was performed 
using 7 patients; they were exposed to natural sunlight after oral riboflavin 
administration. The results have shown no adverse effects on the cornea 
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(Rubinfeld et al., 2019). Another case study also stated that high-doses of 
dietary riboflavin and direct sunlight could provide a safe and inexpensive 
mode of treatment for keratoconus (Nguyen and Jarstad, 2020). However, the 
effectiveness and effects on the cornea needed to be further experimented with 
in detail. 
 
2.8 Wound healing response of the cornea 
 
The wound healing response of cornea can vary from species to species, as well 
as it can vary depending on the type of wound. For example, the healing 
process of a wound that only involve epithelium will be different from that of 
a wound involving both epithelium and Basement membrane etc. (Stepp et al., 
2014). One may assume that the cornea is highly resistant to stimuli, such as 
mechanical injury. An injury to some areas of human body, leads to immediate 
keratocyte activation, deposition and remodelling of the tissue in question. In 
contrast, corneas elicit a limited fibrotic response on the corneal stroma which 
ultimately promotes healing without any scarring or any contractures that 
might alter the shape of the cornea (Binder, 1994; Grosvenor, 1995). In an 
incisional injury to the cornea, immediately after the injury keratocytes 200-
300µm deep in the stroma undergo fragmentation and then disappear. The 
process of repair starts with the activation of keratocytes adjacent to the 
acellular zone at the wound edge and within six hours after the injury, 
keratocytes increase in size with enlarged nucleoli (Fini, 1999). The number of 
vesicles and phagosomes also increases. Within 24 hours of an injury, activated 
keratocytes migrate to the acellular zone immediately next to the injury and 
start the wound healing process.  
 
Keratocyte loss is evident immediately following CXL treatment. In a study in 
which different radiation doses were compared, irradiation cytotoxic to 
keratocytes was reported to be in the range of 0.5-0.7mW/cm2. Four hours after 
treatment, apoptotic changes of the keratocytes were evident in the anterior 
50µm of the stroma. However, 24 hours after treatment, the loss was evident in 
deeper regions of the cornea. In humans, apoptotic changes of the keratocytes 
can extend up a corneal stromal depth of 300µm, within the usual 3mW/cm2 
surface irradiation (Wollensak, Spoerl, et al., 2004).  
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It is believed that both the diameter of the CFs and interfibrillar distance 
(separating these CFs within a bundle) plays an essential role in maintaining 
corneal transparency. Reduced transparency of human corneas has been linked 
to increased thickness of CFs and reduction in the number of CFs within the 
corneal stroma (Cinton, Hassinger, Kublin, & Cannon, 1978). In an injury to the 
cornea, the CFs get disarranged. This alteration in the CF arrangement is 
mainly in the anterior part of the corneal stroma. Sometimes, abnormal 
alterations in the CFs might persist for as long as 1.5 years following the injury. 
However, after crosslinking of the collagen stroma the architecture of the CFs 
in the crosslinked cornea never returned to its normal status. This is a reason 
for the belief that these crosslinked corneas were probably are not as strong as 
the normal tissue (Cinton et al., 1978). Changes in the CF morphology following 
crosslinking treatment has not yet been reported in the literature.   
 
The wound healing processes of rabbit and porcine corneas have been 
investigated in vitro (Medin & Davanger, 1987; Summerlin, Miller, Harris, & 
Good, 1973). However, many of these studies have evaluated the reactions of 
the cornea to incisional injuries. It was unable to find any study in which 
changes in the CF morphology had been evaluated following crosslinking 
treatment in vitro. According to the study by Glickstein et al. (1975), in a cut 
injury the epithelial migration can be found until the Descemet’s membrane 
within 48 hours following the injury (Glickstein , Cameron, & Yanoff, 1975) 
while another study noticed a  loss of keratocytes in wound edges within 24 
hours after the cut injury with a reduced or unchanged number of keratocytes 
along the wound edge after three to five days. After 21 days, the keratocytes 












 Animal model with structural similarity to 
human corneal collagen fibrillar (CF) 
arrangement 
 
This chapter has been accepted for publication in 2020 (Appendix 1) as:  
Sandeepani K. Subasinghe, Kelechi C. Ogbuehi, Logan Mitchell, George J. Dias 
(2020) Animal model with structural similarity to human corneal collagen fibrillar 





The morphology of porcine and rabbit corneas are generally believed to be similar 
to that of the human (Brunette et al., 2011; Fernandez-Bueno et al., 2008). Therefore, 




Porcine and rabbit models have been used extensively to study different parts of 
the eye including the ciliary epithelium, trabecular meshwork, aqueous outflow, the 
neuroretina and retinal vascularization. Both models have also been used to 
develop new imaging techniques of the eye (Rosolen et al.,2002; Rosolen et al.,2001). 
These two have also been used as models in the study of pathologies associated 
with glaucoma (Ruiz-Ederra et al., 2005) and cataract (Sugiura et al., 1999). Different 
surgical techniques of the retina, vitreous and lens were experimented on porcine 
eyes (Ghosh & Arnér, 2002). Rabbit corneas are also commonly used to test different 
topical medications and modes of ophthalmic drug delivery systems (Oh et al., 2007; 
Xiong et al., 2008). Furthermore, these animal models have been used to investigate 
the anatomy, pathophysiology, biomechanics and immunology related to visual 
sciences (Majo et al., 2008). More recently, these animal models have also been used 
to evaluate the effects of corneal collagen crosslinking treatment which is, perhaps, 
the most promising treatment option for keratoconus (Gregor Wollensak & Spoerl, 
2004; Wollensak et al., 2004). 
 
Although many studies have used either porcine or rabbit corneas as an 
experimental model, only a few have compared their morphological similarities to 
the human cornea.  Furthermore, we have not been able to find any investigations 
that had compared the CF diameter, interlamellar distance and interfibrillar 
distance, of porcine and rabbit corneas, and compared these values with that of the 
human. Detailed corneal morphology of these animal models are required to choose 
a suitable model to investigate different corneal pathologies and their related 
complications that could be extrapolated to human. Therefore, this chapter will be 
presenting the general morphological arrangement of corneal collagen fibrils (CFs) 
in normal porcine, rabbit and human corneas. Furthermore, an attempt will be 
made to determine which of the two animal models is more structurally closer to 




3.2.1 Animal and human corneas 
The study was conducted with: five pairs of porcine eyes (10 samples) aged at 9 
months – 12 months, obtained from an abattoir ("South Kill", Milton, New Zealand, 
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formal approval was taken from the animal ethics committee of the University of 
Otago prior to the project, Appendix 2); five pairs (10 samples) of New Zealand 
White rabbit corneas aged at 15 months, obtained from University of Otago, 
Christchurch campus, New Zealand (Animal ethics committee approval number: 
AUP 18-196, Application number: CG4/17, Appendix 2) and five pairs (10 samples) 
of human corneas retrieved from bequeathed cadavers to the Department of 
Anatomy, University of Otago (Human ethics committee, University of Otago, 
Ethics committee reference code: H18/041, Appendix 2). The animal corneas were 
retrieved within six hours, and human corneas, due to logistical constraints, within 




3.3.1 Retrieval of corneas: 
 
Retrieval of human corneas was performed by a technician at Rhinds Funeral 
Services in Christchurch, New Zealand. The technician was trained in excising 
corneas from eyeballs in-situ by the primary author. The primary author retrieved 
all the animal corneas.  
 
3.3.2 Excision of the corneal flap 
 
Aseptic techniques were followed from the time of corneal retrieval to histological 
sample preparation. The eyes were cleaned by several washes of sterile saline (0.9% 
wt/vol NaCl), followed by immersion in 1% (wt/vol) polyvinylpyrrolidone-iodine 
(PVP-I) for two minutes, 0.1% (wt/vol) sodium thiosulfate (to neutralize the iodine) 
for one minute, and another wash of sterile saline (Armitage, 2011). The orbital area 
and surrounding skin was cleaned with water, and the operative area of the skin 
was then prepared according to the standard pre-operative skin preparation, and 
the operation field was isolated with sterile drapes. The eyelids were opened by a 
sterile cotton-tipped applicator and kept open by a solid blade eye-speculum. The 
corneas were excised by cutting 2-3 mm outside the corneoscleral junction with a 
curved iris scissors. The eyeballs were extracted according to the instructions given 





The excised corneal flaps were examined with a dissection microscope, and corneas 
with any signs of pathology or scarring were excluded. The selected corneal buttons 
were bisected, and one half was fixed in 10% neutral buffered formalin solution, 
processed and embedded in paraffin for histological examination. The blocks were 
sectioned from the center to the periphery of the cornea in the following manner: 
the first two consecutive sections were cut at 4µm thickness, and one sample was 
stained by Hematoxylin-Eosin (H&E) and the other stained with Masson Trichrome 
(MT) staining (Appendix 3). The stained sections were examined under a light 
microscope (Olympus BX61) (to visualize the morphological features of the collagen 
fibrils and the distribution of keratocytes within the corneal stroma). This sequence 
of sectioning was repeated twice more to cover a wider range of the corneal surface. 
Therefore, per sample there were three alternate sections stained with H&E and 
three sections stained with MT.  
 
Subsequently, the remaining halves of the excised corneas were processed for 
Transmission Electron Microscopy (TEM) (CM100 BioTWIN Philips Transmission 
Electron Microscope) (Appendix 4). In summary, the excised corneal halves were 
directly transferred to a primary fixative containing 4% paraformaldehyde, 2% 
glutaraldehyde in 0.15M cacodylate buffer, and stored until further processing. The 
samples were then washed in 0.15M cacodylate buffer and osmicated in 1% OsO4 
and 1.5% potassium ferrocyanide in 0.1M cacodylate buffer. Following this, the 
samples underwent several washes in double distilled water (DDH2O) and 
followed by dehydration (with different concentrations of ethanol). Finally, the 
samples were embedded in silicon molds, and polymerized for 48 hours at 60ºC, 
and sectioned with a Leica UC7 ultramicrotome using a Diatome diamond knife 
and mounted on formvar coated copper slot grids. The sections were stained with 
1% uranyl acetate and 3% lead citrate using a LKB ultrostainer. From each specimen, 
three sections, selected from three random areas, were analyzed for detailed 
ultrastructural morphology form each specimen. 
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The detailed structural analysis of these sections was carried out to measure the 
minimum diameter of CFs, interfibrillar distance and interlamellar distance (a 
detailed explanation of the procedure is explained in Chapter 4, 4.3). 
 
3.4 Data Analysis 
 
The mean values of all the samples were calculated for porcine, rabbit and human 
corneas and compared using one-way ANOVA to check if there was a significant 
difference between species and to find the animal model that was closer/ similar to 
human. Statistical analysis was performed using the GraphPad Prism (Version 8.4.3, 
©1994- 2020 GraphPad Software, LLC) under the guidance of Dr. Ari Samaranayaka 






H&E and MT staining allowed the visualization of the general arrangement of 
corneal CF morphology in all three species. The outermost layer, the epithelium 
consists of stratified, non-keratinized squamous cell layer that uniformly extending 
from limbus to limbus. Just below the epithelium is the Bowman's layer (or 
Bowman's membrane) followed by the corneal stroma which provides the bulk of 
the structural framework of the cornea. All three species showed a well-demarcated 
Bowman's layer (Figure 3.1).  The distribution of collagen fibers within the corneal 
stroma was also visible in all the species with MT staining (Figure 3.1). The 
Descemet membrane, beneath corneal stroma was visible in the human corneas. 
However, the rabbit had a much thicker Descemet membrane compared to both 
human and porcine corneas. Finally, the single-layered endothelium was evident in 
all three species (Figure 3.1).  
 
3.5.2 Transmission Electron Microscopy (TEM) 
 
A. Collagen fibrillar (CF) diameter 
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The mean CF diameter of the human cornea was 24.52 ± 2.10 nm while porcine and 
rabbit corneal mean CF diameters were 32.87 ± 0.87 nm and 32.57 ± 1.97 nm 
respectively. When comparing CF diameter with one-way ANOVA, there were 
statistically significant differences between each species (p < 0.0001). Human CF 
diameters were significantly different from those of porcine and rabbit corneas 
(Figure 3.2, Figure 3.3) being approximately 8 nm smaller than the other two 
species. Figure 3.2 illustrates how the mean values of the collagen fibrillar distance 
were measured. Figure 3.3 represents the graphical comparison of CF diameter and 
interfibrillar distance of the three species. 
 
B. Interfibrillar distance 
 
When comparing the mean values of the interfibrillar distance, it was evident that 
humans (46.10 ± 2.44nm) had a smaller mean value compared to porcine (53.33 ± 
2.24nm) and rabbit (52.87 ± 2.73) models. The difference was statistically significant 
between species (p < 0.0001) (Figures 3.2 and 3.3).  As illustrated in Figure 3.3, while 
both rabbit and porcine interfibrillar distances were statistically different to 
humans, these values were similar between the two.   
 
C. Interlamellar distance 
The mean interlamellar distance of porcine cornea was 6460±1180nm while rabbit 
and human values were 4410±1330nm and 2190±820nm, respectively. When the 
mean values were compared between the species using one-way ANOVA, there 
was a significant difference between species (p= 0.0007) (Figures 3.4 and 3.5). Figure 
3.5 demonstrates that porcine interlamellar distance is closer to human, but 









Figure 3.1 – Light microscopy image of the porcine, rabbit and human cornea 
A, B – structure of the porcine cornea (A – H&E staining, B- MT staining) 
C, D – structure of the rabbit cornea (C - H&E staining, D- MT staining) 
E, F - structure of the human cornea (E- H&E staining, F- MT staining) 
a, c, e - BLACK arrows - Descemet's membrane, BLUE arrows - Endothelium 






Figure 3.2– Mean interfibrillar distance and minimum fibrillar diameter of normal 













Figure 3.3 – Comparison of mean values of collagen fibrillar diameter and interlamellar distance of porcine and rabbit with the human corneal 

















Figure 3.5 - Comparison of mean values of interlamellar distance of porcine and rabbit with 














Corneal pathologies, including keratoconus and their associated complications, and 
the treatments for these conditions are commonly investigated and evaluated on 
animal models. Many animals including rabbit (Helena et al., 1998), mouse (Wilson et 
al., 1996), rat (Reid et al., 2005), bovine (Kamma-Lorger et al., 2009) and porcine 
(Fernandez-Bueno et al., 2008) corneas have been used in the past to investigate 
different oculovisual pathologies related to visual sciences. When evaluating the 
effects of corneal collagen crosslinking, most of the animal studies have been carried 
out on either rabbit (Wollensak & Iomdina, 2009; Wollensak et al., 2004) or porcine 
corneas (Lanchares et al., 2011; Seiler et al., 2014) due to their similarities to the human 
cornea. Although donor human corneas are ideal for investigating these pathological 
conditions, their applications are limited mainly due to insufficient availability. 
Therefore, identifying suitable animal model or models will provide researchers with 
an informed choice when selecting an animal model for vision science research. In the 
present study, we have found porcine corneas were structurally closer to humans than 
the rabbits when considering corneal interlamellar distance. Interfibrillar distance and 
CF diameter of porcine and rabbit corneas were very similar, but were significantly 
different to human. 
 
Few studies have investigated the structural features of the corneal stroma in humans 
and animals (Davis, 1929; Maurice, 1957).  The CF diameter within the corneal stroma 
in human was estimated to be in the range of 20 - 23 nm (Maurice, 1957), while for 
rabbits and porcine corneas the corresponding CF diameters were 12.5 - 32.50 nm 
(Cox, Farrell, Hart, & Langham, 1970) and 35.7 ± 1.60 nm,  respectively (Hayes et al., 
2013). The fibrillar diameter values of the current investigation are similar to those in 
the literature. An X-ray diffraction study that was performed to measure the 
interfibrillar distance of different animal species has found the interfibrillar distances 
of porcine and rabbit corneas to be 65.6 ± 50 nm and 65.8 ± 50 nm respectively (Gyi, 
Meek, & Elliott, 1988) which are about 25% higher than the values from this study. In 
an electron microscopy study of human corneas, the interfibrillar distance was found 
to be 38 ± 7.80 nm (Akhtar et al., 2013) where the difference is not statistically 
significant from our study. The differences in the values of the interfibrillar distance 
of rabbit and porcine were probably the result of different investigation techniques 
used in those studies. 
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None of the studies published so far has compared the CF diameter, interfibrillar 
distance and interlamellar distance of porcine and rabbit corneas with the human. Our 
study demonstrated that human corneal CF diameter was generally smaller than 
those of porcine and rabbit corneas. When comparing rabbit with porcine corneas, we 
found that the diameter difference was not statistically significant. The interfibrillar 
distance also showed a similar pattern between porcine and rabbit corneas, but was 
significantly different from human. Although the rabbit interlamellar distance was 
significantly different from human, porcine did not significantly differ from that of 
humans. This makes the porcine model being closer to humans than the rabbits with 
regard to the interlamellar distance. 
 
The presence or absence of Bowman's layer in the porcine cornea is debatable. A 
histological study by Bartholomew et al. (1997), showed the presence of a Bowman's 
layer in the porcine cornea (Bartholomew et al., 1997). However, Jay et al. (2008), 
stated that Bowman's layer was absent in porcine corneas (Jay et al., 2008). Cafaro et 
al. (2009), described that the Bowman's layer is only absent at the limbus of the porcine 
cornea (Cafaro et al., 2009). Although more recent investigations have identified a 
Bowman's layer being in the porcine cornea. However, it is not developed to a similar 
degree as in the human cornea  (Nautscher et al., 2016). In our study, a Bowman's layer 
was clearly visible in porcine corneas (Figure 3.1 A, B). Similar to porcine corneas, 
different studies have different views regarding the presence or absence of the 
Bowman's layer in the rabbit cornea. In our study, the Bowman's layer was also 
evident in rabbit corneas (Figure 3.1 C,D), a contradictory finding to some previous 
studies (Davis, 1929). For instance, Davis in 1929, stated that there was no definitive 
layer of a Bowman's membrane, occasionally, in some of the rabbit corneas showed a 
definitive condensation of stroma underneath the epithelium. This condensation was 
considered to be as a part of the stroma rather than a separate layer (Davis, 1929). 
However, in our study, we were able to clearly identify a well-demarcated Bowman's 
layer immediately below the epithelium in all of the rabbit corneas examined. 
Supporting the results of our study, Hayashi et al. 2002,  described the existence of a 
Bowman's layer of 3µm thickness in the rabbit cornea (Hayashi, Osawa, & Tohyama, 
2002). Another study stated that the Bowman's layer is absent in adult rabbits while it 
can be present in early developmental stages of the rabbit cornea (Wilson & Hong, 
2000). This supports the results of our study because all our corneal samples were 
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obtained from young rabbits. Descemet's membrane was present in all three species 
(Figure 3.1). However, in our study, some of the rabbit corneas had heavily stained 
thick Descemet's membrane, which may be a characteristic feature of an ageing cornea 
as suggested by Davis et al.  (1929), who mentioned that in rabbits the Descemet's 
membrane become thicker in older animals (Davis, 1929) which contradicts our 
results. 
 
In conclusion, when comparing the CF diameter and interfibrillar distance of porcine 
and rabbit corneas with the human, it is evident that both of these animal corneas are 
not structurally identical to that of humans. However, both animal models have 
corneas sufficiently similar to the human cornea to be considered as research models. 
Furthermore, when both porcine and rabbits were compared, they have similar CF 
diameter and interfibrillar distance measurements. In general, both animals have 
significantly smaller CF diameters and interfibrillar distances compared to human. 
Therefore, for the next study (Chapter 4), we have used both rabbit and porcine cornea 
to evaluate morphological changes of the corneal stroma following CXL treatment and 


























CHAPTER 4  
Choosing an optimal animal model that 
mimics reactions of humans following 
Conventional Crosslinking treatment 
 
This chapter has been submitted for publication as an original research article in 
Current Eye Research Journal titles, Morphological alterations of porcine and 
rabbit corneas following Conventional Crosslinking Treatment (C-CXL) . The 




Keratoconus (KC) is a disease included in a broader range of conditions called 
corneal ectasias (keratectasia) which leads to spontaneous, non-inflammatory, self-
limiting ectasia of the cornea that results in localised corneal thinning with 
protrusion of the thinned cornea. Generally, this condition is managed by refractive 
correction, initially with spectacles but often rigid gas permeable lenses are used for 
mild to moderate cases. Severe forms of KC are treated by corneal transplantation 
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(penetrating keratoplasty or lamellar keratoplasty such as deep anterior lamellar 
keratoplasty (DALK) (Boimer et al., 2011) 
 
In recent years, corneal crosslinking (CXL) treatment with ultraviolet light (UVA) 
and riboflavin has been introduced as a minimally invasive treatment option to 
arrest the progression of keratectasia, and has revolutionised the treatment of KC 
(Jouve et al., 2017). Different animal models have been used to study corneal 
pathologies and their associated complications. Of these animals, porcine and rabbit 
corneas have been in use for many decades due to their similarity to human corneas. 
In Chapter 3, we discussed which animal model is closest to the human in relation 
to collagen fibrillar diameter, interfibrillar distance and interlamellar distance. In 
this chapter, we will be evaluating each of these animal models according to how 
they respond to crosslinking treatment to find the animal model that reacts similarly 
to humans. After that, the effects of crosslinking treatment will be evaluated using 
the same parameters such as the diameter of the collagen fibrils, interfibrillar 
distance and interlamellar distance to find the optimal animal model that mimics 
reactions of human corneas. This study will allow future researchers to study the 
therapeutic and side effects of crosslinking treatment.      
 
Swelling of the cornea from storage in culture media and effects on the hydration 
properties of the cornea due to the use of iso-osmolar riboflavin for crosslinking 
have emerged as factors that may affect the final measurements of CF diameter and 
interfibrillar distance. Therefore, two separate preliminary experiments were 
conducted to investigate the effects of these factors on the cornea. According to 
these initial studies, it was evident that corneal oedema/swelling due to storage in 
the culture media has a minimal effect on the corneal collagen fibrillar diameter and 
the interfibrillar distance following CXL treatment when compared to corneas 
stored in de-swelling solutions. Furthermore, it was also evident that the hydration 
effect of iso-osmolar riboflavin had no statistically significant impact on the corneal 
CF diameter and interfibrillar distance of a cornea compared to corneas which were 
not exposed to riboflavin solution (Appendix 6). 
 
In this chapter, we will examine and compare the morphology and CF arrangement 
of the healthy rabbit, porcine and human corneas with and without conventional 
CXL treatment. In addition, they will be compared with each other to find the 
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optimal animal model that mimics reactions of humans following CXL treatment. 
We have also looked into the reactions of keratocytes when exposed to CXL 
treatment in porcine, rabbit and human corneas.  
 
4.2 Materials  
 
4.2.1 Animal and human corneas 
 
 
The study was conducted with ten pairs of healthy porcine eyes obtained from the 
abattoir ("South Kill", Milton, New Zealand, formal approval was obtained from the 
animal ethics committee of University of Otago before the project, Appendix 2), ten 
pairs of healthy New Zealand White rabbit corneas obtained from the University of 
Otago, Christchurch, New Zealand (ethics approval was obtained from the Animal 
research ethics committee of the University of Otago, Animal ethics approval 
number: AEC 8/15D/601, Application number: CG4/17, Appendix 2) and ten pairs 
of healthy human corneas retrieved from bequeathed cadavers to the Department 
of Anatomy, the University of Otago (Human ethics committee, University of Otago, 
Ethics committee reference codes: H18/041, Appendix 2). The animal corneas were 
retrieved within six hours, and human corneas, due to logistical constraints, within 
24 hours post-mortem. In each pair, one cornea was used as the control with only 
epithelial debridement, while the other underwent epithelial debridement followed 
by CXL treatment. Left and right eyes were chosen randomly to be treated with CXL 
treatment and to act as controls. When the right eye was chosen for crosslinking 
treatment in every alternate animal on the same species. For instance, when the 
right eye was used for crosslinking treatment in one animal, for the next animal on 
the same species, the crosslinking was performed on the left eye, and again the right 
eye was chosen for crosslinking treatment of the following animal. The same 
method of randomisation was done for the human samples. 
 
4.2.2 Preparation of riboflavin solution 
 
Riboflavin solution with a 0.1% Riboflavin in 20% Dextran solution was prepared 
in a sterile condition within a biological safety hood as described by Søndergaard 
et al. (2010)(Søndergaard et al., 2010). 
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1. 0.1g of Riboflavin powder (R7774, Sigma-Aldrich, New Zealand)  measured 
and dissolved in 100ml of phosphate-buffered saline (PBS) using a magnetic 
stirrer. 
2. 20g of Dextran T500 (Pharmacosmos, Denmark) was added to the Riboflavin 
PBS solution and allowed to dissolve further. 
3. Once riboflavin was adequately dissolved, the final solution was aliquoted 
into 10ml sterile falcon tubes.  
4. The falcon tubes were covered with aluminium foil to prevent UV light -
exposure 
 
4.2.3 Preparation of culture media to store the excised corneal flap 
 
One litre of cell culture medium was prepared to contain Eagle's Minimal Essential 
Medium (MEM) with 20.0mM of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
solution (HEPES) buffer, 2.0mM of L-glutamine, 26mmol/L of NaHCo3 (S5761- 
Sigma Aldrich. New Zealand), 5% Foetal bovine serum(FBS) - 10437028, 
Thermofisher Scientific, New Zealand - and 1% of Antibiotic-antimycotic 
containing: 10,000units/ml penicillin, 10mg/ml streptomycin and 25µg/ml 




4.3.1 Retrieval of corneas 
 
Retrieval of the human corneas was performed by the technicians at "Rhinds 
Funeral Services", Christchurch, New Zealand. They had undergone training 
(conducted by the investigator) in excising corneas from an eyeball in-situ while the 
investigator retrieved all the other corneas (porcine and rabbit corneas) from an in-
situ eyeball. 
 
4.3.2 Sterilisation procedure 
 
Aseptic measures were followed from the time of retrieval of the corneas until their 
microstructural analysis. The instruments were sterilised in an autoclave as per 
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manufacturer specifications, and for each procedure, a new sterilised set of 
instruments was used. Before removal of the corneas at the corneoscleral junction, 
the corneas and the conjunctival sac were irrigated thoroughly, by several washes 
in sterile saline (0.9% wt/vol NaCl).  Followed by immersion in 1% (wt/vol) 
polyvinylpyrrolidone-iodine (PVP-I) for 2 minutes, 0.1% (wt/vol) sodium 
thiosulfate (to neutralise the iodine) for 1 minute, and another several washes of 
sterile saline solution (Armitage & Easty, 1997).  
 
First, the orbital area and the surrounding skin was cleaned with water and 
operative area of the skin was prepared according to standard pre-operative skin 
preparation. Cleaning started at the medial canthus of the closed upper eyelid and 
moved out, around and below the lid. The cleaning was then continued over the 
bridge of the nose in an ever-widening circular manner. This process was carried 
out twice around the orbital area. Care was taken not to let the povidone-iodine 
solution get into the eye. If the eyes were exposed to povidone-iodine by mistake, 
the exposed eye was rinsed promptly with water to avoid any toxicity to the cornea. 
Before commencing the corneal retrieval process, the operation field was covered 
with sterile drapes (Figure 4.1).   
 
4.3.3 Excision of the corneal flap 
 
Once the operation field was prepared, the eyelids were opened using a sterile 
cotton-tipped applicator and followed by insertion of solid blade eye-speculum. 
Care was taken not to touch the cornea with the solid blade eye speculum when 
inserting it to the eye. The conjunctiva was lifted and cut at the limbus 360° around 
the cornea using iris scissors. The adhesions between the conjunctiva and anterior 
globe were cleared so that the conjunctiva was not in contact with the anterior globe. 
Next, an incision was made through the sclera 2mm from, and parallel to, the limbus. 
This incision was extended 360° around the cornea without perforating the choroid 
or damaging the anterior chamber. When incising the cornea, the scissor blades 
should not be visible in the anterior chamber and care should be taken to avoid 
contact of the scissor blades with the corneal endothelium. When removing the 
cornea one small forcep was used to hold the corneal flap stationary and the second 
set of forcep used to push the ciliary body and choroid downward away from the 
corneal flap. Care was taken not to deform the corneal curvature by pulling since 
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this might cause cross-corneal tension. Furthermore, care was taken to prevent 
entering into the anterior chamber during the excision and prevent the corneal flap 
from contacting the eyelids or other facial skin, since these can result in endothelial 
damage and increase the risk of contamination (Figure 4.1). 
 
4.3.4 Transportation and storage 
 
Removed corneal flaps were then transported in culture media. The culture 
medium used in this study is the same culture medium used for human corneal 
preservation approved by the European Eye Bank Association (Armitage, 2011). 
The corneoscleral button was suspended in 10 ml Eagle's MEM containing HEPES 
buffer (20mM), 26 mmol/l NaHCO3, 2% FBS, two mmol/l  L-glutamine, 10000 
U/ml penicillin,  10mg/ml streptomycin and 25µg/ml amphotericin B, and stored 
at 34 °C in an incubator, with an atmosphere of 5% carbon dioxide and 95% air until 
























Figure 4.1- Excision of corneoscleral flap from a porcine eyeball 
A – Preparation of surgical filed 
B – Cleaning the operating eye with 1% polyvinylpyrrolidone-iodine 
C- Excision of corneoscleral flap 
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4.3.5 Crosslinking treatment 
 
Before crosslinking treatment, the corneas were taken out of the culture media and 
examined with a dissection microscope to exclude any signs of corneal pathology 
such as corneal scarring.  Only healthy corneas were used in this study. Five sets of 
porcine corneas, two sets of rabbit corneas and four sets of human corneas were 
discarded due to the presence of signs of corneal pathology. 
 
The thickness of the central cornea was measured using a Digital Vernier Calliper 
before crosslinking treatment and following CXL treatment. Firstly, the cornea was 
washed in saline solution and placed on a contact lens casing to maintain its 
curvature. A few drops of Sodium Hyaluronate solution (Hylo-fresh, 1mg/ml) were 
applied to the contact lens casing (before placing the cornea) to minimise 
endothelial damage when placing the cornea. The epithelium in the central region 
of the cornea, approximately 9 mm diameter, was cautiously debrided with a 
scalpel blade. We did not remove the entire eyeball from the eye socket and perform 
the treatment on intact eyeball due to the necessity of having the eyeball within the 
orbit of cadavers for subsequent medical training. Therefore, none of the corneas 
that underwent treatment in this study was performed on intact eyeballs. The 
standard CXL treatment protocol (Wollensak et al.,2003a) was used to treat the 
cornea. As a photosensitiser, riboflavin 0.1% solution (10 mg riboflavin-5-phosphate 
in 10 ml dextran T-500 20% solution in PBS) was instilled dropwise every 1 minute, 
for 30 minutes prior to irradiation to allow riboflavin to permeate through the 
cornea. During this time, riboflavin was instilled dropwise every 1 minute. Finally, 
the cornea was irradiated by UVA light (SDZ X-linker, ADX Electronics Limited, 
New Zealand) of 3mW/cm2 for 30 minutes. The riboflavin solution continued to be 
instilled every 5 minutes during the irradiation process (Figure 4.2a). 
 
4.3.5 Tissue processing method 
 
The corneal buttons were bisected soon after CXL treatment, and one half was fixed 
in 10% neutral buffered formalin solution, processed and embedded in paraffin for 
histological examination. The blocks were sectioned in the following manner: the 
first two consecutive sections were cut at 4µm thickness with one sample stained in 
H&E and the second sample stained with MT staining (Appendix 3). The stained 
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sections were examined under a light microscope to visualise the morphological 
features of the CFs and the distribution of keratocytes within the corneal stroma. 
This sequence of sectioning was repeated three times to cover a broader range of 
the corneal surface. Finally, there were three alternate sections stained with H&E, 
and three sections stained with MT (Figure 4.2b). 
 
The remaining half of the excised cornea was placed in a primary fixative solution 
(Appendix 4) and processed for TEM. Three sections from each specimen were 
analysed in this study. These sections were analysed from the anterior\superficial 
region (from within anterior 242µm thickness of the cornea), intermediate region 
(from within the next 107µm depth) and posterior\deep region (from within the 
remaining corneal thickness) (Figure 4.3) and from each region two random areas 
were chosen for detailed ultrastructural analysis. 
 
A. The minimum diameter of each CF was measured using the iTEM 
AnalySIS image processing software. The minimum diameter was measured to 
avoid errors caused by any obliqueness in fibril cross-sections. Collagen fibrils with 
clearly defined borders were chosen to measure the minimum diameter while the 
fibres with indistinct borders were discarded. The discarded fibres were less than 
1% of the total fibre count (Figure 4.3). 
 
B. The same images of fibril cross-sections that were used to measure the 
diameter were used to measure the nearest neighbouring distance/ interfibrillar 
distance between adjacent fibrils using the Fiji-ImageJ software. The measurements 
were taken from the centre of the mass of one fibril to the centre of mass of its nearest 
adjacent fibril (Figure 4.4). 
 
C. One image of a parallel running CF bundle (lamellae) was randomly 
chosen from anterior, intermediate and posterior regions of the cornea, and the 
distance between the adjacent parallel lamellae was measured. Three measurements 
were obtained for each pair of lamellae and of these readings, means were taken as 






Figure 4.2a - Standard Conventional Crosslinking Treatment 
 
A- Corneal buttons stored in culture media, B – Rinsing the corneal buttons prior to crosslinking treatment, C – Application of Sodium 
Hyaluronate solution prior to placing the corneal button on the contact lens casing, D- Removal of central corneal epithelium, E – Application of 


























Figure 4.2b – Corneal tissue preparation   
Corneal	buttons	
Primary fixative 10% neutral buffered formalin solution 
Processed and 
embedded in resin 
Section 1 Section 1 Section 1 
Anterior  (242µm) x 2 areas 
Intermediate (next 107µm) x 2 areas 
Posterior (immediately posterior to 
intermediate) x 2 areas 
Transmission electron microscopy 
Processed and 
embedded in paraffin 
3 alternate sections 
x 4µm 
3 alternate section 
x 4µm 






Figure 4.3 – Measurement of minimum diameter of collagen fibrils 
A- Cornea with different regions of the corneal stroma 
a- anterior region (anterior 242µm thickness of the cornea) , b – intermediate region (the 
next 107µm thickness)  and c – posterior region (the remaining posterior corneal 
thickness) 
B- Original TEM image of collagen fibrillar cross-sections 
C – Oblique cross-sectional fibrillar profiles can be identified depending on how the 
sections have been made (plate II). Plane I, collagen fibrils most likely to have less oblique 
fibrillar profiles. 
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For all of the above parameters (CF diameter, interfibrillar distance,  and 
interlamellar distance), the percentage of the difference between the control and 
treated corneas was calculated. It was compared in different regions of the corneal 
stroma. The use of the percentage of differences allowed us to more effectively 
compare changes between corneas of pigs, rabbit and humans. Furthermore, it 
allowed the identification of any significant differences in the effect of CXL 
treatment in different regions of the cornea.  
 
The formula for calculation of the percentage difference is as follows; 
 
Percentage difference = Measurement following CXL - Original measurement  *100 
                                                    Treatment 
                                      _____________________________________________ 
                                                                                                                                               
                                                                      Original measurement 
 
(Positive values indicated percentage increase while the negative values indicated 
percentage decrease) 
 
Finally, data sets from the porcine and rabbit corneas were compared with those 
from human corneas to find the optimal animal model to evaluate reactions of 
crosslinking treatment. 
 
D. Once the sections were taken for H&E and MT staining, five random sets 
of paraffin blocks from each animal model, including human, were used to analyse 
keratocyte apoptosis following CXL treatment. These paraffin blocks were 
sectioned in 4µm thickness sections that extend transversely through the full 
thickness of the corneal button. This orientation of the paraffin section allowed 
visualisation of all three regions of the cornea (anterior, intermediate and posterior) 
within the same section.  Three consecutive sections were cut from each paraffin 
block using the microtome (HistoCore AUTOCUT, Leica Biosystems) and placed on 
Superfrost Plus microscope slides and deparaffinised before starting the Peroxidate-
based terminal deoxyribonucleotidyl transferase-mediated dUTP-digoxigenin nick 
and labelling (TUNEL) assay (Wilson et al., 1996) described below (TUNEL assay 
kit - HRP-DAB (ab206386). The assay was performed according to the 
manufacturer's instructions at the Histology Unit, the University of Otago 
(Appendix 5).   
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The procedure, in brief; the paraffin sections were rehydrated with several 
concentrations of ethanol followed by permeabilisation using proteinase. 
Then the sections were quenched with endogenous peroxidase and 
incubated in 100µm of    Terminal Deoxynucleotidyl Transferase (TdT) buffer 
at room temperature for 30 minutes, and followed by removal of TdT buffer 
from the specimen (carefully blot the buffer out without touching the 
specimen) and application of  40µm of TdT labelling reaction mix covered 
with a coverslip. This prevented the specimen from dehydrating and assured 
even distribution of the reaction mixture within the specimen. The slides 
were placed in a humidified chamber and incubated at room temperature for 
1.5 hours. The labelling reaction was terminated using a stop buffer 
(Appendix 3), and after removing the stop buffer, the blocking was carried 
out using a blocking buffer (Appendix 3). The Blocking buffer was diluted in 
a 1:25 ratio with 25x conjugate solution (Appendix 3), and then the solution 
was removed from the slide (all of these above mentioned buffers (stop 
buffer, blocking buffer, conjugate solution) are provided by the supplier 
ready to be used). After storing in a humidified chamber for 30 minutes, the 
slides were washed in TBS (Tris-buffered saline) for 5 minutes. The sections 
were developed with Diaminobenzidine (DAB) solution (1:30 dilution) and 
incubated at room temperature for 15 minutes. Finally, the specimens were 
counterstained with Methyl Green solution. As a positive control, tissue 
sections of tonsils were used, and these gave the expected positive results of 











Figure 4.4 – Measurement of distance between collagen fibrils/ interfibrillar distance 
A- Original image of the cross sections of collagen fibrils, B- isolation of collagen fibrillar profiles, C- Numbering each collagen fibril to calculate 
the nearest neighbouring distance (NND) between each fibril profile, D – illustrated how the measurements were taken. As an example; image 
shows a specific collagen fibril and distance to its adjacent collagen fibrils (BLACK lines). While in NND value/ interfibrillar distance should be 




Figure 4.5 – Measurement of Interlamellar distance 
The image illustrates parallel running collagen fibrillar bundle/lamellae/collagen fibre in the anterior region of human cornea. The white 
arrows illustrate the three measurements that were taken and the mean of these three measurements were taken as the interlamellar distance of 





Figure 4.6- TUNEL assay detection of apoptotic keratocytes in corneal stroma 
Apoptotic cells are represented in darkly stained brown colour in porcine (B), rabbit (D) 
and human (F) CXL treated corneas.  The control samples (porcine (A), rabbit (C) and 
human (E) have TUNEL negative cells represented by more lighter stained blue/green 





Following staining with TUNEL assay, TUNEL positive cells were identified by 
counting the cells with prominent immunostaining in a visual field of 20x 
magnification through the entire thickness of the cornea using light microscopy. 
The number of apoptotic cells were counted in ten separate areas of each slide in 
both control and treated samples, as described by Mencucci et al. (2010) (Mencucci 
et al., 2010).  The areas visualised within each of these slides were selected 
randomly. Positive staining of apoptotic cells was represented by cells with dark 
brown nuclei. Lighter shades of brown and shades of blue-green to green-brown 
were considered as negative cells. The positively stained apoptotic nuclei were 
manually countered and recorded for data analysis (Figure 4.6).  
 
4.4 Data Analysis 
 
The mean values of treatment and control samples were taken for all the parameters 
tested and were compared using a standard Student’s t-test.  The percentage 
difference between treated and control corneas was computed for anterior, 
intermediate and posterior regions of the cornea. The mean percentage difference 
of CF diameter, interfibrillar distance and interlamellar distance was then compared 
between anterior, intermediate and posterior regions using one-way ANOVA. 
P<0.05 was considered significant. The calculation of the percentage difference not 
only prevented any errors that might occur due to swelling of the cornea but also 
allowed comparing porcine, rabbit and human with each other.  Depending on the 
ANOVA result, data showing a statistically significant change was chosen to 
calculate the 95% confidence interval (CI) to show up the correlation between 
different regions of the corneal stroma. Ordinary least square (OLS) regression was 
used as another way to statistically compare the changes in CF diameter, 
interfibrillar distance and interlamellar distance with human (reference species). 
The dependent variable is the percentage change, and the independent variables are 
the species (Pig and rabbit are compared against the reference corneas – human). 









Figure 4.7 – Comparison of porcine and rabbit percentage change with the human as the 
reference species 
 
Keratocyte apoptosis was analysed between the control and treatment samples, for 
each animal model, using the Student t-test to check if there was a statistically 
significant difference between the two groups. Statistical analysis was performed 
under the guidance of Dr. Ari Samaranayaka (Senior research fellow, Centre for 
Biostatistics, University of Otago) using GraphPad Prism (Version 8.4.3, ©1994- 




4.5.1 Central Corneal thickness (CCT) 
 
When comparing the mean values of control and treated corneas (Table 4), there 
was a statistically significant decrease in the central corneal thickness following 
CXL treatment in porcine, rabbit and human corneas.  
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Table 4 - Changes in the mean values of pre- and post- CXL treatment and percentage difference between different regions of the cornea 
following CXL treatment  
 
                             Porcine 
 































Central corneal thickness (mm) 
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H&E and MT staining allowed the visualisation of the general arrangement of 
corneal collagen fibre (collagen lamellae) morphology in all the species. The 
distribution of collagen fibres within the corneal stroma was visualised clearly with 
samples stained with MT staining. The outer layer of the epithelium was not present 
due to removal of the epithelium before CXL treatment. However, the deeper layers 
of the corneal stroma were well preserved. In treated corneas, the collagen fibres 
were more tightly packed in the anterior region. The fibres became loosely packed 
in the posterior region with the fibre distribution in this region becoming similar to 
control corneas. No observable pathological changes were seen with standard light 
microscopy in all sections, including the control samples in porcine, rabbit and 
human corneas. Keratocytes were distributed throughout in control corneas, while 
in treated cornea there was heterogeneous patchy keratocyte loss. There was no 
evidence of foreign materials such as riboflavin crystals embedded within the 
corneal stroma (Figure 4.8). 
 
4.5.3 Transmission Electron Microscopy 
 
The results of the TEM investigations will be reported in the following order; 
1. The actual mean values and standard deviations (Table 4) for each species 
and their significant findings will be discussed at the beginning. 
2. The percentage of difference which has been stated earlier (data analysis) 
were plotted to minimise the effect of corneal swelling and to enable the 
comparison across species.  These differences are shown in Figure 4.9, 4.10. 
and 4.11. 
3. Multiple OLS regression results are shown in Table 5, where porcine and 













Figure 4.8 – Light microscopy images of corneal stroma pre- and post-CXL treatment 
Corneal stroma before CXL treatment [Porcine (A,B), rabbit (C,D), human (E,F)] 
Corneal stroma after CXL treatment [porcine (G,H), rabbit (I,J), human (K,L) 
G, H, I, J, K, L – magnified image of the anterior stroma illustrating the distribution of keratocytes. 





Table 5 – Multiple OLS regression which compare the percentage difference of collagen 
fibrillar diameter, interfibrillar distance and interlamellar distance in corneas between 
species  
 
 Coef.                  95% CI  P value 
Fibrillar Diameter     
    Human (reference)     
    Porcine  -5.08 -7.53 -2.63 <0.001 
    Rabbit 2.59 0.14 5.04 0.038 
         
     
Interfibrillar Distance     
    Human (reference)     
    Porcine  0.12 -4.40 4.65 0.957 
    Rabbit -5.89 -10.41 -1.36 0.011 
     
     
Interlamellar distance     
    Human (reference)     
    Porcine  -18.12 -26.53 -9.71 <0.001 
    Rabbit  -33.32 -41.73 -24.92 <0.001 
         
 
Interpretation of results; 
 
A. Collagen fibrillar (CF) diameter;  
 
When evaluating the raw values in Table 5, the CF diameters in the anterior and 
intermediate regions significantly increased in rabbit and porcine corneas. For both 
animals, however, there was no change in CFs in the posterior region. In human 
corneas, the CF diameter was significantly increased in all three regions.  
 
Looking at the percentage values for CF diameter (Figure 4.9) all three species 
showed the same general trend of having the most significant increase in fibril 
diameter in the anterior region, followed by the intermediate and finally the 
posterior region. The percentage increase in rabbit and human CF diameter was 
about four times those of porcine corneas, where the CF diameter was only 
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significantly different between the anterior and posterior regions, whereas for the 
rabbit corneas, all three regions showed statistically significant differences from 
each other.  
 
According to Table 5, which represent data from multiple OLS regression, in 
relation to the human cornea, the percentage CF diameter increase is significantly 
greater in rabbit corneas and significantly less in porcine corneas. 
 
B. Nearest Neighbouring Distance between collagen fibrils (CFs) 
(interfibrillar distance);  
 
When the mean values of control corneas and treated corneas were compared, the 
mean interfibrillar distance of porcine cornea showed a significant decrease after 
CXL treatment in anterior and intermediate regions, but no change in the posterior. 
Rabbit and human corneas showed a statistically significant decrease in all the three 
regions of the cornea (Table 4).   
 
According to Figure 4.10, the general pattern of decrease in the interfibrillar distance 
for each species was more evident in the anterior regions with the effect becoming 
less when moving into deeper regions of the cornea.  When comparing the 
percentage decrease between species, all three regions of the porcine cornea 
(anterior, intermediate and posterior) showed a significant difference between the 
regions. In rabbit cornea, there was a statistically significant difference in the 
percentage decrease between anterior and posterior regions while no significant 
difference was observed between anterior - intermediate and intermediate - 
posterior regions. In contrast to both porcine and rabbit corneas, in human corneas, 
there was no change in the interfibrillar distance in any of the regions following 
crosslinking treatment.  
 
Looking at the multiple OLS regression data (Table 5), in general, in porcine 
corneas, the percentage change of the interfibrillar distance was almost similar to 
humans while human interfibrillar distance was significantly different from rabbit. 
Furthermore, the percentage decrease in the interfibrillar distance in rabbit is 










Figure 4.10- Changes in the interfibrillar distance percentage difference and comparison between  different regions of the cornea (95% 
confidence interval) 
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C. The distance between adjacent collagen lamellae (fibrillar bundles) 
(interlamellar distance);  
 
When investigating the mean values indicated in Table 4, there was no change in 
the interlamellar distance of porcine corneas following crosslinking treatment while 
in both humans and rabbits there was a significant reduction in the interlamellar 
distance. For instance, in rabbits, the interlamellar distance significantly decreased 
in all the regions of the cornea.  In the human corneas, a statistically significant 
decrease in the interlamellar distance, was only evident in the anterior and 
intermediate regions. The posterior region did not show any change. 
 
According to Figure 4.11, the general trend of decrease in the interlamellar 
percentage difference was similar in all the species, whereas the maximum effect 
was evident in the anterior regions of the cornea. In contrast, the amount of decrease 
in the interlamellar distance becomes less in deeper regions of the cornea. The 
porcine interlamellar distance was not changed in any of the regions following 
crosslinking treatment. There were significant differences between all three regions 
of the rabbit cornea. In humans, significant changes in the interlamellar distance 
were only apparent between the anterior and posterior regions of the cornea, with 
the intermediate region showing no change when compared with anterior and 
posterior regions of the cornea following crosslinking treatment.  
 
Table 5 shows that the percentage changes in the interlamellar distance of both 
porcine and rabbit cornea was significantly different from human. In both animals, 
the reduction of the interlamellar distance was significantly less than in human 













Figure 4.11- Changes in the percentage difference of interlamellar distance and their 
comparison between different regions of the cornea (95% confidence interval) 
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4.5.6 TUNEL Assay for Porcine, Rabbit and Human Corneas 
 
Apoptotic keratocytes were visualised in all of the regions of the treated corneas in 
rabbit, porcine and human corneal samples. In control samples, there was minimal 
keratocyte apoptosis, with some samples showing no sign of apoptotic cells (Figure 
4.6). The mean number of apoptotic cells present within the full thickness of porcine 
control corneal stroma was 1.9 ± 0.8, while in treated samples, apoptotic cells 
increased to 22.7 ± 2.0. In rabbit corneas, the corresponding values were 3.4 ± 0.7 
and 25.1 ± 1.1, respectively for the control and treated corneal stroma. In human 
corneas, apoptotic cells were 2.6 ± 1.4 in control samples while in CXL treated 
samples; there was a marked increase in the number of apoptotic cells to 23.7 ± 3.9. 
All three models showed a statistically significant increase in keratocyte apoptosis 
following CXL treatment compared to the control samples (porcine p=<0.001; rabbit 




An increase in the CF diameter in the corneal stroma is a phenomenon that has been 
described in ageing corneas (Blackburn, Jenkins, Rollins, & Dupps, 2019). It was 
stated that the CF diameter increases by 4.5 per cent over a person’s lifetime due to 
age-related glycosylated crosslinking. The corneas of people suffering from diabetes 
mellitus undergo a similar process of “accelerated ageing of the cornea” which also 
results in increasing the CF diameter (Wollensak et al., 2004). The original idea that 
crosslinking might halt the progression of keratoconus came from the initial 
observation that showed people with diabetes and keratoconus had significantly 
reduced progression compared keratoconus patients who did not have diabetes 
(Dahl et al., 2012). Therefore, with the observation that CXL did increase CF 
diameter, it was thought that this was one mechanism by which the cornea could 
resist the progression of keratoconus.   
 
This study shows that CXL treatment significantly increases CF diameter in porcine, 
rabbit and human corneas, with the greatest increase occurring in the anterior 
cornea and the least increase in the posterior cornea (where, sometimes no increase 
occurred). Several studies have described the increased diameter of collagen fibrils 
following crosslinking treatment (Wollensak, 2006; Wollensak et al., 2004). 
	 120	
According to a study by Akhtar et al. (2013), the mean diameter of a normal CF of a 
human cornea is 23.8 ±4.5nm while in a keratoconic cornea it is 21.3 ±2.5nm. 
Following crosslinking treatment, the author reported that the diameter increased 
to 22.4 ±3.1nm. Therefore, it was evident that the corneal CF diameter became 
similar to the normal diameter following crosslinking treatment in keratoconic 
subjects (Akhtar et al., 2013). Another study which was performed on rabbit corneas 
reported a statistically significant increase in the mean values of the CF diameter in 
both anterior and intermediate regions, while no change in the posterior region. The 
increment in the CF diameter in the anterior region was by 12.2% while the posterior 
region showed only 4.6% increment (Wollensak et al., 2004). Their values are similar 
to our rabbit study in which the corresponding increments were 10.9% and 3.7% 
respectively. Mencucci et al. (2010) reported a 22%  increment in human corneal CF 
diameter following CXL treatment in the anterior region while the posterior region 
was without any change (Mencucci et al., 2010). This finding is different to ours, 
where the increment of CF diameter was less than 15 per cent in the anterior region 
with the posterior region showing less than 5 per cent increment. Besides, we 
demonstrated that all three regions of the human cornea showing a statistically 
significant percentage increase in the CF diameter following treatment. Another 
study using transepithelial CXL treatment, stated that this technique only affected 
the CF distribution but not the CF diameter (Mencucci et al., 2013). The difference 
between their results and ours can easily be explained by the difference in the 
crosslinking procedures employed.  
 
When looking at the percentage difference between treated and control corneas of 
different species, all the three regions (anterior, intermediate and posterior) of the 
porcine cornea showed a statistically significant percentage decrease in the 
interfibrillar distance, while humans showed no changes in any of the regions 
following treatment. In rabbits, the change was significant only between anterior 
and posterior regions while no change was observed between anterior - 
intermediate and intermediate – posterior regions. In general the magnitude of the 
change in the interfibrillar distance in porcine cornea was similar to the human. In 
all three species, the effect of decrease in the interfibrillar distance was more in the 
anterior region while the effect of CXL treatment on interfibrillar distance gradually 
become less in deeper regions of the cornea. Not many previous studies have looked 
into the changes in the interfibrillar distance post-CXL treatment. An X-ray 
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scattering study by Hayes et al. (2013), compared the interfibrillar distance between 
standard CXL treatment, in porcine and rabbit corneas, using a hypo-osmolar 
riboflavin solution. They reported a decrease in the interfibrillar distance in whole 
of the corneas treated with the standard method and an increased effect with the 
hypo-osmolar method. They attributed these changes due to increased hydration of 
the cornea (Hayes et al., 2013), which is similar to the results of our study. According 
to this study, the interfibrillar distance was decreased from 61.7 ±2.1nm to 60.3 
±1.6nm following treatment which was similar to our range of decrease in the 
interfibrillar distance.  However, this study did not investigate the interfibrillar 
distance in different regions of the cornea, unlike the present study. Contradicting 
our results, a study by Akhtar et al. (2013) using standard CXL treatment stated that 
interfibrillar spacing of CXL-treated human keratoconic corneas was higher than 
non-treated human keratoconic corneas, which suggests that CXL treatment leads 
to an increase in the interfibrillar distance (Akhtar et al., 2013). However, the 
authors have stated that this increment could be due to postoperative oedema. 
Besides, this study was conducted using only three corneas, limiting the 
generalizability of the results. 
 
According to our study, in general, there was a decrease in the interlamellar 
distance following crosslinking treatment in both human and rabbit corneas. There 
was no change in interlamellar distance in porcine corneas. Human corneas showed 
a statistically significant decreases in the anterior and intermediate regions, but no 
change in the posterior region. When looking at the effects of crosslinking treatment 
on porcine and rabbit corneas, extent of the decrease in the interlamellar distance 
was smaller than for human. None of the currently published literature has 
examined the effects of CXL treatment on interlamellar distance. Additionally, we 
could not find any study that has investigated the changes in the interlamellar 
distance to an extent where the changes of the CXL treatment on different regions 
of the cornea were compared within each other. A study on the interlamellar 
cohesive forces following CXL treatment suggested that the treatment does not 
make any cross-linkages between lamellae in porcine corneas, and it mainly affects 
only the intra- and inter-fibrillar collagen molecule bonds, especially in the anterior 
region of the crosslinked cornea. According to this study, the interlamellar distance 
and different orientations of the fibrillar lamellae impede the formation of crosslinks 
between stromal collagen lamellae (Wollensak et al., 2011). In our study, porcine 
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corneas showed no change in the interlamellar distance following treatment; 
however, both rabbit and human showed a statistically significant decreases in the 
interlamellar distance post-treatment. This may be due to the absence of 
crosslinking between collagen lamellae as suggested by Wollensak et al. 2011. For 
instance, when crosslinks attaching collagen fibrillar bundles (lamellae) to each 
other are absent, the magnitude of increase in the CF diameter and decease in the 
interfibrillar distance have an influence on the distance between adjacent lamellae. 
Therefore, depending on the magnitude of the changes that occur in other factors 
(CF diameter and interfibrillar distance) may have an influence on the interlamellar 
distance. However, this we believe need to be examined further in the future.  
 
In general, we were able to identify that the effect of the crosslinking treatment on 
the corneal stroma seems to be more evident in the superficial regions while the 
crosslinking effect becomes less in deeper regions of the corneal stroma (posterior 
region). This pattern was observed in all the parameters investigated in this study 
(CF diameter, interfibrillar distance and interlamellar distance) The reduced 
crosslinking effect towards the deeper regions of the cornea can be explained by the 
gradual loss of UVA irradiation due to increasing UVA absorption by the riboflavin. 
The anterior localisation of the crosslinking effects is beneficial in the sense that the 
endothelium is protected from photooxidative damage during the treatment. 
Different studies have been performed to evaluate the depth of the crosslinking 
effect, and these studies shown that the amount of crosslinking happening during 
the crosslinking process depends on the strength of the riboflavin solution and the 
time riboflavin is applied on the cornea. Another factor that contributes to the extent 
of crosslinking is the wavelength of the UV light (Schilde et al., 2005; Schumacher 
et al., 2012; Spoerl et al., 2007). According to a study by Schilde et al. (2005), on 
enucleated porcine eyes showed that 65 per cent of riboflavin is absorbed into the 
first 200µm thickness of the corneal stroma, and the next 25-30 per cent is absorbed 
by the next 200µm thickness. Thus the crosslinking effect is largely limited to the 
anterior and intermediate parts of the corneal stroma (Schilde et al., 2005). This 
supports the findings of our study.   
 
The corneal thinning effect caused by the crosslinking treatment has been 
documented in the literature. It is generally found even in the early postoperative 
period (Greenstein et al., 2011) and can continue for 1-3 months following treatment 
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(Kymionis et al., 2009). Several other studies have also described the thinning effect 
of CXL treatment at different time periods, even up to 12 months post-treatment 
(Grewal et al., 2009; Koller, Iseli, Hafezi, Vinciguerra, & Seiler, 2009; Vinciguerra, 
Camesasca, Albe, & Trazza, 2010). In contrast, another study indicated that the 
thinning effect continues for three months of post-CXL treatment, and after which 
the corneal thickness increases until 12 months (Greenstein et al., 2011). In some 
cases, the thinning effect post-CXL treatment was so significant that it resulted in 
endothelial damage (Pang et al., 2016). The results of the present study support 
these previous findings and demonstrate a statistically significant thinning effect 
following CXL treatment in porcine, rabbit and human corneas. However, the 
decrease in the interlamellar distance varied from species to species. Therefore, it 
can be assumed that the decrease in the CCT following crosslinking treatment can 
be mainly a result of the decrease in the interfibrillar distance, while interlamellar 
distance might also have a minor contribution. A study on the hydration properties 
of the cornea following CXL treatment have found no significant change in the CCT 
following CXL treatment. It was assumed that this lack of change in the CCT might 
be a result of compensation of the thinning effect of CXL treatment by an increase 
in CF diameter during the treatment (Kontadakis et al., 2013). We also noted a 
statistically significant increase in the CF diameter post-CXL treatment although 
unlike the study by Kontadakis et al. (2013), we had a significant reduction in the 
CCT following treatment. In keratoconus patients, the CF diameter is around 
21.30nm (Akhtar et al., 2013), whereas according to our study, this value was  
increased to 26.12nm post- treatment. Therefore, we could state that CXL treatment 
not only result in thinning of the cornea but also by making the CF thicker, it makes 
the cornea denser. We postulate that formation of a denser cornea results in 
successfully resisting the continued corneal deformation in keratoconus.    
 
Changes in the CCT, CF diameter,  interfibrillar and interlamellar distance can also 
be influenced by other factors such as corneal hydration (Wollensak  et al., 2007), 
oedema (Dohlman, Hedbys, & Mishima, 1962; Wollensak et al., 2007), keratocyte 
apoptosis (Mazzotta et al., 2008; Wollensak et al., 2004) and changes in the 
glycosaminoglycans (Michelacci, 2003). For instance, it is believed that the CXL 
treatment has an effect on the corneal hydration immediately after the procedure 
and its effects on the swelling properties of the cornea (Gregor Wollensak, Aurich, 
et al., 2007). Another study described that CXL effects not only the swelling 
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properties of the cornea under induced oedema but also the hydration status of the 
cornea under dehydrated condition (Kontadakis et al., 2013). Therefore, to evaluate 
the effect of hydration (due to extra 30 minutes exposure to riboflavin during CXL 
treatment and due to storage of cornea in culture media prior to CXL treatment) on 
the parameters we measure in this study, we have performed a preliminary study 
which has been described in Appendix 6. This preliminary study, found out that 
corneal swelling due to storage in culture media and extra 30 minutes riboflavin 
exposure on the treated cornea, compared to the control cornea which was not 
exposed to the above conditions, has no significant effect on the CF diameter and 
the interfibrillar distance. In addition, the present study, rather than comparing 
absolute values, we have compared the percentage difference between different 
regions of the cornea (anterior, intermediate and posterior regions). All these factors 
enabled us to mitigate errors that might occur due to the increased hydration of 
corneas stored in culture media. None of the previously published studies has taken 
into consideration the percentage difference when comparing these parameters.  
 
Keratocytes, or corneal fibroblasts are one of the primary cell types in the corneal 
stroma and are responsible for maintaining the corneal transparency and 
mechanical stability. In the new-born, these cells comprise 40% of the stromal 
volume but this substantially decreases to 10% in the adult cornea (Jester, Petroll, & 
Cavanagh, 1999). Synthesis and maintenance of the collagen fibrils and the 
extracellular matrix within the corneal stroma is affected by these keratocytes 
(Hahnel, Somodi, Weiss, & Guthoff, 2000). In a mechanical injury to the corneal 
epithelium, there is keratocyte apoptosis. This is a response initiated to prevent 
further damage to the corneal stroma by pathological organisms, and prevent 
further inflammation of the cornea that may subsequently result in loss of its 
transparency. Thereafter, over a period of weeks to a few months, the cornea will 
be restored to its normal status (Müller et al., 2020; Wilson, 2000). A study by 
Mencucci et al. (2010) stated that CXL treatment with UVA and riboflavin not only 
leads to keratocyte apoptosis but also promotes keratocyte repopulation at the same 
time (Mencucci et al., 2010). According to a study on rabbits to identify keratocyte 
apoptosis using different UVA irradiances from 0.75 to 4mW/cm2, noted that the 
keratocyte loss depends on the dose of the UVA irradiation applied. For instance, 
the dose of irradiation used in CXL treatment leads to keratocyte apoptosis up to 
300µm depth of the corneal stroma soon after the crosslinking treatment. Keratocyte 
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apoptosis was more significant 24 hours after treatment than immediately following 
the CXL treatment (Wollensak, 2006; Wollensak et al., 2004).  Similar results have 
been reported in human corneas by in vivo confocal microscopy (Mazzotta et al., 
2007a; Mazzotta et al., 2008) and in vitro study on keratocytes (Wollensak, Spoerl, 
Reber, & Seiler, 2004). Supporting the above studies, we identified significant 
keratocyte apoptosis following CXL treatment in rabbits, porcine and human 
samples. The amount of keratocyte apoptosis post-CXL treatment in porcine, rabbit 
and humans seems to be of similar intensity. 
 
There were several limitations to the present study. The first limitation is concerning 
the CCT. Not all the CCT measurements were obtained from the same location at 
the centre of the cornea and it was difficult to find the exact same position for all the 
samples. The second limitation is the accessibility of human corneas. The corneas 
used in the present study were retrieved from cadavers donated to the Anatomy 
Department. However, obtaining a cornea within 24 hours post mortem was 
difficult. Therefore, the investigation was limited to only ten pairs of human corneas. 
When preparing samples for TEM examination, studies have found that it leads to 
shrinkage of the specimen due to the extensive dehydration process  during the 
sample preparation  (Fullwood & Meek, 1993). Therefore it is likely that some tissue 
shrinkage occurred during the preparation of the TEM samples.  
 
In summary, the present study assessed the corneal CF diameter, interfibrillar 
distance, interlamellar (CF bundle) distance, keratocyte apoptosis and changes in 
the CCT following crosslinking treatment.  CXL treatment leads to an increase in 
CF diameter, decrease in interfibrillar distance, and a decrease in interlamellar 
distance. The general pattern is that these changes were greatest in the anterior 
region of the corneal stroma, followed by the intermediate region, followed by the 
posterior region. This means that sometimes the changes in the posterior region did 
not reach the level of statistical significance. Also, while the changes in CF diameter 
and the interfibrillar distance were substantial, those for interlamellar distance were 
much less. All the species showed statistically significant keratocyte apoptosis and 
a significant reduction in the CCT following CXL treatment. The net effect of all 
these changes following conventional crosslinking (using the Dresden protocol) 
was a reduction in corneal thickness and a concurrent increase in corneal density 
probably resulting in an increased corneal stiffness that would explain how the 
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crosslinked human cornea is better able to resist the deformation caused by 
keratoconus, as has been reported in the literature. 
 
One advantage of this study is that we used percentage difference to compare the 
changes between species so as to negate the effects of different starting dimensions 
of the measured parameters and of increased corneal hydration.  
 
When choosing an optimal animal model that mimics reactions in human corneas, 
even though both models (rabbit and pig) can be used to study the effect of CXL on 
the human cornea, the magnitude of the differences in the changes post-CXL 
treatment in porcine corneas, compared to humans, were less than the rabbits. 
Therefore, it could be concluded that porcine corneas are a superior model than 











Evaluating the short- and long-term 




The wound-healing response of the cornea has been studied in detail. It is believed 
that the wound-healing response of cornea varies from species to species and, 
depends on the type of wound. The outcome of a corneal wound depends on 
whether its basement membrane is damaged or preserved during an injury. When 
the basement membrane is intact, the possibility of having corneal scar formation is 
much less than when it is destroyed (Au - Castro et al,.  2019). In CXL treatment, 
epithelial debridement is performed without damaging the basement membrane, 
enabling it to regenerate the corneal epithelium and prevents corneal scarring. The 
wound-healing processes of rabbit and porcine corneas have been investigated in 
vitro (Medin & Davanger, 1987; Stepp et al., 2014; Summerlin et al., 1973). However, 
these studies were performed to evaluate the reactions of the cornea to incisional 
injuries with very few evaluating the changes in the collagen fibril (CF) morphology 
within the corneal stroma in epithelium-debrided corneas (Stepp et al., 2014). No 
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in-vitro model has been developed to investigate the changes of the stromal CFs 
following crosslinking treatment.   
 
Few studies have investigated the short- and long-term reactions of the corneal 
stroma following CXL treatment. However, all of these studies were performed in 
vivo on different animal models (Bottós et al., 2008; Salomão et al., 2011; Tabibian et 
al., , 2017). Therefore, the use of human corneas to evaluate the morphological 
changes of CFs following treatment remains practically impossible, especially if the 
purpose of the study is to investigate the effects of treatment for specific time points. 
This necessitated us to develop an in vitro model for human corneas, that would 
allow us evaluate the effects of CXL treatment on the cornea over a fixed time points. 
In many eye banks, the human donor corneas are stored in culture media for 4-5 
weeks, without any adverse outcomes to the quality of the cornea, prior to being 
used for transplant surgeries (Pels, Beele, & Claerhout, 2008).  
 
Therefore, the present study aimed to preserve crosslinked corneas in culture media 
for two weeks and to investigate the changes in the CF morphology over that 
period. Understanding the morphological changes that occur in CFs following CXL 
treatment in an in vitro model would enable investigators to develop better 
treatment options for the patients with keratoconus without directly testing these 
new techniques on humans and live animals. Additionally, this will allow for future 
research to improve the existing treatment techniques of CXL treatment and 
investigate its effect on the cornea for an extended time.  
 
The present chapter discusses the changes of collagen fibrillar morphology, over a 
period of two weeks following CXL treatment in vitro and the measures that were 
taken to improve the viability of crosslinked cornea in a culture medium.  
 
A preliminary study was conducted using three pairs of porcine corneas (before 
performing the main study with the human corneas) to identify the maximum 
duration a crosslinked cornea can be kept in a culture medium (until the cornea 
becomes opaque and shows signs of corneal death, such as loss of corneal CF 
architecture or signs of endothelial damage). These features were examined with 
phase-contrast microscopy every three days after placing the cornea in the culture 
medium. It was concluded that the maximum time that porcine corneas can be 
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maintained in culture media (using the methods that we employed) is two weeks, 
and this time frame was chosen to culture the human samples (discussed in 5.2).  
 
5.2 Morphological changes of the stromal collagen fibrils 




The study was conducted using 15 pairs of human corneas. These corneas were 
retrieved from cadavers bequeathed to the Department of Anatomy at the 
University of Otago (Human ethics committee, University of Otago, Ethics 




A. Retrieval of corneas: 
 
Retrieval of the human corneas was performed by technicians at "Rhinds Funeral 
Services", Christchurch, New Zealand. All technicians had undergone prior training 
in excising corneas from eyeballs in-situ by the investigator. All corneas were 
obtained within 24 hours post-mortem.  
 
B. Sterilisation procedure and Excision of the corneoscleral flap 
 
Aseptic measures were followed from the time of retrieval of the corneas until their 
histopathological examination. Sterilisation procedure and the method of excision 
of the corneoscleral flap was exactly the same as described in Chapter 4 (4.3). 
 
C. Transportation and storage 
 
Removed corneoscleral flaps were then transported in a culture medium. The 
culture medium used in this study is the same as that used for human corneal 
preservation and approved by the European Eye Bank Association (Armitage, 
2011). Once received in the laboratory, the corneoscleral button was suspended in 
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10 ml of Eagle's Minimal Essential Medium (MEM) with 20.0mM of 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic solution (HEPES) buffer, 2.0 mM of L-
glutamine, 26mmol/L of NaHCo3 (S5761- Sigma Aldrich. New Zealand), 5% Foetal 
bovine serum(FBS) - 10437028, Thermofisher Scientific, New Zealand - and 1% of 
Antibiotic-antimycotic containing: 10,000units/ml penicillin, 10mg/ml 
streptomycin and 25µg/ml amphotericin (A5955, Thermofisher Scientific, New 
Zealand), and stored at 34 °C in an incubator until the crosslinking treatment which 
was performed within the next 24 hours. 
 
Five time points were used to analyse the changes that occurred in the morphology 
of collagen fibrils following CXL treatment. The time points were as follows: 
1. Immediately following CXL treatment; 
2.  24 hours after CXL treatment; 
3. Three days following CXL treatment; 
4. 1 week flowing CXL treatment; and 
5. Two weeks following CXL treatment.  
 
For each human, one cornea was used as the control with only epithelial 
debridement, while the other was treated with CXL treatment. Three sets of corneas 
were evaluated at each time point. Before crosslinking treatment, corneas were 
taken out of the culture medium and examined with a dissection microscope to 
exclude any signs of corneal pathology such as corneal scarring. Only healthy 
corneas were used in this study. During this study, five sets of corneas were 
discarded due to signs of pathology such as corneal scarring.  
 
D. Crosslinking treatment 
 
The crosslinking treatment was performed according to Wollensak et al. (2003) as 
described in Chapter 4 (4.3). As photosensitiser, riboflavin 0.1% solution (10 mg 
riboflavin-5-phosphate in 10 ml dextran T-500 20% solution in PBS was applied 30 
minutes before the irradiation to allow riboflavin to permeate through the cornea. 
During this time, riboflavin was instilled dropwise once per minute. Finally, the 
cornea was irradiated by UVA light of 3mW/cm2 for 30 minutes. The riboflavin 




Soon after CXL treatment, both treated, and control corneas were transferred into 
separate 75 ml sterile tissue culture flasks filled with culture media. The culture 
media and the method of culturing the cornea used for this study component were 
the same as previously described (Doughman et al., 1974; Summerlin et al., 1973). 
The culture media consisted of following ingredients; Eagles MEM with Earl's salt 
but without L-glutamine (51412C, Sigma-Aldrich, New Zealand), with 10% foetal 
bovine calf serum (FBS), 1% L-Glutamine, antibiotic antimycotic mixture 
(1000U/ml Penicillin, 10000 µm Streptomycin, 25µg per ml Amphotericin) (Culture 
medium 1). 
 
The corneoscleral flap was placed in the culture medium with the epithelial side 
down and examined with Phase-contrast microscopy to ensure that the 
endothelium was intact. Once confirmed that there were no signs of endothelial 
damage the culture flask containing the corneal samples were stored in a tissue 
culture incubator at 34 ºC with an atmosphere of 5% carbon dioxide and 95% air. A 
gravity feeding technique was used for pipetting the organ culture medium into the 
tissue culture flask. The culture medium was replaced every three days using sterile 
pipettes. Following each medium change, and before taking out the cornea for 
further processing at each time point, corneoscleral flaps were examined with a 
Phase-contrast microscope to confirm an intact endothelium (Figure 5.1 and Figure 
5.2). At each time point, the presence of an undamaged endothelium was confirmed 
with the Phase-contrast microscope, and these three sets of corneal samples (both 
treated and control) were taken out of the culture media for further processing. 
 
In the corneas that were taken out of the culture media, the central region was 
chosen to make a sample, and the sectioned corneal samples were placed in a 
primary fixative solution (Appendix 4) and processed for TEM (CM100 BioTWIN 
Philips Transmission Electron Microscope). Three sections from each specimen 
were analysed in this study. These sections were analysed from the 
anterior/superficial regions (from within anterior 242µm thickness of the cornea), 
intermediate region (from within the next 107µm depth) and posterior/deep region 
(from within the remaining corneal thickness). From each region, two random areas 
were chosen for detailed ultrastructural analysis. The parameters analysed were the 
minimum diameter of the CF, interfibrillar distance and interlamellar distance. A 
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detailed description of the procedure of how these parameters were analysed has 
been described in Chapter 4.   
 
For all of the above parameters (CF diameter, interfibrillar distance and 
interlamellar distance), the percentage of the difference between the control and 
treated corneas were calculated for different regions of the corneal stroma. These 
percentage differences were compared at different time points (24 hours, three days, 
one week and two weeks) for each region to analyse the changes in the morphology 




Figure 5.1 – The technique of maintenance of corneas in a culture medium 
A – Crosslinking treatment of excised corneal flap 
B – Placement of the cornea in the culture medium epithelial side down 
C – Storing the samples in an incubator at 37 ºC with an atmosphere of 5% carbon dioxide 
and 95% air 





Figure 5.2 – Evaluation of endothelium at each time points before taking the cornea out of the culture medium for further processing 
A – Control corneal endothelium (without any intervention), B -Immediately following CXL treatment, C -- 24 hours following CXL treatment, 
D – 3 days following CXL treatment, E – 1 week following CXL treatment, F – 2 weeks following CXL treatment, 





5.2.3 Data Analysis 
 
The percentage of the difference between treated and control corneas were computed 
for anterior, intermediate and posterior regions of the cornea. The mean percentage 
differences of CF diameter, interfibrillar distance and interlamellar distance were then 
compared at different time points for each region using one-way ANOVA. P<0.05 was 
considered significant. Statistical analysis performed using the GraphPad Prism 
(Version 8.4.3, ©1994- 2020 GraphPad Software, LLC) under the guidance of Dr Ari 
Samaranayaka, a Senior Research Fellow at the Centre for Biostatistics, the University 




A. Collagen fibrillar (CF) diameter 
 
There was no notable difference in the increased percentage difference of the CF 
diameter in all the regions from the 24 hours after CXL treatment until the two weeks 
after CXL treatment (anterior p=0.13, intermediate p=0.06 and posterior p=0.24) 
(Figure 5.3). In other words, the increase in the CF diameter observed immediately 
following CXL treatment did not change significantly over the following two-week 
period. A week following CXL treatment, the CF diameter stabilized, even though 
there was no significant change from immediately after CXL to two weeks later 
(Figure 5.3). 
 
B. Interfibrillar distance 
 
In general, the decrease of the interfibrillar distance between treated and control 
corneas did not change significantly during two weeks in vitro – i.e. the reduction in 
the interfibrillar distance seen in chapter 4 immediately following CXL did not alter 
significantly for the next 2 weeks (anterior p=0.20, intermediate p=0.74 and posterior 
region p= 0.38) (Figure 5.4). 








Figure 5.3 - Changes in the collagen fibrillar diameter percentage difference in different time 










Figure 5.4 - Changes in the interfibrillar distance percentage difference in different time 








Figure 5.5 - Changes in the interlamellar distance percentage difference in different time 






C. Interlamellar distance 
 
The decrease in the interlamellar distance that was seen immediately following CXL 
treatment did not alter significantly over the next 2 weeks (anterior p=0.14, 
intermediate p= 0.33 and posterior p= 0.53) - Figure 5.5.  
 
Even though the increase in collagen fibril diameter seen immediately following CXL 
did not change significantly over the two-week period of this study, a trend was noted 
where in the anterior portion of the stroma the CF diameter increase was greatest 
immediately following CXL treatment and gradually settled to a lower value over the 
next fortnight (Figure 5.3). In the intermediate and posterior portions of the cornea 
though, immediately following CXL treatment the CF diameter were about the 
smallest, rising to a higher (both not statistically different) value after 2 weeks (Figure 
5.3). A similar (but not identical) trend was seen for interfibrillar and interlamellar 
distance (Figure 5.4 & Figure 5.5) 
 
5.3 Can we extend the viability of in vitro crosslinked corneas 
beyond two weeks? 
 
The initial plan of this in vitro study was to investigate the changes in the CF 
morphology for an extended period (i.e. a month), which would allow for 
investigating the changes that occur post-CXL treatment. However, we could not 
maintain the excised corneas in vitro for longer than two weeks. By the third week all 
the cultured corneas were showing signs of death, with the cornea becoming opaque 
and swollen. Besides, when evaluating the endothelium, there were signs of 
endothelial damage such as changes in the distribution of endothelial cells within the 
cornea (Figure 5.6). Therefore, in this section, we will be discussing the modifications 
and alterations that were performed to the existing protocol to try and maintain the 










Figure 5.6 – The comparison between a normal cornea and a cornea with defective 
endothelium following CXL treatment 
A – Normal cornea 
B – Cornea kept in culture media for 3 weeks (corneal swelling with increased opacity of the 
corneal stroma) 
C - Endothelium of a normal cornea (5x magnification) 
D – Endothelium of a cornea cultured for 3 weeks (5x magnification) 
E- Endothelium of a normal cornea (20x magnification) 
F – Damaged endothelium of a cornea cultured for 3 weeks (20x magnification) 
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5.3.1 Materials and Methods 
 
This part of the study was conducted using 12 pairs of porcine corneas and three pairs 
of human corneas. The porcine corneas were obtained from the abattoir ("South Kill", 
Milton, New Zealand) while the three pairs of human corneas retrieved from cadavers 
bequeathed to the Department of Anatomy, University of Otago.  The investigator 
excised both porcine and human corneas. The animal corneas were retrieved within 
six hours, and human corneas, due to logistical constrains, within 24 hours post-
mortem. 
 
Three sets of corneas (both porcine and human) were used in every step of 
modifications made to the existing protocol. The status of the corneal endothelium 
was examined using Phase-contrast microscopy at 24 hours, three days, one week, 
two weeks, and three weeks after placing the corneoscleral flap in the culture medium. 
Any corneas with signs of corneal pathology such as corneal scarring was discarded - 
only healthy corneas were used in this study. The number of human and porcine 
corneas rejected due to corneal pathology was two and three respectively (Figure 5.7).  
 
A. Using corneas in situ with the eyeball for CXL treatment 
 
Three sets porcine of corneas were used for this part of the study. The eyeballs were 
extracted according to the instructions given by the eye bank association of America 
(Eye Bank Association of America, n.d.) (https://restoresight.org/what-we-
do/publications/medical-standards-procedures-manual/). Preparation of the 
surgical field and sterilisation was carried out as described in Chapter 4. Once the 
operation field was prepared, a cotton-tipped applicator was used to open the upper 
eyelid gently. Once the eyelid was lifted towards the head, a speculum was 
introduced. Care was taken when inserting the speculum so that it did not touch the 
cornea. At the lateral edge of the cornea at the limbus, the conjunctiva was grasped.  
Then a 360° cut was made around the cornea with a round-tipped scissors. There were 
two main advantages in cutting the conjunctiva. One, being able to easily access the 
intraocular muscles and optic nerve, while the other benefit is the option of removal 
of the membrane that may be contaminated with bacteria.  
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Once all the extraocular muscles and optic nerve were cut, the eyeballs were 
enucleated from the orbital socket and transported in a container with culture 
medium. The culture medium used in this study is the same culture medium used for 
human corneal preservation approved by the European Eye Bank Association 
(Armitage, 2011) which has been described in Chapter 4. These corneas were then 
stored in an incubator at 34 ºC with an atmosphere of 5% carbon dioxide until the 
crosslinking treatment which was performed within the next 24 hours. 
 
The following day the eyeball, along with its extraocular muscles was taken out of the 
culture medium and placed in an empty contact lens casing (eyeball placed in casing 
facing upward). Both eyeballs of each pair underwent corneal epithelial debridement, 
but only one eyeball was treated with CXL as previously described. Following CXL 
treatment, the corneoscleral flap was excised as described before (5.3), and both 
treated and untreated corneas were transferred to separate sterile tissue culture flasks 
(Figure 5.7).     
 
The culture media and the method of culturing used for this component of the study 
are the same as described in section 5.2.2 above (Doughman et al., 1974; Summerlin et 
al., 1973) where the corneas were stored for a month (Culture media 1).  
 
The corneal endothelium was examined at 24 hours, three days, one week, two weeks, 










Figure 5.7 – Optimizing the in vitro protocol to investigate wound healing process 
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B. Changing the culture media 
 
Three sets of porcine corneas were used for this part of the study. The corneoscleral 
flaps were excised and stored in the culture medium until the time of CXL treatment. 
(described in 5.2.2). Crosslinking treatment was also performed as described in 
Chapter 4. Once the corneas were crosslinked, the corneas – both control and 
crosslinked - were transferred into individual sterile tissue culture flasks with a new 
culture medium. This new culture medium is the same as the culture medium that is 
used in Eye banks to store healthy corneas before transplantation (Culture medium 
2).   
 
Once transferred into the culture medium, both treated and control corneas were 
examined for the status of the corneal endothelium at 24 hours, three days, one week, 
two weeks, and three weeks using phase-contrast microscopy (Figure 5.6). 
 
C. Using human corneas instead of porcine corneas 
 
Three pairs of porcine corneas and three pairs of human corneas were used in this 
study. The excision of the corneoscleral flap from the eyeball, transport, storage and 
CXL treatment was performed as previously described for both human and porcine 
corneas. One cornea from each pair was treated using CXL treatment while the other 
(control cornea) underwent only epithelial debridement. This process was repeated 
for the remaining corneal samples as well. Once treated, both treated and control 
samples were transferred into individual cell culture flasks containing organ culture 
media (Culture medium 1).  Once transferred into the culture medium both treated 
and control corneal endothelia were examined at 24 hours, three days, one week, two 
weeks and three weeks using phase-contrast microscopy (Figure 5.6). 
 
D. Using corneas without epithelial debridement or CXL treatment 
 
This part of the study was conducted using three pairs of human corneas. One cornea 
out of each pair was stored in the culture medium that is used in the Eye banks 
(Culture medium 2) while the remaining corneas were stored in the same tissue 
culture medium which was used in the first part (5.2) of the study (Culture medium 
1). Corneal samples  that were store in Culture medium 2 were stored in tissue culture 
 144 
incubator in 5% carbon dioxide and 95% air. The culture medium was changed every 
7 days. The left and right corneas were chosen randomly for the above procedures. 
The corneas used did not undergo any interventions (i.e. without epithelial 
debridement or CXL treatment). Once transferred into the culture media, the corneas 
were examined for the status of the corneal endothelium at 24 hours, three days, one 





The maximum time a CXL-treated cornea can be kept in a culture medium in this 
study was two weeks, even with modification of the culturing protocol. Following the 
initial two weeks, endothelium gradually becomes disintegrated. The transparency of 
the cornea was not maintained, as it became more opaque by the end of three weeks. 
(Figure 5.6).  
 
The three pairs of corneas without any interventions (without epithelial debridement 
and CXL treatment) which were kept in two different culture media (culture medium 
1 and culture medium 2) were maintained for four weeks without any signs of 
endothelial damage visible from the phase-contrast microscopy. Although slight 
swelling was evident in the corneal stroma, corneal transparency was maintained for 
one month. Two corneas which were placed in Culture medium 1 and one cornea 
which was placed in Culture medium 2 were cloudy after two days of placing them 
in the culture media. However, within the next week, these corneas became 
transparent (as transparent as the rest of the samples). The appearance of the 




5.4.1 Morphological changes of the stromal collagen fibres following CXL 
treatment in vitro; 
 
Few studies have been performed to examine the long-term changes of the corneal 
stroma following CXL treatment. Most studies were performed to look into changes 
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in the refractive indices and keratometric values of the cornea following crosslinking 
treatment (De Bernardo et al., 2015; Goldich et al., 2014; Tiveron Jr et al., 2017). Some 
of the studies illustrated an improvement of visual acuity and improvement of 
keratometric values following CXL treatment (Ghanem et al., 2014; Rechichi et al., 
2013). Few studies demonstrated different failure rates, while others reported no 
notable progression following the CXL treatment (Au - Zyablitskaya, Au - Munteanu, 
Au - Nagasaki, & Au - Paik, 2018; Ernst, Ruchelli, Carreon, & Huff, 2019). Very few in 
vivo laboratory studies have described the wound healing process of corneal stroma 
following CXL treatment (Table 2). However, we could not find any study that has 
investigated the reactions of crosslinked cornea in vitro. This lack of knowledge 
necessitated us in looking at developing an in vitro model to culture a CXL-treated 
cornea to evaluate the long-term effects of CXL treatment.  
 
In the present study, we were able to maintain the viability of the crosslinked corneas 
for two weeks in a culture medium. Chapter 4, we showed that the CXL treatment 
leads to an increase in the CF diameter and decrease in the interlamellar and 
interfibrillar distance of the human cornea soon after the CXL treatment, which also 
concurs with the present study. The effect of the crosslinking treatment was more 
prominent in the anterior corneal stromal region and decreased towards the posterior 
regions as has been reported by the other studies and as demonstrated in chapter 4 
(Mastropasqua, 2015; Wollensak et al., 2003a). In addition to the above findings, our 
results in this chapter show that the increase in the CF diameter and decrease in the 
interfibrillar and interlamellar distances, following crosslinking process, did not vary 
significantly over a period of two weeks in vitro. As the mechanical properties of the 
collagen fibrils depend mainly on CF diameter than the CF length (Silver, 
Christiansen, Snowhill, & Chen, 2000), we can postulate that the increased mechanical 
properties of the crosslinked corneas do not alter for at least two weeks following CXL 
treatment. Although there are no in vitro studies with which to compare our results, 
one of the prospective clinical studies suggests that most of the keratometric values 
become worse within the first month following CXL treatment, with the values 
gradually becoming normal after a month, stabilising after 6 months (Hersh et al., 
2011). Furthermore, in a study performed on transepithelial CXL-treated corneas, at 
three months, the morphological alterations of epithelium and upper stroma become 
almost normal (Mencucci et al., 2013). Although in our study we were only able to 
monitor the changes in CXL-treated corneas for two weeks, it appears that the changes 
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to these parameters (CF diameter, interfibrillar and interlamellar distance) were 
stabilized after the first week of CXL treatment, with almost no change happening 
between weeks 1 and week 2. The effect of crosslinking treatment on the CF diameter 
on the anterior cornea was maximum immediately following CXL treatment 
stabilising at a lower (but statistically insignificant) value after two weeks. For the 
intermediate and posterior stromal regions the treatment effect of CXL was low 
immediately after CXL treatment increasing to a higher (but statistically insignificant) 
value that appears to have stabilised at two weeks. It is possible that if we had been 
able to maintain the corneas longer in the culture media we would have observed a 
significant decrease or increase compared to the changes we saw immediately post-
crosslinking. 
 
The results from this chapter show that when the treated corneas were maintained in 
a culture medium for two weeks, the reduction in the interfibrillar distance and 
interlamellar distance did changed during that time in vitro. It is known that the 
hydration status of the cornea influences the interfibrillar distance and interlamellar 
distance of a crosslinked cornea. For instance, when crosslinking using hypo-osmolar 
riboflavin, instead of decrease in the interfibrillar distance, an increase was observed 
(Hayes et al., 2013). In addition, it is known that the corneas stored in organ culture 
media have a high chance of swelling (Müller, Pels, & Vrensen, 2001). The corneas that 
we have used in this study were excised from the eyeball and were de-epithelialized 
prior to placing them in culture medium. This results in disruption of the normal 
epithelial barrier and increases the possibility of swelling. However, as there were no 
changes in the interfibrillar and interlamellar distance during the first two weeks of 
the cornea in vitro, it can be assumed that the swelling that happens during the initial 
first two weeks did not significantly affect on the interfibrillar and interlamellar 
distances of the crosslinked cornea. 
 
In conclusion, the effect of crosslinking on the cornea does not change within the first 
two weeks after the CXL treatment. The increase in the CF diameter and decrease in 
the interfibrillar distance and interlamellar distance remain unchanged for at least two 
weeks.  
 
5.4.2 Can we extend the viability of in vitro crosslinked corneas beyond 
two weeks? 
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The transparency of the cornea is maintained mainly by CF arrangement and its 
hydration status. The hydration status is supported by the pumping action of the 
endothelium, which acts as the barrier between the corneal stroma and the anterior 
chamber (Fini & Stramer, 2005). When the endothelium gets disrupted, its barrier 
function ceases, facilitating swelling of the debrided corneal stroma, further 
facilitating damage to the endothelium. Therefore, the integrity of the endothelium is 
one of the vital factors that influences the longevity of the cultured cornea. Initially, 
our study was performed on corneoscleral flaps which were removed from the 
eyeball. These excised corneoscleral flaps were kept in a contact lens covering to 
maintain their curvatures during the crosslinking treatment. The contact lens cases on 
which the corneoscleral flaps were placed had to be lubricated with hyaluronic acid 
eye drops to prevent endothelial damage. At first, we thought that even with this 
procedure, there might be a negative effect on the corneal endothelium, which might 
be a reason for the inability to maintain the corneas for more than two weeks. 
Therefore, to overcome this issue, the CXL treatment was performed on intact eyeballs 
(undisturbed endothelium). Following the CXL treatment, the corneoscleral flap was 
removed from the eyeball and transferred to a culture medium. However, even with 
the treatment performed on an intact eyeball, we could not maintain the cornea for 
more than two weeks. Therefore, this confirmed that placing the corneoscleral flap on 
the contact lens casing did not make any significant adverse effect on the corneal 
endothelium.  
 
We could not find any study that evaluated the changes in the CFs following CXL 
treatment in organ culture media. Most of the corneal wound healing research has 
been conducted on cell cultures, where a specific type of cell was cultured to 
investigate the effects of growth factors (Carrington & Boulton, 2005; Ma, Zhao, 
Boulton, & Albon, 2011), drugs (Yamada, Yanai, Nakamura, Inui, & Nishida, 2004) 
and bacteria (Spurr-Michaud, Barza, & Gipson, 1988). In eye banks using organ 
cultured medium, the generally accepted time to store corneoscleral flaps before 
transplant is one month. This is the time-period when the corneas seem to have 
maximum viability. When the storage time is prolonged for more than four weeks, the 
endothelial density is significantly lost (Madzak & Hjortdal, 2018). Therefore, in the 
present study, we planned to maintain the corneoscleral flap in culture medium for 
four weeks.   
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Our study used the same culture medium used by Summerlin, 1973, to maintain 
human corneoscleral flaps for a duration of one month (Culture medium 1). That 
study was conducted to evaluate the effects of culture medium on human corneal 
scleral flaps (Summerlin et al., 1973). It found that some of the organ cultured corneas 
became cloudy after 48 hours in culture. However, after 48 hours these corneas 
managed to regain their transparency. Similar results were observed in our study, 
where few of our cultured corneas also became cloudy after placing them in the 
culture medium. However, they became transparent within the next 48 hours. Unlike 
the present study, the corneoscleral flaps used in the study by Summerlin did not 
undergo any interventions (epithelial debridement or CXL treatment) before 
culturing. Therefore, we wanted to find a different culture medium which might allow 
us keep the CXL-treated cornea for an extended period in culture medium. 
Consequently, we used a culture medium which is currently being in use in European 
eye banks to store corneoscleral flaps before transplant surgery (Culture medium 2) 
(Armitage, 2011). As this culture medium has widely been used in clinical practice to 
maintain donor corneas for a month, we planned to use it to evaluate the changes in 
the CFs following CXL treatment. However, even with this culture medium, we were 
unable to maintain the crosslinked corneas beyond two weeks. 
 
Our initial study, which was discussed in 5.3, was conducted using human corneas, 
and in these we were able to evaluate the reactions to CXL treatment for two weeks in 
vitro. However, we used porcine corneas to investigate the possibility of extending the 
survival time in vitro. The porcine cornea was chosen in this study due to its easy 
accessibility, and its superiority over the rabbit cornea as an animal model for CXL, as 
demonstrated in Chapter 4. However, when it proved not possible to maintain porcine 
corneas in Culture medium 2 (which is the medium that has been used to preserve 
human corneas in eye banks), we wanted to check whether the preservation time of 
corneas depend on the species. Therefore at the next stage, we used few human 
corneoscleral flaps to evaluate reactions of crosslinked corneas in vitro using the eye 
bank culture media (Culture media 2). This experiment also demonstrated that, even 
for treated human cornea in Culture medium 2, it was difficult to maintain these 
beyond two weeks in vitro, similar to porcine corneas. This, in turn, allowed us to 
confirm that the corneal preservation time for Culture medium 2 does not vary 
between human and porcine corneas. In addition, both human and porcine corneas 
used in this study were excised by the investigator, unlike in the main study where a 
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technician trained by the investigator excised the human corneas. As a result, we 
exclude inter-operator variability, during the corneal removal process as a cause of 
reduced survival times of the corneas in a culture media.  
 
The corneal epithelium is a tissue that can self-renew with the stem cells present at the 
corneoscleral junction (Di Girolamo, 2015). Effective wound healing of the epithelium 
is an essential factor in maintaining the corneal transparency and vision (Ljubimov & 
Saghizadeh, 2015). It is believed that an epithelial wound that does not damage the 
epithelial basement membrane can heal without scarring. In contrast, if the wound 
penetrates the Basement membrane, it will result in scar formation (Stepp et al., 2014). 
In our study, crosslinking treatment was performed on epithelial debrided wound 
without any damage to the basement membrane, which is a positive effect of the 
treatment. Epithelial wounds that do not breach the basement membrane usually 
close within 24–72 hours (Iglesia & Stepp, 2000). According to a study by Iglesia and 
Stepp, for more substantial epithelial defects, epithelial healing takes significantly 
longer time. During the healing process of a larger epithelial defect, initially the 
basement membrane becomes disassembled and the continuity of the membrane 
becomes disrupted. However, it is believed that when basement membrane is 
disassembled, it upregulates epithelial cell migration and results in new epithelial 
formation (Iglesia & Stepp, 2000). Another study on the wound healing process of 
rabbit cornea stated that in more substantial epithelial defects, where the entire 
corneal epithelium is removed, the reformation of the epithelium occurs over one to 
two weeks (Fujikawa, Foster, Gipson, & Colvin, 1984). In the present study, before 
CXL treatment, the corneas underwent complete epithelial debridement (this can be 
considered as a large epithelial defect, as discussed above) and these treated corneas 
were stored in the culture media for in vitro analysis. The maximum time we could 
culture a treated cornea for was the expected time taken for a complete epithelial 
debridement to heal, which is as described above, 2 weeks. When the corneoscleral 
flaps were maintained for more than two weeks, signs of endothelial damage (with 
significant swelling and loss of transparency) were noted. The barrier functions for 
both endothelium and epithelium have been documented. The swelling rate when the 
endothelium is damaged is much higher than when the epithelium is damaged. For 
instance, according to Maurice 1951, in vivo when the endothelium is damaged the 
swelling is 100 per cent within three hours whilst when the epithelium is damaged 
the effect is six times lower (Maurice & Giardini, 1951). Therefore, we could postulate 
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the reason for not being able to maintain corneas for an extended time was the inability 
of the endothelial pump to sustain its maximum effort in maintaining the hydration 
status of the cornea until the epithelium is fully regenerated (epithelium has failed to 
regenerate as expected within the two weeks in vitro). 
 
According to the results from this part of the study, we can conclude that epithelial 
damage due to de-epithelialisation before crosslinking treatment has an adverse effect 
on maintaining a healthy endothelium in vitro. The importance of the epithelium in 
maintaining endothelium in a cultured cornea can be further confirmed from our 
results as we were able to keep the corneoscleral flaps which did not undergo any 
interventions (corneas with intact epithelium) in vitro for four weeks without any 
signs of endothelial damage. Therefore, we can conclude that although according to 
other studies, the barrier effect of the epithelium is very minimal when compared to 
the endothelium, the epithelium has a significant contribution in maintaining the 
viability of a cornea in vitro and it is an essential factor to be considered when 
















Corneal collagen crosslinking (CXL) is one of the popular treatment options 
available for keratoconus and post-refractive corneal ectasia. Although this 
treatment is used frequently in clinical practice to arrest the progression of 
keratectasia, very few studies have evaluated the morphological changes of the 
corneal stroma post-treatment. These existing studies have used rabbit corneas to 
evaluate the changes of collagen fibrils (CFs) post-CXL treatment (Wollensak, 
Iomdina, Dittert, & Herbst, 2007; Wollensak et al., 2004). However, there were no 
such studies performed on porcine corneas that investigated the effects of CXL 
treatment, despite them being used as a preferred animal model in other areas of 
visual sciences. Furthermore, there are no in vitro studies that have examined the 
changes in the collagen fibril (CF) morphology following CXL treatment in any of 
these experimental models. Therefore, we have little knowledge about how the 
corneas will be reacting to CXL treatment in vitro.  
 
In the past, both porcine and rabbit models were used to study corneal pathologies 
and their associated complications. The main reason for using these two animal 
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models was their morphological similarity to humans (Brunette et al., 2011; 
Fernandez-Bueno et al., 2008). However, there were no studies performed to 
compare the collagen fibrillar morphology of normal porcine and rabbit cornea with 
the human. Such a comparison is necessary as it can provide researchers an 
informed choice in selecting an animal model for vision science research.  
 
Therefore, the following are the central objectives of this thesis;  
1. Determine if both normal porcine and rabbit cornea are structurally similar 
to the normal human cornea to be used as experimental models  
2. Investigate the effects of CXL treatment on corneal stroma of porcine, rabbit 
and human models and compare these effects with each other to find out the 
optimal animal model that reacts similarly to the human corneal model. 
3. Evaluate the changes in the collagen CF morphology in vitro post-CXL 
treatment. 
 
The structure of the normal cornea in both porcine and rabbit were observed to be 
similar to that of the human model, where the epithelium, Bowman’s membrane, 
stroma, Descemet membrane and endothelium were evident. In contrast to some of 
the published literature, the Bowman’s membrane was identified in both porcine 
and the rabbit corneas in this study. Although it is believed that a prominent 
Descemet’s membranes could only be seen in older rabbits, a very prominent 
Descemet’s membrane was observed in the young rabbits used in this study, 
contrary to some findings in the literature. Upon the evaluation of the CF diameter 
and interfibrillar distance of normal porcine and rabbit cornea in comparison with 
human corneal CFs, it was evident that none of these animals’ corneas were 
structurally identical to human corneas but was similar to one another. In general, 
both animals have significantly smaller CF diameters and interfibrillar distances 
compared to the human corneal stroma. In addition, the interlamellar distance of 
porcine corneas seems to be similar to that of humans (Chapter 3). 
 
The reaction of the cornea to crosslinking treatment was analysed for porcine, rabbit 
and human with Light Microscopy, TEM and TUNNEL assay (Chapter 4). Porcine 
and rabbit corneal stromal reactions were compared with that of human corneal 
stroma to find out which animal model closely mimicked the reaction of the human 
corneal stroma. H&E and MT staining allowed for visualisation of the general 
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arrangement of corneal collagen fibre morphology in all the species. In CXL-treated 
corneas, the collagen fibres were more tightly packed in the anterior region. The 
fibres became loosely packed in the posterior region with the fibre distribution in 
the region becoming similar to control corneas. Significant keratocyte apoptosis was 
observed following CXL treatment in porcine, rabbit and human samples. The 
amount of keratocyte apoptosis post-CXL seems to be of similar intensity in all of 
the species. The TEM results showed that the CXL treatment leads to an increase in 
CF diameter, a decrease in the interfibrillar distance, and a decrease in interlamellar 
distance. The general pattern is that these changes were most significant in the 
anterior region (which is within the anterior 242µm thickness of the cornea), 
followed by the intermediate region (the subsequent 104µm thickness), and the 
posterior region (region immediately posterior to the intermediate region). All the 
species showed a statistically significant reduction in the central corneal thickness 
(CCT) following CXL treatment. When the magnitude of the difference in CF 
diameter, interfibrillar and interlamellar distance of porcine and rabbit models was 
compared against that of the human corneas, the magnitude of difference shown by 
the porcine cornea was less than the rabbit in comparison with a human. Therefore, 
it can be concluded that the porcine corneas are superior to rabbit corneas in 
evaluating changes in the corneal stroma following CXL treatment. The above 
findings address a significant knowledge gap and will serve to help future 
researches to evaluate reactions of conventional CXL treatment in an animal model 
that reacts in a similar manner to human, which will assist in extrapolating the 
effects of CXL treatment to human (Chapter 4). 
 
The morphological alterations of the CFs following crosslinking treatment in vitro 
for two weeks were studied (Chapter 5). The in vitro study is a novel approach for 
evaluating the effects of CXL treatment over time. According to the obtained results, 
the increase in the CF diameters, decrease in interfibrillar distance and decrease in 
the interlamellar distance following corneal stromal collagen crosslinking, did not 
change for up to two weeks in vitro. 
 
It also includes an investigation to optimise the existing in vitro protocol to extend 
the viability of a crosslinked cornea in a culture medium beyond the 2-week period. 
However, after repeated attempts, it was concluded that it was not feasible to 
maintain the corneas for more than two weeks in vitro despite making changes to 
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the existing protocols. This suggested that the epithelial damage due to de-
epithelialisation before crosslinking treatment bears an adverse effect on 
maintaining a healthy endothelium in vitro beyond two weeks. The critical 
importance of the epithelium in maintaining corneal endothelium in vitro was 
further confirmed in the study as the corneoscleral flaps which did not undergo any 
interventions (corneas with intact epithelium) in vitro were healthy and viable for 
four weeks without any signs of endothelial damage.  
 
In summary, it was evident that both porcine and rabbit models have a similar 
corneal structure (epithelium, Bowmen’s membrane, Descemet membrane and 
endothelium) to the normal human cornea. Despite having a similar structure, 
collagen fibrillar morphology of porcine and rabbit corneas are different from 
human. However, the collagen fibrillar morphology of both porcine and rabbit 
models are similar to one another. Therefore, we concluded that these animal 
models are sufficiently similar to be used as experimental models. Looking into the 
effects of CXL treatment on corneal CF morphology, the porcine model seems to be 
the model that behave similar to humans than the rabbit. Furthermore, it was 
observed that the CXL treatment, leads to an increase in CF diameter and decrease 
in interfibrillar and interlamellar distance in porcine, rabbit and human corneas. 
These alterations in the CFs remained unchanged for two weeks post- CXL 
treatment in vitro. Hence, it can be concluded that the epithelium plays a vital role 
in maintaining the viability of the cornea in vitro, and is a critical factor to be 
considered when maintaining corneas in culture medium. 
 
6.2 Future directions 
 
One of the limitations of this study was the difficulty in obtaining viable human 
corneas. The corneas used in this study were retrieved from cadavers bequeathed 
to the Department of Anatomy, University of Otago. Out of these corneas, only 
those which were resected within 24 hours post-mortem could be used for 
experiments. Twenty-four hours is the acceptable time frame to harvest viable eyes, 
according to the guidelines set by the Eye banks. Adhering to this guideline made 
it difficult to obtain a higher number of corneas, and hence the sample size was 
limited to only 30 pairs of human corneas for the whole project. 
 
 155 
It would have been preferable if all the samples used in this project were excised at 
the same time post-mortem. However, due to logistical constraints, human corneas 
were retrieved within 24 hours post-mortem while the rabbit and porcine corneas 
were retrieved within 6 hours post-mortem.  
 
The sample preparation process for TEM leads to a shrinkage of the specimen due 
to the extensive dehydration process (Fullwood & Meek, 1993). Therefore, it is likely 
that some tissue shrinkage occurred during the preparation for TEM. This may have 
had an effect on the CF diameter, interfibrillar distance and interlamellar distance 
values.  
 
Another possibility to maintain these crosslinked cornea for a longer time, is to use 
long-term preservative mediums such as Glycerol. Glycerol seems to have 
antimicrobial and antiprotease properties that allow it to maintain the corneal 
structure for a longer time. In this procedure, the corneas were dehydrated using a 
vacuum and stored in toom temperature (Chaurasia et al., 2020; Feilmeier et al., 
2010; Li et al., 2012). However, this method of storage is recommended for 
procedures that do not require a viable endothelium. This needed to be analysed 
since the CXL treatment used in this study, the epithelium has to be removed prior 
to CXL. 
 
In the future, the hydration changes of the crosslinked cornea in vitro can be 
examined further with the use of different culture media and much larger sample 
groups. The present study evaluated the changes in CFs following conventional 
crosslinking treatment, where the removal of the epithelium is one of the vital steps 
in the crosslinking process. The in vitro technique described in this study could be 
far more effective if a transepithelial technique was used for crosslinking treatment, 
where the removal of the epithelium is not necessary. This may have enabled the 
maintenance of crosslinked corneas beyond two weeks in vitro. This would pave the 
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Abstract
Corneal collagen crosslinking has revolutionized the treatment of keratoconus and post-refractive corneal ectasia in the past
decade. Corneal crosslinking with riboflavin and ultraviolet A is proposed to halt the progression of keratectasia. In the original
BConventional Dresden Protocol^ (C-CXL), the epithelium is removed prior to the crosslinking process to facilitate better
absorption of riboflavin into the corneal stroma. Studies analyzing its short- and long-term outcomes revealed that although
there are inconsistencies as to the effectiveness of this technique, the advantages prevail over the disadvantages. Therefore,
corneal crosslinking (CXL) is widely used in current practice to treat keratoconus. In an attempt to improve the visual and
topographical outcomes of C-CXL and to minimize time-related discomfort and endothelial-related side effects, various mod-
ifications such as accelerated crosslinking and transepithelial crosslinking methods have been introduced. The comparison of
outcomes of these modified techniques with C-CXL has also returned contradictory results. Hence, it is difficult to clearly
identify an optimal procedure that can overcome issues associated with the CXL. This review provides an up-to-date analysis
on clinical and laboratory findings of these popular crosslinking protocols used in the treatment of keratoconus. It is evident from
this review that in general, these modified techniques have succeeded in minimizing the immediate complications of the C-CXL
technique. However, there were contradictory viewpoints regarding their effectiveness when compared with the conventional
technique. Therefore, these modified techniques need to be further investigated to arrive at an optimal treatment option for
keratoconus.
Keywords Crosslinking . Conventional crosslinking protocol . Cornea . Dresden protocol . Keratoconus
Introduction
Keratoconus (KC) is a spontaneous, non-inflammatory ectasia
of the cornea with an incidence of 1 in 2000, generally affect-
ing young patients [1]. According to more recent literature,
incidence and prevalence of KC are much higher than the
older literature. A recent review has shown that the incidence
and prevalence might be as five- to tenfold higher than the
older values [2]. This condition impairs vision by causing
irregular astigmatism of the cornea and in more advanced
cases, corneal scarring. Therefore, refractive correction is
frequently the treatment of choice. Initially with spectacles
but often rigid gas permeable lenses are used to correct the
irregular astigmatism [3]. When refractive correction is no
longer possible due to severe irregular astigmatism, corneal
scarring, or previous rupture of the Descemet membrane, the
treatment for advanced KC has been penetrating keratoplasty
(PK). Other treatment options available for mild to severe
forms of KC are deep anterior lamellar keratoplasty
(DALK), anterior lamellar keratoplasty (ALKP), and
intrastromal corneal ring segment (ICRS) [4, 5].
In recent years, corneal crosslinking (CXL) treatment has
been introduced as a minimally invasive treatment option to
stop the progression of keratectasia and it has revolutionized
the treatment of KC and other corneal ectasias including
pellucidal marginal degeneration (PMD) and iatrogenic
ectasia. It has also been used for the management of other
conditions such as bullous keratopathy (BK), infectious ul-
cers, ulcerative keratitis, and other causes of corneal edema
[6]. According to the literature published, CXL for PMD
seems to be an effective mode of treatment although the
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crosslinking effect is mainly confined to the central part of the
cornea while PMD affects the peripheral cornea [7, 8].
Progressive corneal ectasia following photorefractive sur-
gery such as laser in situ keratomileusis (LASIK) and
photorefractive keratectomy (PRK) is a well-known com-
plication [6, 9]. While, prophylactic CXL treatment has
been advocated for patients prior to PRK in an attempt to
prevent this complication [10]. Kanellopoulos and Binder
in 2011 suggested on a combination treatment using si-
multaneous CXL and PKR in patients with post-LASIK
ectasia to improve visual outcomes. This protocol is com-
monly referred to as the BAthens protocol^ [11]. The an-
timicrobial activity of riboflavin and ultraviolet A (UVA)
and corneal resistance to CXL have been described in litera-
ture [12, 13]. These characteristics of riboflavin and UVA
make CXL treatment a good option for managing infective
keratitis and infectious ulcers, as CXL can improve the corne-
al ability to resist proteolytic enzymes secreted by infective
microorganisms. However, this treatment has shown poor re-
sponse to fungal and acanthamoebic infections and for infec-
tions penetrating deep into the corneal stroma [14, 15]. It was
recently suggested that crosslinking treatment can be benefi-
cial for BK as the formation of interfibrillary links between the
collagen in corneal stroma during CXL would increase the
difficulty of water to fill in thus diminishing the rate of corneal
edema [16]. According to some studies, CXL for BK resulted
in considerable improvement in vision and post-operative
pain. These beneficial effects disappeared about 3 months af-
ter the initial CXL treatment [17, 18].
Crosslinking is the process of formation of chemical brid-
ges after chemical reactions between proteins and other mol-
ecules [19]. Improving mechanical properties of a material
with crosslinking is not novel in biological sciences.
Crosslinking can be initiated by different factors including
chemical catalysts, heat, pressure, and radiation (beta and/or
gamma) [20]. Dentists use ultraviolet light (UV)-mediated
crosslinking to polymerize composite filling materials [21].
In the polymer industry, UV light is widely used to cure ad-
hesives by polymerization [22, 23]. Chemical-mediated
crosslinking of type I collagen with glutaraldehyde has been
used to stabilize prosthetic heart valves [24, 25]. Crosslinking
occurs naturally within corneas during the aging process
where the collagen fibrillar diameter increases by 4.5% over
a person’s lifetime due to age-related glycosylated
crosslinking [26, 27].
Strengthening of corneal collagen by crosslinking was ini-
tially described in the 1990s when researchers at the Technical
University of Dresden, Germany discovered that diabetic pa-
tients were rarely diagnosed with keratoconus due to a
glycosylation-mediated crosslinking process that occurs with-
in the corneal collagen fibers. They were set to develop a
technique that would induce similar crosslinking effects in
healthy keratoconic subjects [25]. After extensive
investigations, collagen CXL with riboflavin and UVA light
was introduced as an effective treatment mode for keratoconus
[28, 29]. This is a complex photochemical process that
consists of an aerobic phase (Type II photochemical ki-
netic mechanism) and an anaerobic phase (Type I photo-
chemical kinetic mechanism). During the aerobic phase,
riboflavin molecules absorb UVA and get excited to form
an excited singlet or reactive triplet riboflavin state. The
excited triplet riboflavin interacts with the triplet oxygen
species in the atmosphere to form active singlet oxygen.
This singlet oxygen interacts with carbonyl groups of
collagens to form crosslinks. During the anaerobic phase,
oxygen depletion causes the triplet riboflavin to form
riboflavin radicals that interact with corneal stroma, cre-
ating crosslinks between collagen molecules [30–32]
(Fig. 1).
CXL treatment is the only minimally invasive surgical pro-
cedure in current practice that has been proposed to halt the
progression of keratoconus and is considered the Bgold
standard^ procedure to halt the progression of keratoconus
[33–35]. According to Global Consensus of Keratoconus
and Ectatic Diseases published in 2015, currently, 83.3% of
ophthalmic physicians are performing CXL as a treatment
modality for keratoconus and all the physicians who do not
currently have access to this technique are willing to use this
procedure once it becomes available [36]. Several techniques
have been developed in the past decade to increase the effica-
cy of CXL. The conventional Dresden protocol (C-CXL),
accelerated corneal crosslinking (A-CXL), corneal epitheli-
um-on/transepithelial (T-CXL) techniques using chemical en-
hancers, and iontophoresis crosslinking techniques (I-CXL)
are some of the commonly used and currently investigated
procedures in clinical practice. This review provides an up-
to-date analysis on clinical and laboratory findings of the cur-
rent crosslinking protocols used in the treatment of
keratoconus.
Conventional Dresden protocol
The Dresden protocol was introduced by Wollensask
et al. in 2003 as a treatment option for keratoconus.
The technique involves the removal of the corneal epi-
thelium followed by application of riboflavin solution
(0.1% riboflavin in 20% dextran solution) to the de-
epithelialized cornea 30 min before the cornea is irradi-
ated with UVA. Then the cornea is UVA irradiated
(wavelength, 370 nm and power, 3 mW/cm2 or 5.4 J/
cm2) for another 30 min [29]. The riboflavin solution is
applied every 3–5 min during the irradiation process.
Usually, an 8-mm area of the central cornea is irradiated.
Currently, this technique is considered the standard treat-
ment to stop the progression of keratoconus in adults and
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is frequently used in outpatient setting [37]. The epithe-
lial removal prior to CXL treatment is used to prevent
the shielding effect of the epithelium and to ensure ade-
quate penetration of riboflavin to the corneal stroma [38,
39]. The riboflavin facilitates absorption of UVA and
also prevents UVA damage to the endothelium [40].
The area of the epithelial removal may vary from 5 to
9 mm in diameter [41–43]. The corneal epithelium can
be removed manually using a self-constructed triple-
blade scalpel [44], blunt hockey knife [41], or blunt spat-
ula [45] or by simply wiping off the epithelium with or
without the use of alcohol [46] or by trans-epithelial
phototherapeutic keratectomy (t-PTK) using a 213-nm
solid-state laser system [47]. Corneal responses and the
effectiveness of C-CXL treatment in halting the progres-
sion of keratoconus has been investigated in both labo-
ratory and clinical settings, and key finding of these
studies are summarized in Tables 1 and 2.
Laboratory studies
Parameters Spoerl et al. first described crosslinking of cornea
using ultraviolet light with a wavelength of 254 nm and 0.5%
riboflavin in 20% dextran [28]. Several laboratory studies
have since tried to prove the effectiveness of the CXL as a
treatment option for keratoconus. When evaluating the effec-
tiveness of this technique, the parameters of the C-CXL pro-
tocol need to be maintained throughout. For instance, increase
in the exposure time of UVA light has led to structural weak-
ness in porcine cornea. The resultant weakness was believed
to be due to either the destruction of collagen crosslinks or an
outcome of tissue damage caused by excessively long UVA
exposure [57]. Wernli et al. [113] indicated that UVA intensity
of 40 to 45 mW/cm2 could be used to achieve increase corneal
stiffness in porcine corneas when applied for 2 min. However,
no significant increase in corneal stiffness could be achieved
when the intensity was increased to a range of 50 to 90 mW/
Fig. 1 Mechanism of corneal
collagen crosslinking with
riboflavin. Aerobic and anaerobic
pathways of formation of
crosslinks within collagen fibers
following crosslinking treatment
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Table 1 Laboratory studies on conventional crosslinking treatment
Author (reference) Investigative techniques Type of study Animal model No. of eyes Key findings
Tabibian et al. [48] Biomechanical testing In vivo Mice 18 No differences in the stress-strain
curves following repeated CXL
Hatami-Marbini and
Rahimi [49]
Biomechanical testing Ex vivo Bovine 25 Post-CXL—increase equilibrium
stress, maximum stress, and tangent
modulus (p < 0.01).
Increasing the hydration—decrease in
equilibrium stress, maximum stress,
and tangent modulus (p < 0.01).
Matteoli et al. [50] OCT Ex vivo Porcine 24 Reduction of CT (34%) immediately
after CXL treatment.
Treated CS effect 42% compared with
control corneas.
Beshtawi et al. [51] SAM Ex vivo Human 6 Speed of sound measurement increase
(square foot of thickness) by a
factor of 1.039× in CXL cornea
AS andPS increased by factor of 1.019×
Labate et al. [34] AFM Ex vivo Human 7 YM increased at AS (1.1–1.5×), mean
hysteresis decrease—0.9×–1.5×
Seifert et al. [52] AFM Ex vivo Porcine 16 YM maximum at the corneal surface
and decreased within next 200 μm
Maximum CS higher (p < 0.01) than
posterior 100 μm
MSF at the corneal surface 8.1,
MSE—1.7×
Hayes et al. [53, 54] Enzymatic digestion
studies and X-ray scat-
tering study
Ex vivo Porcine, sheep, and
rabbit
117 CT decrease after riboflavin
application and UVA exposure
CXL treatment induces crosslinks
within collagen molecules and/or
between collagen fibrils and the
proteoglycan
CXL do not effect on hydrodynamic
behavior of cornea
CXL increase enzymatic digestion
Dias et al. [55] AFM Ex vivo Human 24 CXL increase AS stiffness 1.9 times
than the control corneas
PS not significantly affected
Akhtar et al. [56] TEM In vivo Human 9 Diameter of CXL treated corneas
increased
CXL treatment has no effect on
hemidesmosomes, BM, Bowman’s
layers CFs diameter smaller than
normal but larger than KC
Interfibrillar distance increased
CXL treatment normalizes PG
synthesis
Lanchares et al. [57] Biomechanical
testing/uniaxial tensile
testing
Ex vivo Porcine 17 30-min UVA CXL with riboflavin
increased stiffness
60-min UVA-radiated decrease stiff-
ness
Wollensak et al. [40] Biomechanical testing,
pachymetry, and
histology (H&E, PAS)
Ex vivo Porcine 72 CXL mainly occur at intra- and
interfibrillar CF, absent interlamel-
lar CXL
Crosslinking effect on interlamellar
cohesion, upheld by interlacing
collagen lamellae and PG
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Table 1 (continued)
Author (reference) Investigative techniques Type of study Animal model No. of eyes Key findings
Kling et al. [58] Biomechanical testing
and Scheimpflug
imaging
Ex vivo Porcine 38 Immediate decrease in CT following
riboflavin installation
CXL effective in preventing an
increase in anterior corneal radius
in the horizontal than in the vertical
meridian
1.54 reduction in corneal thinning, 2.8
reduction in corneal apical rise
Increase IOP, YM (1.096
± 0.30 kN/m2)
Mencucci et al. [59] TUNEL assay, Western
blot analysis,
immunohistochemistr-
y, and light microscopy
In vivo Human 15 CXL stimulates keratocyte apoptosis
and repopulation
CF diameter increased by 22.6%
compared with control, 16.1%
compared with KC. Not
significantly different on PS
Wollensak and Iomdina
[60]
Biomechanical testing In vivo Rabbits 9 Increase YM by 78.4–87.4%, ultimate
stress by 69.7–106.0%







Pilot study Human 5 Keratocyte apoptotic changes a depth
of 300 μm with demarcation line
Spherical structures evident until the
depth of 300 μm
Bottós et al. [62] Immunofluorescence
confocal microscopy
Ex vivo Porcine 25 Maximum CXL of CF in anterior
stroma
CXL effect is more in
de-epithelialized than corneas with
epithelium intact
Keratocyte apoptosis up to
250–300 μm depth
Wollensak and Redl [63] Pepsin extraction of




Ex vivo Porcine 40 CFs has a very strong chemical
stability following CXL treatment
High molecular weight collagen
polymers present at crosslinked
corneas
Wollensak et al. [64] Light microscopy,
biomicroscopy, and
OCT
Ex vivo Porcine 25 Swelling pattern—intense in AS
(242 μm), for next 238 μm
(hydration factor 2.2),
non-crosslinked posterior 135 μm
(hydration factor 2.7)
Sensitivity of swelling response is in
relation with degree of CXL
OCT not suitable for clinical control
of CXL effect
Kohlhaas et al. [65] Biomechanical testing Ex vivo Porcine and human 40 and 10 Significant stiffening in AS (200 μm).
75–70% of UVA irradiation
absorbed within 200 μm and next
20% absorbed in the next 200 μm
of cornea
Endothelium preserved
Schilde et al. [66] Biomechanical testing Ex vivo Porcine 20 Resistance to enzymatic digestion is
high in CXL corneas
CXL of the CFs extends pass the first
anterior 200 μm to next 200 μm of
cornea
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cm2 [113]. The osmolality of the riboflavin solution is another
factor to be considered for optimal results. For instance, a
decrease in the corneal thickness by 54% of its original thick-
ness due to hyperosmolality of the riboflavin solution was
reported in literature [58]. In contrast, hypoosmolar riboflavin
solutions are used in current practice to increase the thickness
of thin corneas prior to CXL treatment [114]. The degree of
the riboflavin penetration controls the extent of the
crosslinking effects by confining the energy of the UVA light
to the riboflavin-absorbed areas of the cornea. However, it was
also noted that the concentration and changes in exposure time
of the riboflavin had minimal effect on the penetration quality
of the riboflavin solution in porcine, rabbit, and human cor-
neas [41, 115].
Stiffening effectMany biomechanical studies have proven the
stiffening effect of C-CXL treatment and the factors contrib-
uting to it [52, 55]. Most biomechanical studies that investi-
gated the stiffening effect of C-CXL treatment were per-
formed on porcine models [50, 116, 117] while few studies
have been conducted on bovine [118], rabbit [60], and human
corneas [65]. It is evident that the C-CXL effect is more
pronounced at the anterior part of the corneal stroma while it
gradually decreases towards the posterior surface [50, 51, 65,
116]. More precisely, the crosslinks are more confined to the
anterior 242 μm of cornea with the next 107 μm (intermediate
zone) with smaller degree of crosslinking [64]. The difference
in the degree of crosslinking is caused by the rapid loss of
UVA irradiance across the cornea due to riboflavin-enhanced
UVA absorption. Tabibian et al. stated that the repeated
crosslinking of the same cornea within a short time does not
provide any additional biomechanical stiffness (cumulative
stiffening effect) on the treated mouse cornea [48]. Another
study described a decrease in viscous response along with an
increase in elastic response in the human anterior stroma at a
nanoparticle level [34]. The stiffening effect following CXL
treatment and its association with hydration properties of the
cornea were investigated on bovine models. It is evident from
these studies that when the corneal hydration decreases, there
is a high possibility of increase in the Young’s modulus (YM)
or increase in the stiffening effect [49, 118]. The degree of the
stiffening effect varies in different species such as porcine
corneas having a 1.3 times stiffening effect, while in humans,
the stiffening effect was limited to 1.039 times when
Table 1 (continued)
Author (reference) Investigative techniques Type of study Animal model No. of eyes Key findings
65% of riboflavin absorbed in anterior
200 μm and 25–30% absorbed in
next 200 μm
Spoerl et al. [13] Micrometer and histology
(H&E)
Ex vivo Porcine 30 Shrinkage temperature—AS
(75 ± 1.2 °C) than PS (70 ± 0.8 °C)
Wollensak et al. [41] TUNEL assay, TEM, and
histology
Ex vivo New Zealand white
rabbits
38 Keratocyte apoptosis present at
anterior 50 μm 4 h post-treatment
Cytotoxic UVA irradiation range from
0.5–0.7 mW/cm2
Wollensak et al. [41] Morphometric computer
software
In vivo NZ white albino rabbit 10 CF diameter increased 12.2%
(3.96 nm) in AS and 4.6%
(1.63 nm) in PS
Average increase of anterior CF with
CF—9.3% (3.1 nm)
Spoerl et al. [13] Enzymatic assay
(collagenase, pepsin,
and typsin) and light
microscopy
Ex vivo Porcine 80 CXL treatment significantly increases
resistance to collagenase, pepsin,
and trypsin digestion in the anterior
half of the cornea
Wollensak et al. [67] Biomechanical testing In vivo Porcine and human 20 and 5 Increased in YM by factor 1.8 in
porcine and 4.5 in human corneas
Mean CT—850 μm± 70 (SD) in
porcine, 550 ± 40 μm in human
corneas
Increase stress by 71.9% in porcine
and 328.9% in human corneas
CXL, crosslinking; YM, Young’s modulus; OCT, optical coherence tomography; SAM, scanning acoustic microscopy; AFM, atomic force microscopy;
TEM, transmission electron microscopy; UVA, ultraviolet A; PG, proteoglycan; CFs, collagen fibrils; CF, collagen fiber; BM, basement membrane;
H&E, hematoxylin and eosin; PAS, periodic acid-Schiff; NZ, New Zealand; IOP, intraocular pressure; TUNEL, TdT-mediated dUTP nick-end labeling;
AS, anterior corneal stroma; PS, posterior corneal stroma; MSF, mean stiffening factor; MSE, mean stiffening effect; CT, corneal thickness; CS, corneal
stiffening
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compared with non-crosslinked corneas [51, 119].
Additionally, across the entire depth of the cornea, a mean
stiffening factor of 1.7 [52] and 1.8 [52, 67] was documented
in porcine models. The mean stiffening factor is determined
by division of YM of each sample in the region of interest by
the YM of the posterior 100 μm of the cornea. An increase of
YM by 78.4–87.3% in rabbits [60] and by 42% in human
cornea [50] has also been reported.
Collagen fibersC-CXL treatment results in increased diameter
of the crosslinked type I collagen fibers [56]. A pronounced
increase in the anterior stromal collagen fiber diameter was
evident when compared with posterior stromal fibers. For in-
stance, studies conducted on rabbit corneas have shown a
12.2% (3.96 nm) increment in corneal fibrillary diameter at
the anterior cornea and 4.6% (1.63 nm) increment at the pos-
terior corneal stromal fibers. The average increase in diameter
was 9.3% (3.1 nm) [41]. Furthermore, Choi et al. noted a
103% increase in collagen fiber diameter with a 107% in-
crease in the corneal thickness following CXL treatment in
human corneas in ex vivo model [120]. Increase in fiber di-
ameter has been illustrated in both human [56, 59] and rabbit
[41] corneas, although there have been no studies to date on
the effect of C-CXL on collagen fiber diameter in porcine
corneas. Crosslinking of corneal collagen fibers at an intra-
and interfibrillary levels has been noted by Wollensak and
Redl in 2008 in porcine model. However, in this study, no
crosslinking was evident in between the adjacent collagen
lamellae [63]. An increase in the interfibrillary spacing of
the crosslinked corneas up to a level of a normal cornea was
also recognized in human corneas [56]. In contrast, another
study has suggested non-existence of a direct interfibrillary
crosslinking following CXL treatment in porcine, sheep, and
rabbit corneas [53]. Some studies suggest that the crosslinking
effects are not limited to collagen molecules but also affect the
protein network surrounding the collagen [54, 62]. Thus, it is
evident that the C-CXL treatment results in increased collagen
fiber diameter of the crosslinked corneas with visible
intrafibrillary crosslinks. However, the presence of
interfibrillary crosslinks and crosslinking within the adjacent
lamellae needs to be investigated further.
Keratocytes Research has shown that immediately following
CXL treatment, there was marked damage to the corneal
keratocytes, cell shrinkage, chromatin condensation, and apo-
ptotic bodies at the anterior and the intermediate zone of the
corneal stroma reaching a corneal tissue depth of 250–300 μm
[59, 61]. However, after the initial keratocyte apoptosis, with-
in the next few months following the treatment, these
keratocytes gradually repopulated [121]. In rabbit corneas,
the initial apoptosis was completed by 3 days and gradual
repopulation of keratocytes could be observed from day 7
with attaining completion by 6 weeks post-treatment. While
in human corneas, keratocytes repopulation was completed by
6 months post-CXL treatment [59, 64]. This highlights the
fact that the crosslinking procedure is able to stimulate a dis-
tinct biological response that can induce both apoptosis and
cell proliferation. The degree of keratocyte apoptosis depends
on the radiation dose used for crosslinking procedure. For
instance, a study by Wollensak et al. stated that cytotoxic
UVA irradiance for keratocytes can be achieved at an irradia-
tion dose of 0.5–0.7 mW/cm2 on a rabbit model [122].
Enzymatic degradation of collagen Collagen degradation due
to the action of enzymes (human typsin-2, cathepsin K) within
the tear film contributes to the thinning effect of the cornea in
keratoconus [123]. The corneas treated with CXL treatment
have a high resistance to enzymatic digestion which in turn
results in lengthening of the turnover time of collagen fibers
[13, 66].
In general, there are limited laboratory studies on the ultra-
structural alterations of the crosslinked corneas with a major-
ity of studies focusing on the biomechanical properties follow-
ing C-CXL treatment. This highlights the importance of de-
tailed investigation into the fine morphological changes that
occur following CXL to further understand and evaluate the
long-term effects of the C-CXL protocol.
Clinical studies
Wollensak et al. performed the first clinical study of C-CXL in
2003 [29]. Subsequently, many clinical studies have been per-
formed to investigate the effectiveness of this technique and
the summary of the results from the years 2010–2017 are
depicted in Table 2. The effectiveness of the C-CXL technique
in halting the progression of keratoconus has been discussed
in literature through both prospective and retrospective studies
[69, 78, 80, 96]. Most of these published clinical studies in-
troduce C-CXL treatment as an effective mode of halting the
progression of keratoconus with few subjects requiring a sec-
ond treatment (2 patients out of 241 eyes) [124].
Corneal responses to crosslinking C-CXL improves corneal
curvature parameters such as keratometric values along with
visual and topographic parameters [83, 93, 109, 125]. The
extent of visual acuity improvement was directly correlated
with the topographic parameters [91]. It was apparent that the
C-CXL technique resulted in improving uncorrected distance
visual acuity (UCDVA) and best-corrected visual acuity
(BCVA) in keratoconic eyes without causing any changes to
the anterior chamber volume (ACV), corneal volume (CV),
and anterior chamber depth (ACD) [82, 83, 110]. There were
noted cases of slight decrease in UCDVA and BCVAvalues at
4–5 years post-CXL treatment [84, 97]. In some cases, im-
provements in visual acuity were observed without any asso-
ciated change in keratometry values. In most of these cases,
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Table 2 Clinical outcomes following Conventional Dresden Protocol in literature (2010–2017)
Author (reference) Follow-up Type of study Number of eyes Key findings
Recalde et al. [68] 12 months Prospective 24 Tear film function not altered
Tiveron Jr. et al. [69] 12 months Retrospective 100 SCDVA—improved 33%, stable 62% patients
82% stabilized or improved apex value
improved keratometric values and SCDVA
Höllhumer et al. [70] – Case report 6 Substitution of dextran (T-500) with dextran
results in loss of vision from permanent cor-
neal opacity
Polat et al. [71] 1 year Retrospective 45 Improved K values, corneal curvature, anterior
chamber parameters
TCT decrease, CV increased
Kelkar et al. [72] 2 years Prospective 47 ImprovedBCVA,K values decreased, IOP increased
Patchmetry reduced with reduced corneal thickness
Kosekahya et al. [73] 12 months Prospective 93 Decreased Kmax, anterior elevation, anterior
astigmatism, thinnest corneal
Increased posterior astigmatism and posterior
elevation values
Toprak et al. [74] 2 years Prospective 29 Improve CDVA, Kmax, visual acuity and
topographic indices
Parissi et al. [75] 5 years Longitudinal follow-up 19 Sub-basal nerves not regenerate to healthy level
Abnormal nerve migration
Pang et al. [76] Before and after CXL Prospective 26 No changes in the endothelial cell density
CCT decrease
Kim et al. [77] 60 months Retrospective 9 BCVA improved with mean keratometry increased
Decrease TCT, Kmax, corneal astigmatism
Giacomin et al. [78] 4 years Retrospective 40 Stable topography, visual acuity, reduced apical
keratometry
Reduced CT
Lang et al. [79] 36 months Prospective 29 Decreased corneal refractive power, Kmax, CCT
No changes in visual acuity
Poli et al. [80] 6 years Prospective 36 In bilateral keratocorus results of one eye almost
similar to the outcome of the remaining eye
CDVA, UDVA improved, reduced CCT,
increased IOP
Malta et al. [81] 1 month Retrospective 59 Mean depth of demarcation line greater
centrally than nasally and temporally
No correlation between the demarcation line
and corneal pachymetry
De Bernardo et al. [82] 24 months Prospective 57 Stable ACV, ACD, CH, CHF
Improvement in BCVA, decrease of the Kmax,
CV, CTP, increased AL
Sedaghat et al. [83] 1 year Prospective 97 Improved UCVA and BCVA
Decreased average keratometry, astigmatism,
CT, CV in anterior and increased posterior
elevation, average progressive index, CH, CRF
Anterior BFS and elevation without change and
posterior BFS and elevation increased
Khan et al. [84] 3 years Prospective 71 Improved UCVA 31%, BCVA 56.3%
Decreased spherical equivalent, Kmax, CCT
Decreased Kmax in 60.6%
Viswanathan et al. [85] 20 months Prospective 25 Visual acuity, astigmatism, keratometry value
improve
Reduce corneal curvature
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Table 2 (continued)
Author (reference) Follow-up Type of study Number of eyes Key findings
Kymionis et al. [86] 5 years Prospective 25 UCVA, BSCVA, visual acuity, keratometry
improved
No change ECD, CCT
Kumar Kodavoor et al. [87] 12 months Retrospective 35 Improved BCVA, decrease in Kmax
Decrease cylindrical and spherical equivalent
Steinberg et al. [88] 2 years Retrospective 20 Reduction flat and steep meridian of
topographic asymmetry parameters
Kmax not statistically reduced
Decreased TPCT and CT at apex
Goldich et al. [89] 36 months Prospective 17 Reduced Kmax
BSCVA, UCVA, visual acuity, corneal
thickness stable
No change ECD, CH, CRF, fovea thickness
Kránitz et al. [90] 25 months Prospective 50 Decreased TCT
Improved keratoconic indices, keratomeric values
Ghanem et al. [91] 24 months Prospective 42 Improved UDVA, CDVA, spherical equivalent,
HOA
Keratometric values decreased
Changes in HOA do not correlated with
improvement of visual acuity
Wittig-Silva et al. [92] 36 months Prospective 100 Improved Kmax, UCVA, and BSCVA
Decrease CT
O’Brart et al. [93] 6 years Prospective 29 Increased mean spherical equivalent error
Improved CDVA, astigmatism
Reduced corneal wave form values
Improvevisual and topographic parameterswith time
Legare et al. [94] 24 months Retrospective 30 Reduced TCT
Increased keratoconus indices
Stable Kmax, refractive measurements
Improved UDVA not significant difference in
mean UDVA
Vinciguerra et al. [95] Retrospective 400 Keratoconus stabilized in all pediatric groups
Better functional and morphological results in
18–30 years of age with better pachymetric
and aberrometric results
Rechichi et al. [96] 1 year Prospective 28 Improved CDVA, UDVA, keratoconus indices
Decreased mean spherical equivalent, CT
Endothelial cell count stable
Corneal demarcation line at 250.41 ± 21.89 μm
centrally
Hashemi et al. [97] 5 years Prospective 40 Improved CS, BSCVA, UCVA, Kmax
No significant change in keratometric values
Decrease anterior elevation, posterior elevation
Refraction decreased within first year and
remain stable
Lamy et al. [98] 2 years Prospective 68 Improved CS, BSCVA
Decrease in C-Kmax C-Kmax
Ivarsen and Hjortdal [99] 1 year Retrospective 28 Decreased Kmax, CT initially decreased, CDVA
unchanged
CXL on advance keratoconus is effective and
safer method but prone for complications
Graefes Arch Clin Exp Ophthalmol (2018) 256:1363–1384 1371
227
Table 2 (continued)
Author (reference) Follow-up Type of study Number of eyes Key findings
Viswanathan and Males [100] 24 months Prospective 51 Improve visual acuity, Kmax, logMAR BSCVA
No statistical difference central CT, spherical
equivalent, cylindrical power
Poli et al. [101] 36 months Prospective 55 Improved UCVA, BSCVA
Keratomeric vales were improved but not
significant
IOP and endothelial densities were not changed
Kymionis et al. [86] 12 months Prospective 14 Improved UDVA, CDVA
Reduced mean keratometry, endothelial density
Chatzis and Hafezi [102] 36 months Prospective 52 Reduced Kmax, after 36 months Kmax has a
tendency to progress
CDVA takes longer time to improve
Children, the effect of CXL does not last longer
as in adults
Kránitz et al. [103] 1 year Prospective 40 Improved manifest sphere, UDVA, CDVA
Decrease TCT, posterior elevation, keratometric
values
Corneal flattening evident on anterior and
posterior surfaces
Arora et al. [104] 12 months Prospective 15 Improved in UDVA, CDVA, apical K, Kmax
No significant changes flat K, steep K
Caporossi et al. [105] 36 months Prospective 77 Improved UCVA, BSCVA, SAI, K values
Worsening of topographic and pachymetric values
Faster functional recovery in thinner corneas
(< 450 μm) than thicker corneas
Greenstein et al. [106] 12 months Prospective 82 Decrease in thinnest pachymetry
Statistically insignificant changes in apical,
pupil-center pachymetry
Hersh et al. [107] 12 months Prospective 71 Improved UDVA, CDVA
Increase Kmax (1 month), decrease Kmax
(1–3 months), no change from 6 to
12 months
Visual acuity and corneal steepness worsen at
1 month, resolute to baseline from 3 months
Spoerl et al. [108] 12 months Prospective 50 No significant differences in CH and CCT
O’Brart et al. [109] 18 months Prospective 24 Improve keratometric topographic parameters
No change in patchymetry values, UCVA,
BSCVA, refractive cylinder correction,
spherical equivalent refractive error
Improved BSCVA
Caporossi et al. [110] 48 months Perspective 363 Reduced mean K, coma aberration
Improved corneal symmetry, UCVA, BCVA
Sinha et al. [111] Immediately after CXL Prospective 16 Elastic modulus increment 110.8 ± 48.1%
The corneal shape varied to different patients
Sedaghat et al. [112] 6 months Case series 56 CH, CCT, CH, and CRF not changed
SCDVA, spectacle-corrected distance visual acuity; KC, keratoconus; C-CXL, conventional corneal collagen crosslinking; BCVA, best-corrected visual
acuity; BSCVA, best spectacle-corrected visual acuity; CDVA, corrected distance visual acuity; CCT, central corneal thickness; CV, corneal volume;
ACV, anterior chamber volume; ACD, anterior chamber depth; AL, axial length; UCVA, uncorrected visual acuity; AGC, apical gradient curvature;
BFS, best-fit sphere; ECD, endothelial cell density; TPCT, thinnest point in corneal thickness; BDVA, best-corrected distance visual acuity; UDVA,
uncorrected distance visual acuity; HOA, corneal higher order aberrations; CH, corneal hysteresis; CRF, corneal resistance factor; CS, contrast sensi-
tivity; C-Kmax, central-Kmax; IOP, intraocular pressure; SAI, surface asymmetry index; TCT, thinnest corneal thickness; CTP, corneal thinnest point;
Kmax, steepest keratometry
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the visual outcome was improved due to reduction of irregular
astigmatism [126, 127].
When evaluating the anterior corneal elevation changes
with the Orbscan II, it was apparent that the changes in the
anisotropy of collagen distribution influenced the shape of the
cornea following CXL treatment [128]. Following C-CXL
treatment, different degrees of improvement in keratometric
values including steepest keratometry values (Kmax) were re-
corded. A decrease in Kmax by − 2.24 diopters (D) [110], −
2.57 D [124], − 2 D [100], − 1.16 D [93], − 1.68 D [95], and −
0.74 D [92] has been reported in literature. The improvement
of Kmax was not associated with the age and gender of the
patients [92]. A clinical study to evaluate biomechanical prop-
erties such as corneal hysteresis (CH) and corneal resistance
factor (CRF) before and after CXL revealed no significant
difference in the parameters following crosslinking treatment
[112]. The absence of significant changes in CH and CRFwas
also noted in other studies conducted 6 months after CXL
treatment [89, 129]. However, Spoerl et al. noted that the
biomechanical properties of CXL-treated corneas are signifi-
cantly different from that of the healthy corneas [108].
The flattening effect of the crosslinking treatment on ante-
rior corneal surface has been well documented [103]. A sig-
nificant increase in the posterior Bastigmatism^ and posterior
elevation values despite flattened anterior corneal surface,
12 months following CXL treatment has been reported in
literature [73]. These findings are similar to the study of
Steinberg et al., suggesting an ongoing posterior ectasia de-
spite a stabilized anterior corneal surface following CXL treat-
ment [88]. When these values are compared with the non-
treated keratoconus subjects, the increment of posterior eleva-
tion values and posterior astigmatism values following CXL
treatment are not statistically significant [130]. On the con-
trary, another study described a flattening effect on both
anterior and posterior corneal surfaces with a significant de-
crease in the posterior elevation values [103]. Another study
indicated absence of any significant changes in the posterior
elevation values following CXL treatment [131].
CXL causes thinning of the cornea, an effect of which starts
at the commencement of the procedure and continues until 1–
3months following treatment [72, 132]. However, recovery of
the corneal thickness starts from 3 months and reaches the
baseline thickness (thickness of the cornea prior to CXL treat-
ment) by 1 year [106, 107]. In some cases, the thinning effect
immediately following CXL treatment was significant enough
to result in endothelial damage [76], while in other cases, no
significant thinning effect was noted after the procedure [94,
100] The average corneal thickness increase within 12months
post-CXL treatment was 20 μm from the 3-month baseline
values [106]. Kim et al. stated that even after 5 years, there
was a statistically significant decrease in the corneal thickness
in comparison with the baseline values prior to crosslinking
treatment [77]. According to Polat et al., the first 6-month to 1-
year period is considered the optimal healing and remodeling
stage of the cornea. During this period, the maximum
rethickening effect of cornea post-CXL treatment can be ob-
served. In the aforementioned study, the corneal thickness pre-
CXL treatment was 436.20 ± 32.15 μm, and after 1 year fol-
lowing CXL treatment, the value was increased to 454.10 ±
45.70 μm [71].
Corneal innervation and tear film The C-CXL technique does
not damage the limbal stem cells, and epithelial regrowth
completes within several days of treatment [133]. The corneal
subepithelial nerve fibers start to regenerate at an early stage
(1 month after CXL treatment) whereas anterior-midstromal
nerve fibers regenerate from the deep stromal nerve plexus
between 2 and 3 months post-operatively. Six months post-
Fig. 2 Innervation to the corneas
with subbasal nerve plexus and
subepithelial erve plexus. A,
Epithelium; B, basal lamina; C,
stroma; D, terminal nerve endings
within the epithelium; E, subbasal
nerves; F, subepithelial nerve
plexus within the corneal stroma
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treatment, the corneal sensitivity was fully restored with a
complete regeneration of nerve fibers within the corneal stro-
ma [133] (Fig. 2). However, another study described of a
progression in the abnormal nerve migration even after 5 years
post-CXL treatment and the corneal sub-basal nerves did not
regenerate to reach the level of a healthy cornea following C-
CXL treatment [75]. Therefore, given the widespread use of
this treatment for management of keratoconus, abnormal
nerve migration post-CXL treatment should be recognized
and further investigated.
Corneal denervation leads to dry eye, which is one of the
most recognized complications of corneal refractive surgeries
[134]. The tear film plays a significant role in preventing
evaporation and prevents eyes from drying. The patients suf-
fering from keratoconus have disturbed tear film function with
reduced Goblet cells within the conjunctival epithelium and
significantly lower values of tear film break-up time (TFBUT)
as a result [135]. Another promising effect of the CXL treat-
ment is that it does not appear to have any adverse effects on
the tear film parameters including TFBUT, osmolality, ocular
surface index, Schirmer test score, and tear clearance [68].
Riboflavin The effect of riboflavin on the crosslinking process
has been discussed in literature. This includes the factors such
as the concentration and time of exposure of riboflavin to
corneal tissue that needs to be considered for a better outcome
[136–138]. The corneal tissue strongly absorbs the UV light,
and the absorbed light converts into heat and dissipates into
the corneal tissue causing thermal damage. Therefore, the
cooling effect of riboflavin on the corneal surface is an added
benefit in preventing thermal injury to the cornea [139]. The
use of a dextran solution is a vital component in the CXL
treatment. For instance, substitution of dextran (T-500) with
dextran sulfate in riboflavin solutions has resulted in the loss
of vision and permanent corneal opacity in some cases [70].
The main purpose of adding dextran is to increase the viscos-
ity of the riboflavin drops and to create an isotonic solution
from a hyperosmolar riboflavin solution which prevents ex-
cessive swelling of the corneal stroma [140]. In some cases,
hypoosmolar solutions of riboflavin have been used to induce
swelling of the thin corneas to make them suitable for C-CXL
treatment. [114].
CXL for younger age groups The effectiveness of the C-CXL
treatment on younger age groups has given variable outcomes.
While some studies have shown an improvement of
keratometric values with a reduction in the progression of
the disease within the age group of 9–18 years [74, 85, 87,
104], others illustrate adverse outcomes such as worsening of
topographic and patchymetric values long term in the same
age group [102, 105]. In general, determining the effective-
ness of crosslinking treatment on younger patients has been
difficult due to the effect of continuous growth and
development. Vinciguerra et al. stated that the effectiveness
of the C-CXL treatment is optimal in patients within the age
group of 18–30 years [95], while Viswanathan et al. illustrated
promising results in patients in a much younger age group (8–
17 years) [85]. In general, performing C-CXL at an early stage
of keratoconus seems to have produced effective results com-
pared with advanced stages of keratoconus in pediatric and
adolescent groups [104].
Protocol variations
Although the Dresden protocol is commonly used in clinical
practice, alternative protocols are currently introduced to over-
come some of its drawbacks. The complications related to C-
CXL were mostly associated with the large epithelial defects
that occur during epithelial removal prior to treatment.
Complications associated with epithelial removal prior to C-
CXL may vary from minor effects such as delayed epithelial
closure to more advanced complications such as corneal scar-
ring, infectious keratitis and corneal perforation [141–144].
Prolonged treatment time is also another drawback that has
to be addressed whenmodifying the existing C-CXL protocol.
In an attempt to improve the visual and topographical out-
comes of C-CXL, various modifications such as accelerated
crosslinking and transepithelial crosslinking methods have
been introduced in clinical practice.
Accelerated CXL
A-CXL treatment is based on the BBunsen-Roscoe law of
photochemical reciprocity^ where the same photochemical
effect can be achieved by reducing the irradiation interval
but keeping the total energy level constant by a corresponding
increase in the irradiation intensity. Therefore, cumulative
dose has to be maintained while applying a higher irradiation
dose for a shorter period of time [30, 145]. The main advan-
tage of this protocol in comparison with C-CXL is the reduced
treatment time. Theoretically, the infection risk might also be
reduced as the de-epithelialized cornea is exposed for a shorter
period of time [146]. Several different accelerated protocols
with a cumulative dose of 5.4 J/cm2 have been described.
However, these experimental and clinical studies have shown
conflicting outcomes. More recently, pulsed light accelerated
crosslinking with 8 min of UVA exposure at 30 mW/cm2 with
an energy dose of 7.2 J/cm2 was introduced as an effective
mode of treating KC [147]. A clinical study with a 1-year
follow-up stated that the functional outcome of the pulsed
light A-CXL is better than the continuous light A-CXL
[148] with a capability of penetrating deeper into the corneal
stroma when compared with continuous light A-CXL treat-
ment [149].
A study that used stress-strain measurements of porcine
corneas reported that A-CXL produced equivalent corneal
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stiffening effects (compared with C-CXL) with a radiation
dose of 10mW/cm2 for 9min [119]. In contrast, Hammer et al.
stated that the biochemical effect of CXL decreases with high
irradiance/short irradiation time [150]. There were also report-
ed cases of stiffer anterior cornea resulting from the C-CXL
than from the A-CXL treatment [151]. A few clinical studies,
using different intensities and exposure times, have illustrated
contradictory results concerning the efficacy of A-CXL com-
pared with C-CXL. Favorable outcomes with improved visual
acuity and keratometric values (K values) were noted in a 12-
month follow-up study following A-CXL [152, 153].
Improved visual acuity and decrease in keratometric values
were observed in A-CXL than in C-CXL on one of the studies
which used an irradiation of 10mW/cm2 for 9 min [154] while
another study with the same irradiation dose did not note a
significant difference in visual, keratometric, and aberrometric
results between the A-CXL and C-CXL protocols [155].
Similar results were observed in A-CXL treatment under
30 mW/cm2 exposure for 3 min [156, 157]. In one of the
studies, 1-year post-CXL keratometry value (Kmax) reduction
was statistically significant in A-CXL than C-CXL [156, 158],
while in other cases, the reduction of keratometry values was
more significant in C-CXL-treated corneas than A-CXL-
treated corneas [46, 158, 159]. A study by Razmjoo et al.
stated no significant difference in improving visual acuity
and refractive errors in the A-CXL procedure in comparison
with C-CXL with a 6-month follow-up study [157]. While in
some cases, non-significant changes in the keratometric
values were observed in A-CXL, whereas the K values were
significantly decreased in conventional treatment [159, 160].
When evaluating the safety and the efficacy of CXL treat-
ment, accurate measurement of the depth of the CXL effect is
important. The cytotoxicity of the CXL treatment and non-
regenerative nature of the corneal endothelial cells should also
be taken into consideration when choosing an effective thera-
peutic procedure. Therefore, various methods have been sug-
gested to measure depth of the CXL treatment. Measurement
of the crosslinked depth with the corneal demarcation line was
first described by Seilar and Hafezi using the slit-lamp
biomicroscope. Later, it has been investigated using confocal
microscopy, optical coherence tomography, and Scheimpflug
imaging [161]. The corneal demarcation line represents the
transition zone between the crosslinked anterior stroma and
untreated posterior corneal stroma, with effectiveness of the
crosslinking treatment confined to the anterior stroma. More
recent studies have illustrated that the demarcation line can be
deeper in the central part of the corneas compared with its
peripheral part where at the central part, it is usually visible at
a depth of 300–320 μm following C-CXL treatment [86, 162,
163]. When investigating the corneal stromal demarcation line
depth of C-CXL and A-CXL protocol, both protocols have
shown to preserve corneal limbal stem cells [43, 164].
Furthermore, topographic studies have revealed that the effect
of corneal flatteningwas less in A-CXL than in the C-CXLwith
a deeper corneal demarcation line visible with the former tech-
nique [46, 159]. Another study suggested a lack of demarcation
line depth where the demarcation line was not clearly evident in
A-CXL [165]. The epithelial thickness decreased immediately
following A-CXL procedure and was gradually recovered and
achieved the post-operative thickness after 1 month post-
treatment [166]. The temperature increment due to both C-
CXL and A-CXL techniques were below the threshold of ther-
mal injury (50 °C) to corneal collagen fibrils [167].
Although, with disputable clinical and laboratory results,
many studies have suggested A-CXL procedure as an effec-
tive method to stabilize the progression of keratoconus both in
adults [168, 169] and in children [170]. In general, when an-
alyzing the literature, surgical protocols reported for A-CXL
are very different and unlikely comparable. Therefore, it is
very difficult to deduce a reliable conclusion. However, in
general, it seems likely that A-CXL with an irradiation dose
of 10mW/cm2 for 9min has a better therapeutic result than the
A-CXL with a higher irradiation dose for a shorter exposure
time (for example, 30 mW/cm2 for 3 min).
Epithelium-on/transepithelial technique
The principal clinical drawbacks of the C-CXL such as a
painful recovery process, prolonged visual recovery due to
the large epithelial defect, and the inability to perform C-
CXL on thin corneas due to the risk of endothelial damage
has encouraged clinicians to look for a method of crosslinking
without epithelial debridement. Therefore, T-CXL was devel-
oped where the corneal epithelium is left intact prior for the
CXL treatment. Preservation of the epithelial layer conserves
corneal morphology and makes the procedure more comfort-
able for patients [171–173]. It was also noted that the collagen
fiber arrangement become similar to normal corneas after
3 months post T-CXL treatment [172]. In addition, another
study describes that T-CXL can be used as an effective mode
of treatment for keratoconic patients with thin corneas [174].
According to current published data, this technique has signif-
icantly improved the BCVA, manifest refraction, refractive
and corneal astigmatism, and maximum K values in
keratoconic patients [175, 176]. The recovery of corneal sen-
sitivity following crosslinking with and without epithelial re-
moval has illustrated that corneal sensitivity is restored
12 months following surgery with both techniques.
However, T-CXLmight affect the corneal sensitivity to a less-
er degree than C-CXL treatment [177]. Studies to compare
riboflavin penetration into the corneal stroma with and with-
out removal of epithelium illustrated that the time-dependent
riboflavin penetration was maximal only after the removal of
the epithelium [60, 62, 138]. The corneal epithelial cells are
connected by tight junctions, which play a vital role in
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epithelia functions [178]. These tight corneal junctions limit
the diffusion of riboflavin into the stroma during T-CXL pro-
cedure. Additionally, the epithelium absorbs part of the UVA
and prevents the amount of UVA reaching the corneal stroma
and resulting in reduced crosslinking effect [138, 179].When
evaluating the riboflavin distribution into the corneal stroma,
it was evident that the application time and riboflavin concen-
tration have a little influence on how riboflavin is diffused into
stroma. For instance, it was evident that an increase in the
application time affects the uptake of riboflavin into a lesser
degree [115].
Different techniques have been proposed in the literature to
increase the riboflavin penetration into the cornea without
epithelial debridement. Some of the strategies used are chang-
ing the physiochemical properties of riboflavin molecule with
the use of chemical enhancers [180]; performing mechanical
disruption of corneal epithelium [96]; increasing the applica-
tion time of riboflavin [181]; iontophoresis [182]; ultrasound
enhanced penetration of riboflavin [98, 183]; the use of
intrastromal channels to introduce riboflavin to bypass the
corneal epithelium [117, 184, 185]; transepithelial delivery
of riboflavin with microneedles [186]; and nanotechnology-
based transepithelial crosslinking [187]. Although these tech-
niques have overcome some of the immediate post-operative
complications of C-CXL, their effectiveness seems to be less
than that of conventional CXL thus their utility is still a matter
of debate [188–192]. Two of the commonly investigated tech-
niques are discussed in the following paragraphs.
Use of chemical enhancers to increase the riboflavin
penetration
One of the main aspects in achieving adequate penetration of
riboflavin is to use different chemical enhancers. However,
most parts of these chemical agents are toxic to the epithelium.
Some of the commonly investigated chemicals are
benzalkonium chloride (BAC), ethylenediamine tetraacetic
acid (EDTA), d-alpha-tocopheryl polyethylene-glycol 1000
succinate, tetracaine, proparacain, ethanol, and gentamicin
[193–198]. The use of a combination of these enhancers
seemed to have an improved effect with topical hydrophilic
drugs achieving a better intraocular penetration [199, 200].
For instance, in conjunction with proparacaine, gentamicin
and BAC have shown promising improvements in visual acu-
ity and refractive indexes following T-CXL [201]. Another
study performed on rabbit corneas suggested BAC as an ef-
fective enhancer that allows microscopically evident
crosslinking at the anterior cornea [202]. However, when
compared, the percentage of increase in corneal rigidity in
rabbit cornea following T-CXL using BAC was significantly
lower in comparison with the C-CXL technique [60]. A clin-
ical study by Leccisott and Islam using 51 patients suffering
from keratoconus suggested a favorable effect of T-CXL with
absence of any notable complications. However, in this study,
the corneal curvature was not improved with the T-CXL pro-
cedure [44]. In addition, the absence of any significant im-
provement in corrected distance visual acuity value (CDVA)
and topographical parameters following T-CXL has also been
reported in a study conducted with 61 keratoconic eyes [203].
In contrast, a different study illustrated a significant improve-
ment of maximum K values and CDVA at 6 months follow-up
in T-CXL treatment [204].
Iontophoresis CXL
Iontophoresis is a technique which results in enhancing pene-
tration of different solutions using a small electric current.
This technique has been introduced in many fields of medi-
cine [205–207] including drug delivery to intraocular com-
partments [208–210]. However, more recently, this technique
has been tested in corneal crosslinking in order to increase the
penetration of riboflavin through the tight junctions of the
corneal epithelium without debridement of the epithelium
[211] . However, the absorption of riboflavin into the stroma
was reduced by half in I-CXL compared with C-CXL [212,
213]. From the total riboflavin absorbed, 15–20% of ribofla-
vin was absorbed by the corneal epithelium [214]. Therefore,
C-CXL technique seems to have greater and deeper riboflavin
saturation when compared with I-CXL technique [182]. A
study to investigate modifications in human corneas following
I-CXL and C-CXLmethods suggested that the I-CXL induced
less tissue damage and better stromal remodeling compared
with C-CXL treatment [182].
I-CXL increases the mechanical rigidity of the corneas
when compared with T-CXL treatment with tromethamine
[215]. Biomechanical resistance acquired by I-CXL-treated
corneas was greater than the biomechanical resistance induced
by C-CXL treatment [167]. Lombardo et al. noted that biome-
chanical strengthening of the cornea is more pronounced with
the C-CXL treatment than with the I-CXL treatment,
12 months following the crosslinking procedure [216]. I-
CXL induced quicker improvement of visual acuity compared
with C-CXL with a significant improvement in the CDVA
values within 3 months compared with C-CXL treatment
[217]. A few studies have stated that both the techniques have
almost similar therapeutic effects on crosslinking [211, 213,
218]. In contrast, many studies that compared long-term ef-
fects of I-CXL and C-CXL stated that the I-CXL was less
effective in arresting the disease progression of keratoconus
compared with C-CXL treatment [33] The Kmax value of I-
CXL-treated corneas seemed to be stable at 2 years, whereas it
decreased significantly after 1–2 years following C-CXL
treatment [33, 212, 216]. In contrast, another study noted a
reduction in the Kmax values in both I-CXL and C-CXL treat-
ment groups [212]. However, according to this study, Kmax
reduction (− 1.05 ± 1.51 D) following the C-CXL treatment
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is statistically greater compared with the I-CXL treatment (−
0.31 ± 1.87 D). This suggests that in general, the C-CXL treat-
ment is more effective than the I-CXL treatment for the treat-
ment of keratoconus [217]. Although the I-CXL technique has
been researched for years, long-term follow-up studies with a
larger number of participants have to be conducted to assess
the effectiveness of this technique when compared with the C-
CXL technique.
Conclusion
The introduction of corneal crosslinking is one of the most
promising recent developments in the management of corneal
ectasia. There are many long- and short-term studies which
have evaluated the effectiveness of different crosslinking
treatments used in the current practice. However, these clinical
and laboratory studies have illustrated contradictory results
regarding the effectiveness of these techniques in the treat-
ment of keratoconus. When comparing conventional
crosslinking with other crosslinking methods, the efficacy of
these modified techniques still seems to be lower than that
with C-CXL. It is evident from this review that in general,
these modified techniques seem to have contradictory results
regarding its effectiveness. However, these techniques appear
to be able to overcome some of the immediate complications
of the C-CXL technique. Therefore, more research is needed
before these techniques are widely adopted in clinical practice.
Future research will further elucidate and consolidate the po-
sition of CXL among the most innovative surgical therapies in
ophthalmology.
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Abstract
Rabbit and porcine corneas have been used in scientific research due to their structural similarity to the human cornea. Cur-
rently, there are no studies that have compared corneal collagen fibrillar diameter, interfibrillar distance and interlamellar 
distance between human and animal models. Ten pairs of porcine, rabbit, and human corneas were used. These were analysed 
using light and Transmission Electron microscopy. The collagen fibrillar diameter, interfibrillar distance and interlamellar 
distance were statistically compared between porcine, rabbit and human corneas. The human, porcine and rabbit; mean col-
lagen fibrillar diameters were: 24.52 ± 2.09 nm; 32.87 ± 0.87 nm; and 33.67 ± 1.97 nm. The mean interfibrillar distances were: 
46.10 ± 2.44 nm; 53.33 ± 2.24 nm; and 52.87 ± 2.73 nm, respectively. The collagen fibrillar diameter and interfibrillar distance 
of porcine and rabbit corneas were significantly different (p < 0.001) to the human corneal values but not form each other. 
The interlamellar distance of human, porcine and rabbit corneas was: 2190 ± 820 nm; 6460 ± 1180 nm; and 4410 ± 1330 nm, 
respectively. All the comparisons were statistically different, in porcine versus rabbit at the p < 0.01 level and both porcine 
and rabbit versus human at the p < 0.001 level. Histologically, all five layers (epithelium, Bowman’s layer, stroma, Descemet 
membrane and endothelium) of the cornea were visible in all the three species. While neither animal model was structurally 
identical to the human cornea, they are both relatively close to being used as models to study the biomechanical effects of 
external insults/treatments to be extrapolated to the human cornea.
Keywords Collagen fibrils · Corneal stroma · Human cornea · Porcine cornea · Rabbit cornea
Introduction
The morphology of porcine and rabbit corneas are gener-
ally believed to be similar to that of the human (Fernandez-
Bueno et al. 2008; Brunette et al. 2011). Therefore, these 
animal models have been used in vision-related scientific 
research for several decades.
Porcine and rabbit models have been used extensively to 
study different parts of the eye including the ciliary epithe-
lium, trabecular meshwork, aqueous outflow, the neuroretina 
and the retinal vascularization. Both models have also been 
used in the development of new imaging techniques of the 
eye (Rosolen et al. 2001, 2002). These two have also been 
used as models in the study of pathologies associated with 
glaucoma (Ruiz-Ederra et al. 2005) and cataract (Sugiura 
et al. 1999). Different surgical techniques of the retina, vit-
reous and lens were experimented on porcine eyes (Ghosh 
and Arnér 2002). Rabbit corneas are also commonly used 
to test different tropical medications and modes of oph-
thalmic drug delivery systems (Xiong et al. 2008; Oh et al. 
2007). Furthermore, these animal models have been used 
to investigate the anatomy, pathophysiology, biomechan-
ics and immunology related to visual sciences (Majo et al. 
2008). More recently, these animal models have also been 
used to evaluate the effects of corneal collagen crosslinking 
treatment which is, perhaps, the most promising treatment 
options for keratoconus (Wollensak et al. 2004; Wollensak 
and Spoerl 2004).
Although many studies have used either porcine or rabbit 
corneas as experimental models, only a few have compared 
their morphological similarities to the human cornea. Fur-
thermore, we have not been able to find any investigations 
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that had compared the collagen fibrillar diameter, interla-
mellar distance and interfibrillar distance, of porcine and 
rabbit corneas, and compared these values with that of the 
human. Detailed corneal morphology of these animal mod-
els is required to choose a suitable model to investigate dif-
ferent corneal pathologies and their related complications 
that could be extrapolated to human. Therefore, this paper 
will be presenting the general morphological arrangement of 
corneal collagen fibrils in normal porcine, rabbit and human 
corneas. Furthermore, an attempt will be made to determine 
which of the two animal models is more structurally closer 
to the human cornea.
Materials and method
Animal and human corneas
The study was conducted with: five pairs of porcine eyes 
(10 samples) aged at 9 months—12 months, obtained from 
an abattoir ("South Kill", Milton, New Zealand); five pairs 
(10 samples) of New Zealand White rabbit corneas aged at 
15 months, obtained from University of Otago, Christchurch 
campus, New Zealand (Animal ethics committee approval 
number: AUP 18–196, Application number: CG4/17) and 
five pairs (10 samples) of human corneas retrieved from 
bequeathed cadavers to the Department of Anatomy, Uni-
versity of Otago (Human ethics committee, University of 
Otago, Ethics committee reference code: H18/041). The ani-
mal corneas were retrieved within six hours, and human cor-
neas, due to logistical constraints, within 24 h post-mortem.
Retrieval of corneas
Retrieval of human corneas was performed by a technician 
at Rhinds Funeral Services in Christchurch, New Zealand. 
The technician was trained in excising corneas from eyeballs 
in-situ by the primary author. The primary author retrieved 
all the animal corneas.
Excision of the corneal flap and sample preparation
Aseptic techniques were followed from the time of cor-
neal retrieval to histological sample preparation. The eyes 
were cleaned by several washes of sterile saline (0.9% wt/
vol NaCl), followed by immersion in 1% (wt/vol) polyvi-
nylpyrrolidone-iodine (PVP-I) for two minutes, 0.1% (wt/
vol) sodium thiosulfate (to neutralize the iodine) for one 
minute, and another wash of sterile saline (Armitage 2011). 
The orbital area and surrounding skin were cleaned with 
water, and the operative area of the skin was then prepared 
according to the standard pre-operative skin preparation, 
and the operation field was isolated with sterile drapes. The 
eyelids were opened by a sterile cotton-tipped applicator 
and kept open by a solid blade eye-speculum. The corneas 
were excised by cutting 2–3 mm outside the corneoscleral 
junction with a curved iris scissors.
The excised corneal flaps were examined with a dissec-
tion microscope, and corneas with any signs of pathology or 
scarring were excluded., The selected corneal buttons were 
bisected, and one half was fixed in 10% neutral buffered 
formalin solution, processed and embedded in paraffin for 
histological examination. The blocks were sectioned in the 
following manner: the first two consecutive sections were 
cut at 4 µm thickness, and one sample stained by Hematoxy-
lin–Eosin (H and E) and the other stained with Masson Tri-
chrome (MT) staining. The stained sections were examined 
under a light microscope (Olympus B × 61) ( to visualize 
the morphological features of the collagen fibrils and the 
distribution of keratocytes within the corneal stroma). This 
sequence of sectioning was repeated twice more to cover a 
wider range of the corneal surface. Therefore, per sample 
there were three alternate sections stained with H and E and 
three sections stained with MT.
Subsequently, the remaining halves of the excised cor-
neas were processed for Transmission Electron Microscopy 
(TEM) (CM100 BioTWIN Philips Transmission Electron 
Microscope). In summary, the excised corneal halves were 
directly transferred to a primary fixative containing 4% par-
aformaldehyde, 2% glutaraldehyde in 0.15 M Cacodylate 
buffer, and stored until further processing. The samples were 
then washed in 0.15 M cacodylate buffer and osmicated in 
1%  OsO4 and 1.5% potassium ferrocyanide in 0.1 M caco-
dylate buffer. Following this, the samples were undergone 
several washes in double-distilled water  (DDH2O) and fol-
lowed by dehydration (with different concentrations of etha-
nol). Finally, the samples were embedded in silicon molds, 
and polymerized for 48 h at 60 ºC, and sectioned with a 
Leica UC7 ultramicrotome using a Diatome diamond knife 
and mounted on formvar coated copper slot grids. The sec-
tions were stained with 1% uranyl acetate and 3% lead citrate 
using a LKB ultrostainer. From each specimen, three sec-
tions, selected from three random areas, were analyzed for 
detailed ultrastructural morphology.
The detailed structural analysis of these sections was 
carried out to measure the minimum diameter of collagen 
fibrils, interfibrillar distance and interlamellar distance.
Collagen fibrillar diameter
The minimum diameter of each collagen fibril was measured 
using the iTEM AnalySIS image processing software. The 
minimum diameter was measured to avoid errors caused by 
any obliqueness in fibril cross-sections. Collagen fibrils with 
clearly defined borders were chosen (Fig. 1a) and those with 
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indistinct borders were discarded. The discards were less 
than 1% of the total fibrillar count.
Interfibrillar distance
The same images that were used to measure the fibrillar 
cross-sectional diameter were used to measure the nearest 
neighbouring distance/ interfibrillar distance between adja-
cent fibres with Fiji-ImageJ software. The measurements 
were taken from the centre of the mass of one fibril to the 
centre of mass of its nearest adjacent fibril ( Fig. 1c).
Interlamellar distance
One image each of a parallel running collagen fibrillar 
bundle (lamellae/ collagen fibre) were randomly cho-
sen from anterior, intermediate and posterior regions of 
the cornea, and the distance between the adjacent par-
allel lamellae was measured. Three measurements were 
obtained for each pair of lamellae. Therefore, there 
were three readings from each region and the mean of 
these three readings was taken as the final measurement 
(Fig. 1d).
Data analysis
The mean values of all the samples were calculated for 
porcine, rabbit and human corneas and compared using 
one-way ANOVA to check if there was a significant differ-
ence between species and to find the animal model that was 
closer/similar to human. Statistical analysis was performed 
using the GraphPad Prism (Version 8.4.3, ©1994–2020 
GraphPad Software, LLC).
Fig. 1  TEM micrograph illustrating the process of measuring the 
interfibrillar distance and interlamellar distance. a TEM micrograph 
of fibril profile. b Isolation of each fibril profile using the ImageJ 
software. c Interfibrillar distance to the nearest neighbouring fibril. 
The measurement was  taken from the centre on each neighbouring 
collagen fibril. The RED line indicates th measurement taken from 
the centre of two neighbouring collagen fibrils. d Measurement of the 
interlamellar distance (distance between collagen fibrillar bundles). 
Three measurements were taken from parallelly oriented collagen 
lamellae
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H&E and MT staining allowed the visualization of the gen-
eral arrangement of corneal collagen fibrillar morphology 
in all three species. The outermost layer, the epithelium con-
sists of stratified, non-keratinized squamous cell layer that 
uniformly extending from limbus to limbus. Just below the 
epithelium is the Bowman’s layer (or Bowman’s membrane) 
followed by the corneal stroma which provides the bulk of 
the structural framework of the cornea. All three species 
showed a well-demarcated Bowman’s layer (Fig. 2). The 
distribution of collagen fibers within the corneal stroma was 
also visible in all the species with MT staining (Fig. 2). The 
Descemet membrane, beneath corneal stroma was visible in 
the human corneas. However, the rabbit had a much thicker 
Descemet membrane compared to both human and porcine 
corneas. Finally, the single-layered endothelium was evident 
in all three species (Fig. 2).
Transmission electron microscopy (TEM)
Collagen fibrillar diameter
The mean collagen fibrillar diameter of the human cor-
nea was 24.52 ± 2.10 nm while porcine and rabbit corneal 
mean collagen fibrillar diameters were 32.87 ± 0.87 nm 
and 32.57 ± 1.97 nm. When comparing collagen fibrillar 
diameter with one-way ANOVA, there were statistically 
significant differences between each species (p < 0.0001). 
Human collagen fibrillar diameters were significantly dif-
ferent from those of porcine and rabbit corneas (Figs. 3, 4) 
being approximately 8 nm smaller than the other two spe-
cies. Figure 2 illustrates how the mean values of the col-
lagen fibrillar distance were measured. Figure 3 represents 
the graphical comparison of collagen fibrillar diameter and 
interfibrillar distance of the three species.
Interfibrillar distance When comparing the mean values 
of the interfibrillar distance, it was evident that humans 
(46.10 ± 2.44 nm) had a smaller mean value compared to 
porcine (53.33 ± 2.24 nm) and rabbit (52.87 ± 2.73) mod-
els. The difference was statistically significant between 
species (p < 0.0001) (Figs.  3 and 4). As illustrated in 
Fig.  3, while both rabbit and porcine interfibrillar dis-
tances were statistically different to humans, these values 
were similar between the two.
Interlamellar distance The mean interlamellar distance 
of porcine cornea was 6460 ± 1180 nm while rabbit and 
human values were 4410 ± 1330 nm and 2190 ± 820 nm, 
respectively. When the mean values were compared 
between the species using one-way ANOVA, there was 
a significant difference between species (p = 0.0007) 
(Figs. 5 and 6). Figure 5 demonstrates that porcine inter-
lamellar distance is closer to human but significantly dif-
ferent from the rabbit.
Discussion
Corneal pathologies, including keratoconus and their asso-
ciated complications, and the treatments for these condi-
tions are commonly investigated and evaluated on animal 
models. Many animals including rabbit (Helena et al. 1998), 
mouse (Wilson et al. 1996), rat (Reid et al. 2005), bovine 
(Kamma-Lorger et al. 2009) and porcine (Fernandez-Bueno 
et al. 2008) corneas have been used in the past to investigate 
different oculovisual pathologies related to visual sciences. 
When evaluating the effects of corneal collagen crosslinking 
treatment most of the animal studies have been carried out 
on either rabbit (Wollensak and Iomdina 2009; Wollensak 
et al. 2004) or porcine corneas (Seiler et al. 2014; Lanchares 
et al. 2011) due to their similarities to the human cornea. 
Although donor human corneas are ideal for investigating 
these pathological conditions, their applications are limited 
mainly due to insufficiency in availability. Therefore, identi-
fying suitable animal model or models will provide research-
ers with an informed choice when selecting an animal model 
for vision science research. In the present study, we have 
found porcine corneas were structurally closer to humans 
than the rabbits when considering corneal interlamellar dis-
tance. Interfibrillar distance and collagen fibrillar diameter 
of porcine and rabbit corneas were very similar, but were 
significantly different to human.
Many studies have investigated the structural features of 
the corneal stroma in human and animals (Maurice 1957; 
Davis 1929). The collagen fibrillar diameter within the cor-
neal stroma in a human was estimated to be in the range 
of 20–23 nm (Maurice 1957) while for rabbits and porcine 
corneas the corresponding collagen fibrillar diameters were 
12.5–32.50 nm (Cox et al. 1970) and 35.7 ± 1.60 nm, respec-
tively (Hayes et al. 2013). The fibrillar diameter values of the 
current investigation are similar to those in the literature. An 
X-ray diffraction study that was performed to measure the
interfibrillar distance of different animal species has found
the interfibrillar distances of porcine and rabbit corneas to be
65.6 ± 50 nm and 65.8 ± 50 nm (Gyi et al. 1988) which are
about 25% higher than the values from this study. In an elec-
tron microscopy study of human corneas, the interfibrillar
distance was found to be 38 ± 7.80 nm (Akhtar et al. 2013)
where the difference is not statistically significant from
our study. The differences in the values of the interfibrillar
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Fig. 2  Light microscopy image of the porcine, rabbit and human cor-
nea. A, B – structure of the porcine cornea ( a H and E staining, b 
MT staining). c, d Structure of the rabbit cornea (c H and E staining, 
d MT staining). e, f Structure of the human cornea (c, H and E stain-
ing, d MT staining). a, c, e BLACK arrow—Descemet’s membrane, 
BLUE arrows—Endothelium. RED arrows—Bowman’s layer,
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distance of rabbit and porcine were probably the result of 
different investigation techniques used in those studies.
None of the studies published so far has compared the 
collagen fibrillar diameter, interfibrillar distance and inter-
lamellar distance of porcine and rabbit corneas with the 
human. Our study demonstrated that human corneal colla-
gen fibrillar diameter was generally smaller than those of 
the porcine and rabbit corneas. When comparing rabbit with 
porcine corneas, we found that the diameter difference was 
not statistically significant. The interfibrillar distance also 
showed a similar pattern between porcine and rabbit cor-
neas but were significantly different from human. Although 
the rabbit interlamellar distance was significantly different 
from human, porcine did not show a significant difference to 
that of humans. This makes the porcine model being closer 
to humans than the rabbits with regard to the interlamellar 
distance.
The presence or absence of Bowman’s layer in the porcine 
cornea is debatable. A histological study by Bartholomew 
et al. (1997), showed the presence of a Bowman’s layer in 
the porcine cornea (Bartholomew et al. 1997). However, Jay 
et al. (2008), stated that Bowman’s layer was absent in por-
cine corneas (Jay et al. 2008). Cafaro et al. (2009), describe 
that the Bowman’s layer is only absent at the limbus of the 
porcine cornea (Cafaro et al. 2009). Although more recent 
investigations have identified a Bowman’s layer being in the 
porcine cornea. However, it is not developed to a similar 
degree as in the human cornea (Nautscher et al. 2016). In our 
study, a Bowman’s layer was clearly visible in porcine cor-
neas (Fig. 2a, b). Similar to porcine corneas, different studies 
have different views regarding the presence or absence of 
the Bowman’s layer in the rabbit cornea. In our study, the 
Bowman’s layer was also evident in rabbit corneas (Fig. 2c, 
d), a contradictory finding to some previous studies (Davis 
1929). For instance, Davis in 1929, stated that there was 
no definitive layer of a Bowman’s membrane, but occasion-
ally, in some of the rabbit corneas a definitive condensa-
tion of stoma was present underneath the epithelium. This 
condensation was considered to be as a part of the stroma 
rather than a separate layer (Davis 1929). However, in our 
study, we were able to clearly identify a well-demarcated 
Bowman’s layer immediately below the epithelium in all of 
the rabbit corneas examined. Supporting the results of our 
study, Hayashi et al. 2002, described the existence of a Bow-
man’s layer of 3 µm thickness in the rabbit cornea (Hayashi 
et al. 2002). Another study stated that the Bowman’s layer 
Fig. 3  Mean interfibrillar distance and minimum fibrillar diameter of 
normal healthy porcine, rabbit and human corneas
Fig. 4  Comparison of mean values of collagen fibrillar distance and interlamellar distance of porcine and rabbit with the human corneal collagen 
fibrils (95% confidence interval)
246
292 S. K. Subasinghe et al.
1 3
is absent in adult rabbits while it can be present in early 
developmental stages of the rabbit cornea (Wilson and Hong 
2000). This supports the results of our study because all our 
corneal samples were obtained from young rabbits. Descem-
et’s membrane was present in all three species (Fig. 2). How-
ever, in our study, some of the rabbit corneas had heavily 
stained thick Descemet’s membrane, which may be a char-
acteristic feature of an ageing cornea as suggested by Davis 
et al. (1929), who mentioned that in rabbits the Descemet’s 
membrane become thicker in older animals (Davis 1929) 
which contradicts our results.
In conclusion, when comparing the collagen fibrillar 
diameter and interfibrillar distance of porcine and rabbit 
corneas with the human, it is evident that both of these ani-
mal corneas are not structurally identical to that of humans. 
However, both of these animal models have corneas suf-
ficiently similar to the human cornea to be considered 
as research models. When both porcine and rabbits were 
compared with each other, they have similar collagen fibril-
lar diameter and interfibrillar distance measurements. In 
general, both animals have a significantly smaller collagen 
fibrillar diameters and interfibrillar distances compared to 
human.
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Introduction: Corneal crosslinking (CXL) has revolutionized the treatment of
keratoconus during the past decade. In the present study, the morphological changes
in the corneal collagen fibrils (CFs) following crosslinking treatment are described.
Materials and Methods: Ten pairs of porcine and rabbit corneas were retrieved. In
each pair, one cornea was the control and the other underwent CXL treatment. The
central corneal thickness (CCT) was measured before and after CXL treatment. Each
treated and control cornea was examined with light microscopy and by transmission
electron microscopy.
Results: (a) The mean CCT was significantly reduced following treatment. (b) CFs were
more closely packed in the anterior region and loosely packed in the posterior region.
(c) CF diameter increased significantly in the anterior and intermediate regions but
declined gradually towards the deeper regions. (d) There was a statistically significant
decrease in the interfibrillar distance over the different regions of the cornea, except for
the posterior region in porcine corneas, where there was no change. (e) The distance
between adjacent collagen lamellae was significantly decreased in all regions of treated
rabbit corneas. There was no change in porcine corneas.
Conclusion: CXL treatment resulted in increased the CF diameter and decreased
interfibrillar distance in the anterior and intermediate regions, while its effects on the
posterior region differed among species. The effect on interlamellar distance was
more prominent in the rabbit model than the porcine model. CXL treatment stiffened
the corneas by increasing CF diameter and decreasing interfibrillar distance in both
rabbit and pig corneas.
K E YWORD S
corneal collagen fibril diameter, cross-linking, keratoconus, porcine corneas, rabbit corneas
1 | INTRODUCTION
Keratoconus (KC) is one of a wide range of diseases called corneal
ectasia that lead to spontaneous, noninflammatory, self-limiting
ectasia of the cornea, resulting in localized thinning with protrusion of
the thinned cornea. This causes myopia and irregular astigmatism,
which can necessitate the use of ridged contact lenses or even a
corneal transplant. KC is one of the most common conditions in which
corneal transplant is indicated. It is caused by a complex interplay of
environmental, genetic, biomechanical and biochemical disorders.
However, the way in which each of these factors influences the devel-
opment of this disease is unclear (Barbara et al., 2019; Romero-
Jiménez, Santodomingo-Rubido, & Wolffsohn, 2010). The incidence
of KC varies greatly among all ethnic groups, most estimates ranging
Received: 14 December 2020 Revised: 11 January 2021 Accepted: 5 February 2021
DOI: 10.1002/ca.23728
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between 50 and 230 per 100,000 population (approximately one per
2,000) (Rabinowitz, 1998). The high prevalence of keratoconus in
New Zealand has been known for more than 30 years (Patel &
McGhee, 2013; Sabiston, 1978).
During recent years, corneal crosslinking (CXL) treatment with
ultraviolet (UVA) radiation and riboflavin has been introduced as a
minimally invasive option to arrest the progression of KC. It has revo-
lutionized treatment of the disease (Jouve et al., 2017). Given its sim-
plicity and low cost, it is an easily affordable treatment option in
developing countries. A global poll of clinicians who treat keratoconus
showed that 83.3% are performing CXL; those who are not, owing to
nonavailability of facilities, are willing to use this technique once it
becomes available (Gomes et al., 2015).
Several animal models including rabbits have been used to study
the morphological alterations of the cornea following CXL treatment
(Mencucci et al., 2010; Wollensak, Iomdina, Dittert, & Herbst, 2007;
Wollensak, Spoerl, Wilsch, & Seiler, 2004). However, no study to date
has investigated the morphological alterations of collagen fibers
(CF) in porcine corneas, despite their anatomical similarity to those of
humans. The present study focuses on investigating and comparing
the morphological alterations in CFs in both porcine and rabbit cor-
neas following Conventional Dresden Crosslinking (C-CXL).
2 | MATERIALS AND METHODS
2.1 | Animals
The study was conducted on 10 pairs of porcine eyes obtained from
the abattoir and 10 pairs of New Zealand White rabbit corneas
obtained from the University of Otago, Christchurch, New Zealand
(ethical approval was obtained from the Animal Research Ethics Com-
mittee of the University of Otago, Animal ethics approval number:
AEC 8/15D/601, Application number: CG4/17). The corneas were
retrieved within 2 hr postmortem. In each pair, one cornea was used
as a control with only epithelial debridement, while the other under-
went epithelial debridement followed by CXL treatment.
2.2 | Retrieval of porcine and rabbit corneas
All of the following procedures were carried out under aseptic condi-
tions. Prior to excision, the corneas were prepared as described by
Armitage and Easty (1997). The corneas were excised by cutting with
curved iris scissors, 2–3 mm outside the corneoscleral junction. They
were stored in the culture medium used for human corneal preservation,
approved by the European Eye Bank Association (Armitage, 2011).
2.3 | Crosslinking treatment
Following epithelial debridement, the central corneal thickness (CCT)
was measured both before and after CXL treatment using a Digital
Vernier Caliper. The standard conventional crosslinking treatment
(C_CXL) protocol (Wollensak, Spoerl, & Seiler, 2003a) was used on the
cornea. As photosensitizer, 0.1% riboflavin solution (10 mg riboflavin-
5-phosphate in 10 ml 20% dextran T-500 in phosphate buffered
saline) was applied for 30 min before irradiation to allow the riboflavin
to permeate through the cornea. Throughout this time, riboflavin was
instilled dropwise every 1 min. Finally, the cornea was irradiated by
UVA at 3 mW/cm2 for 30 min. The riboflavin solution was instilled
every 5 min during the irradiation.
2.4 | Histology
The corneal buttons were bisected after the CXL treatment. The con-
trol corneas were bisected soon after epithelial debridement, and one
half was fixed in 10% neutral buffered formalin, processed, and
embedded in paraffin for histological examination. The blocks were
cut in 4 μm thick sections and stained with hematoxylin–eosin (H&E)
and with Mason Trichrome (MT) staining. The stained sections were
examined under a light microscope to visualize the morphological fea-
tures of the CFs.
2.5 | Transmission electron microscopy
The remaining half of the cornea (for both treated and control cor-
neas) was processed for transmission electron microscopy (TEM) using
a CM100 BioTWIN Philips Transmission Electron Microscope. Two
sections from each specimen were examined. They were imaged as
anterior/superficial region (anterior 242 μm thickness), intermediate
region (next 107 μm thickness), and posterior/deep region (remaining
corneal thickness). From each region, two areas were chosen at ran-
dom for detailed ultrastructural analysis. The minimum diameter of
each fiber was measured using iTEM AnalySIS image processing soft-
ware, evading measurement errors caused by any obliqueness in fibril
cross-sections (Figure 1). The interfibrillar distances were measured
using Fiji-ImageJ software. The distance between two pairs of ran-
domly chosen parallel lamellae from the anterior, intermediate, and
posterior regions was measured and averaged to obtain the inter-
lamellar distance.
2.6 | Data analysis
The mean values from the treatment and control samples were compared
using a standard Student t test. The percentage differences between
treated and control specimens were computed for anterior, intermediate,
and posterior regions of the cornea. The mean percentage differences
were then compared between those three regions using one-way
ANOVA. This precluded any errors that could be caused by swelling of
the cornea. The mean percentage differences in measurements related to
crosslinking treatment were also compared within regions with 95% con-
fidence intervals. p < .05 was considered significant.
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3 | RESULTS
3.1 | Corneal thickness
Following CXL treatment there was a statistically significant decrease
in the CCT for both rabbit (p = .0001) and porcine (p = .00059) cor-
neas. In the porcine corneas, mean CCT was 0.86 ± 0.08 mm follow-
ing treatment and 1.07 ± 0.13 mm prior to CXL treatment; in rabbits
the values were 0.37 ± 0.04 mm and 0.48 ± 0.05 mm, respectively.
3.2 | Histology
H&E and MT staining allowed the general arrangement of corneal CF
morphology to be visualized in both porcine and rabbit specimens.
The distribution of CFs within the corneal stroma was visualized
clearly in samples stained with MT. CFs were more closely packed in
the anterior region and more loosely packed in the posterior region,
where the fiber distribution was similar to that of control corneas. No
pathological changes were observable with standard light microscopy
in any section, including the control samples. No demarcation line was
evident (the demarcation line has been used as an indicator of
crosslinking depth following CXL treatment). Keratocytes were dis-
tributed throughout in control corneas with patchy areas of kerato-
cyte loss in some parts of the treated corneas. There was no evidence
of foreign materials such as riboflavin crystals embedded within the
corneal stroma (Figure 2).
3.3 | Transmission electron microscopy
3.3.1 | Collagen fibril (CF) diameter
The mean CF diameter was increased in all regions of both porcine
and rabbit corneas (Table 1). In both animal models, there were statis-
tically significant increases in corneal CF diameter following CXL
treatment in the anterior and intermediate regions of the cornea. The
posterior region showed no change in either species (Table 1). When
the percentage difference in CF diameter increment was compared
between the different regions using one-way ANOVA, statistically sig-
nificant regional differences were found in both porcine (p = .0024)
and rabbit (p = .0001) corneas (Figure 3). When the mean percentage
differences between different regions were analyzed with 95% confi-
dence intervals (Figure 3), the anterior region differed significantly
from the posterior region in porcine cornea. The intermediate region
did not differ significantly from either the anterior or the posterior
region. In contrast, rabbit cornea showed significant differences
among all three regions (Figure 3).
3.3.2 | Interfibrillar distance
The mean interfibrillar distance between CFs decreased in the anterior
and intermediate regions following treatment of the corneas in both ani-
mal models (Table 1). A t test showed that interfibrillar distance was sig-
nificantly lower in the anterior and intermediate regions of porcine and
rabbit corneas after CXL treatment. The posterior region showed no
change in the porcine cornea (p = .057) but a significant decrease in the
rabbit (p = .020) (Table 1). There were statistically significant percentage
differences between the different regions in both porcine (p = .001) and
rabbit (p = .019) corneas (Figure 4). When these changes were compared
among regions with 95% confidence intervals, all three regions of the
porcine cornea (anterior, intermediate and posterior) differed significantly
while only the anterior and posterior regions differed significantly in rab-
bit cornea. Anterior-intermediate and intermediate-posterior differences
were not significant in the rabbit (Figure 4). In both species, the decrease
in interfibrillar distance was more prominent in the anterior region; the
effects were less in deeper regions.
F IGURE 1 Measurement of minimum diameter of collagen fibrils.
(a) Cornea with different regions of the corneal stroma. a—anterior
region (anterior 242 μm thickness of the cornea), b—intermediate region
(the next 107 μm thickness), and c—posterior region (the remaining
posterior corneal thickness). (b) Original TEM image of collagen fibril
cross-sections. (c) The obliqueness of the cross-sections can be seen
depending on how the sections have been made (II), while if a section is
made along plane I, it is most likely to fewer oblique sections
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3.3.3 | The distance between adjacent collagen
lamellae (interlamellar distance)
The interlamellar distance did not differ significantly between treated
and control specimens in any of the three regions in porcine corneas
(p = .102 by one-way ANOVA) (Table 1). In contrast, the difference
was significant in all three regions in rabbit corneas (p = .0001 by one-
way ANOVA) (Table 1).
4 | DISCUSSION
Crosslinking by UVA and riboflavin has revolutionized the treatment
of keratoconus in recent years. Although this is a popular treatment
option for keratoconus, few studies have investigated changes in the
cornea following CXL treatment. Rabbit and human eye models have
been used to study morphological alterations in the cornea following
crosslinking (Akhtar, Almubrad, Paladini, & Mencucci, 2013; Mencucci
F IGURE 2 Light microscopy images of corneal stroma pre- and post-CXL treatment. (a) Porcine corneal stroma before CXL treatment (H&E
staining). (b) Porcine corneal stroma after CXL treatment (H&E staining). (c,d) magnified image of the anterior region of the porcine cornea
showing the distribution of keratocytes within the corneal stroma. When compared to the control (c), the treated corneas (d) showed tightly
packed collagen fibrils (MT staining). (e) Rabbit corneal stroma before CXL treatment (H&E Staining). (f) Rabbit corneal stroma after CXL
treatment (H&E staining) [Color figure can be viewed at wileyonlinelibrary.com]
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et al., 2010; Wollensak, Wilsch, Spoerl, & Seiler, 2004). In the present
study, we found similar effects on porcine and rabbit corneas follow-
ing conventional CXL treatment.
An increase in CF diameter in the corneal stroma has been
described in aging corneas (Bailey, 1987) and corneas of diabetes
mellitus patients (Wollensak, Wilsch, et al., 2004). During the
crosslinking process, photosensitized reactions of riboflavin to UVA
radiation generate an excitatory triplet state followed by the forma-
tion of free radicals. It is believed that these free radicals form the
crosslinks between CFs, thereby increasing CF diameter and stiffening
the cornea (Wollensak, Wilsch, et al., 2004). In some studies, CXL
treatment led to a 70–300% increase in the biomechanical strength of
the cornea (Wollensak & Spoerl, 2004; Wollensak, Spoerl, &
Seiler, 2003b). Supporting the above finding, Silver, Christiansen,
Snowhill, and Chen (2000) reported that the mechanical properties of
CFs are more dependent on their diameter than their length (Silver
et al., 2000). According to our study, CXL treatment increases the CF
diameter, the change being significant in the anterior and intermediate
regions of both rabbit and porcine corneas; no change was apparent
in the posterior region. There were significant increases in CF diame-
ter within different regions of the treated corneas in both animal
models. The crosslinking effect was more pronounced in the anterior
region of the cornea, gradually declining towards the deeper regions.
This decline can be explained by a gradual diminution of UVA irradia-
tion owing to absorption of the UVA by the riboflavin in the anterior
region of the cornea. Similar findings have been reported in human
(Mencucci et al., 2010; Wollensak, 2006; Wollensak et al., 2003a) and
rabbit (Wollensak, Wilsch, et al., 2004) models.
The arrangement of CFs and their interactions with the proteo-
glycans within the corneal stroma are important for maintaining
TABLE 1 Collagen fibril diameter, interfibrillar distance and interlamellar distance before and after CXL treatment
Porcine (n = 10) Rabbit (n = 10)
Before CXL (control) After CXL p values Before CXL (control) After CXL p values
Collagen fibril diameter (nm)
Anterior 31.17 ± 1.65 35.29 ± 2.50 .0001 29.68 ± 2.36 34.83 ± 2.24 .0001
Intermediate 31.75 ± 1.51 33.59 ± 2.48 .006 31.67 ± 1.85 33.56 ± 1.41 .027
Posterior 32.87 ± 0.88 33.58 ± 2.48 .36 33.67 ± 1.97 34.33 ± 1.99 .119
Interfibrillar distance (nm)
Anterior 64.20 ± 2.95 59.84 ± 3.30 .017 56.88 ± 3.65 47.70 ± 3.30 .0001
Intermediate 62.53 ± 2.71 59.89 ± 1.61 .013 55.54 ± 3.41 49.52 ± 2.04 .002
Posterior 53.33 ± 2.24 55.28 ± 2.04 .057 52.87 ± 2.7 50.94 ± 2.64 .020
Interlamellar distance (nm)
Anterior 1,600.25 ± 1,134.68 2,038.81 ± 1,213.83 .516 4,391.15 ± 2,128.07 2,969.56 ± 1,529.38 .001
Intermediate 2,210.03 ± 1,414.04 2,146.56 ± 1739.94 .557 7,406.34 ± 4,277.30 3,045.00 ± 1,580.08 .0028
Posterior 2,134.18 ± 904.04 1,967.63 ± 800.38 .288 4,314.68 ± 1,338.49 3,559.19 ± 988.80 .01
F IGURE 3 Percentage
differences in corneal collagen
fibrillar diameter within different
regions of the cornea (a) and their
correlations in different regions of
the corneal stroma (95% confidence
interval) (b) [Color figure can be
viewed at wileyonlinelibrary.com]
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corneal transparency (Freegard, 1997). The stromal collagen fibrils lie
parallel to each other in layers (collagen lamellae) organized in an
ordered lattice-like configuration (Hart & Farrell, 1969;
Maurice, 1957). It is believed that proteoglycans function as inter-
fibrillar spacers by attaching their core proteins to the CFs and for-
ming a hydrophilic coating around them (Scott, 1992). CXL treatment
leads to the formation of crosslinks within or between collagen mole-
cules, between CF surfaces, or between the CFs and the
proteoglycan-rich matrix. There is no evidence of crosslinks between
the collagen lamellae (Hayes et al., 2013; Wollensak, Aurich,
Wirbelauer, & Sel, 2010). An X-ray scattering study by Hayes
et al. (2013) compared the interfibrillar distances between standard
CXL treatment and CXL treatment using hypo-osmolar riboflavin. The
interfibrillar distance decreased in corneas treated by the standard
method and increased in those treated by the hypo-osmolar method.
The authors attributed these changes to the hydration properties of
the cornea (Hayes et al., 2013). In contrast, Akhtar et al. (2013) found
using standard CXL treatment that interfibrillar spacing in CXL-treated
keratoconic corneas was higher than in untreated ones, showing that
CXL treatment leads to an increase in interfibrillar distance (Akhtar
et al., 2013). However, the authors stated that this increase could be
due to postoperative edema. Also, that study was conducted using
only three corneas, limiting the generalizability of the results. The pre-
sent study supports the findings of Hayes et al. (2013). We found sig-
nificant differences between treatment and control groups in
interfibrillar distances in the anterior and intermediate regions of both
porcine and rabbit corneas. This was also evident in histology, which
showed CFs more closely packed in the anterior region but becoming
loosely packed in the posterior region, where the fiber distribution
was similar to control corneas. However, the two species differed in
the changes in interlamellar distance: in contrast to the porcine speci-
mens, rabbit corneas showed significant decreases following
crosslinking in the intermediate and posterior regions rather than the
anterior region. The difference could be attributed to an absence of
crosslinking between the lamellae as described in previous literature
(Hayes et al., 2013; Wollensak et al., 2010). However, this needs to be
examined further in the future.
CXL treatment has a thinning effect, which starts at the com-
mencement of the procedure and continues until one to three months
afterward its completion (Greenstein, Shah, Fry, & Hersh, 2011;
Khaled et al., 2017; Kymionis et al., 2009). In some cases, this thinning
effect was significant enough to result in endothelial injury (Pang,
Peng, Fan, Jia, & Wu, 2016). The present study supports these find-
ings and demonstrates a statistically significant thinning effect follow-
ing CXL treatment in both porcine and rabbit corneas. According to
our study, although porcine corneas showed a statistically significant
change in interfibrillar distance in many regions of the cornea follow-
ing CXL treatment, there was no significant change in interlamellar
distance. Nevertheless, porcine corneas showed a statistically signifi-
cant thinning effect following CXL treatment. Therefore, it can be
assumed that the decrease in CCT and increased corneal strength fol-
lowing crosslinking treatment result mainly from a decrease in inter-
fibrillar distance, while interlamellar distance could make a minor
contribution.
As mentioned earlier, the depth of the corneal tissue is relevant
to the effect of CXL treatment. Porcine corneas are considered to be
thicker than human and rabbit corneas. Therefore, when we took
measurements in the posterior region, we considered the areas
F IGURE 4 Percentage differences in interfibrillar distance in different regions of the cornea (a) and their correlations in different regions of
the corneal stroma (95% confidence interval) (b) [Color figure can be viewed at wileyonlinelibrary.com]
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immediately next to the intermediate region (deeper by 107 μm thick-
ness). This allowed us to interpret the results from CXL treatment of
both porcine and rabbit corneas consistently.
In the present study, rather than comparing absolute values, we
compared the percentage differences between different regions of
the cornea (anterior, intermediate, and posterior). This enabled us to
mitigate errors arising from the increased hydration of corneas stored
in culture media. It was evident from this study that standard
crosslinking treatment has a significant effect on CF diameter and
interfibrillar distance with a smaller effect on the interlamellar dis-
tance in a cornea. The changes in the interlamellar distance were evi-
dent only in rabbit corneas. None of the previously published studies
considered the percentage difference when they compared these
parameters.
5 | CONCLUSION
We found that crosslinking treatment had a significant effect on CF
diameter and interfibrillar distance in both porcine and rabbit corneal
stroma. The CCT was also reduced. In both animal models, CXL treat-
ment increased the CF diameter and decreased interfibrillar distance
in the anterior and intermediate regions; its effects on the posterior
region differed between the species. The crosslinking significantly
decreased the interlamellar distance only in the corneal stroma, the
intermediate and posterior regions being more affected than the ante-
rior region, which was a paradoxical finding in our study.
In conclusion, CXL treatment seems to stiffen corneas by increas-
ing CF diameter and decreasing interfibrillar distance in both rabbit
and porcine models. As this study compared percentage differences
between treated and control samples, rather than absolute values, we
were able to mitigate errors arising from increased hydration of the
cornea, which most other studies have overlooked.
CONFLICT OF INTEREST
All authors certify that they have no conflict of interest. We affirm
that this manuscript has been read and approved by all the authors
and the requirements for authorship have been met by all the authors.
Each author believes that the manuscript represents honest work.
ORCID
Sandeepani K. Subasinghe https://orcid.org/0000-0002-0064-0476
REFERENCES
Akhtar, S., Almubrad, T., Paladini, I., & Mencucci, R. (2013). Keratoconus
corneal architecture after riboflavin/ultraviolet a cross-linking: Ultra-
structural studies. Molecular Vision, 19, 1526–1537.
Armitage, W. J. (2011). Preservation of human cornea. Transfusion Medi-
cine and Hemotherapy, 38(2), 143–147.
Armitage, W. J., & Easty, D. L. (1997). Factors influencing the suitability of
organ-cultured corneas for transplantation. Investigative Ophthalmol-
ogy and Visual Science, 38(1), 16–24.
Bailey, A. J. (1987). Structure, function and ageing of the collagens of the
eye. Eye, 1(2), 175–183.
Barbara, R., Turnbull, A. M. J., Malem, A., Anderson, D. F., Hossain, P.,
Konstantopoulos, A., & Barbara, A. (2019). Epidemiology of
keratoconus. In Controversies in the management of keratoconus
(pp. 1–16). Cham: Springer.
Freegard, T. J. (1997). The physical basis of transparency of the normal
cornea. Eye, 11(4), 465–471.
Gomes, P. J. A., Tan, J. D., Rapuano, W. C., Belin, L. M., Ambrósio, S. R.,
Guell, S. J., … Sangwan, S. V. (2015). Global consensus on keratoconus
and ectatic diseases. Cornea, 34(4), 359–369.
Greenstein, S. A., Shah, V. P., Fry, K. L., & Hersh, P. S. (2011). Corneal
thickness changes after corneal collagen crosslinking for keratoconus
and corneal ectasia: One-year results. Journal of Cataract and Refrac-
tive Surgery, 37(4), 691–700.
Hart, R. W., & Farrell, R. A. (1969). Light scattering in the cornea. Journal of
the Optical Society of America, 59(6), 766–774.
Hayes, S., Kamma-Lorger, C. S., Boote, C., Young, R. D., Quantock, A. J.,
Rost, A., … Terrill, N. (2013). The effect of riboflavin/UVA collagen
cross-linking therapy on the structure and hydrodynamic behaviour of
the ungulate and rabbit corneal stroma. PLoS One, 8(1), e52860.
Jouve, L., Borderie, V., Sandali, O., Temstet, C., Basli, E., Laroche, L., &
Bouheraoua, N. (2017). Conventional and iontophoresis corneal cross-
linking for keratoconus: Efficacy and assessment by optical coherence
tomography and confocal microscopy. Cornea, 36(2), 153–162.
Khaled, M. L., Helwa, I., Drewry, M., Seremwe, M., Estes, A., & Liu, Y.
(2017). Molecular and histopathological changes associated with
keratoconus. BioMed Research International, 2017, 7803029.
Kymionis, G. D., Diakonis, V. F., Kalyvianaki, M., Portaliou, D., Siganos, C.,
Kozobolis, V. P., & Pallikaris, A. I. (2009). One-year follow-up of cor-
neal confocal microscopy after corneal cross-linking in patients with
post laser in situ keratosmileusis ectasia and keratoconus. American
Journal of Ophthalmology, 147(5), 774–778.
Maurice, D. M. (1957). The structure and transparency of the cornea. The
Journal of Physiology, 136(2), 263–286.
Mencucci, R., Marini, M., Paladini, I., Sarchielli, E., Sgambati, E.,
Menchini, U., & Vannelli, G. B. (2010). Effects of riboflavin/UVA cor-
neal cross-linking on keratocytes and collagen fibres in human cornea.
Clinical and Experimental Ophthalmology, 38(1), 49–56.
Pang, X., Peng, X., Fan, Z., Jia, H., & Wu, T. (2016). Comparison of central
corneal thickness using ultrasound pachymetry during corneal collagen
cross-linking. 眼科学报, 28(1), 15–19.
Patel, D., & McGhee, C. (2013). Understanding keratoconus: What have
we learned from the New Zealand perspective? Clinical and Experimen-
tal Optometry, 96(2), 183–187.
Rabinowitz, Y. S. (1998). Keratoconus. Survey of Ophthalmology, 42(4),
297–319.
Romero-Jiménez, M., Santodomingo-Rubido, J., & Wolffsohn, J. S. (2010).
Keratoconus: A review. Contact Lens and Anterior Eye, 33(4), 157–166.
Sabiston, D. W. (1978). The crazy cone. Australian and New Zealand Journal
of Ophthalmology, 6(1), 43–45.
Scott, J. E. (1992). Morphometry of cupromeronic blue-stained proteogly-
can molecules in animal corneas, versus that of purified proteoglycans
stained in vitro, implies that tertiary structures contribute to corneal
ultrastructure. Journal of Anatomy, 180, 155–164.
Silver, F. H., Christiansen, D. L., Snowhill, P. B., & Chen, Y. (2000). Role of
storage on changes in the mechanical properties of tendon and self-
assembled collagen fibers. Connective Tissue Research, 41(2), 155–164.
Wollensak, G. (2006). Crosslinking treatment of progressive keratoconus:
New hope. Current Opinion in Ophthalmology, 17(4), 356–360.
Wollensak, G., Aurich, H., Wirbelauer, C., & Sel, S. (2010). Significance of
the riboflavin film in corneal collagen crosslinking. Journal of Cataract
and Refractive Surgery, 36(1), 114–120.
Wollensak, G., Iomdina, E., Dittert, D.-D., & Herbst, H. (2007). Wound
healing in the rabbit cornea after corneal collagen cross-linking with
riboflavin and UVA. Cornea, 26(5), 600–605.
SUBASINGHE ET AL. 7
254
Wollensak, G., & Spoerl, E. (2004). Collagen crosslinking of human and por-
cine sclera. Journal of Cataract and Refractive Surgery, 30(3), 689–695.
Wollensak, G., Spoerl, E., & Seiler, T. (2003a). Riboflavin/ultraviolet-A-
induced collagen crosslinking for the treatment of keratoconus. Ameri-
can Journal of Ophthalmology, 135(5), 620–627.
Wollensak, G., Spoerl, E., & Seiler, T. (2003b). Stress-strain measurements
of human and porcine corneas after riboflavin–ultraviolet-A-induced
cross-linking. Journal of Cataract and Refractive Surgery, 29(9),
1780–1785.
Wollensak, G., Spoerl, E., Wilsch, M., & Seiler, T. (2004). Keratocyte apo-
ptosis after corneal collagen cross-linking using riboflavin/UVA treat-
ment. Cornea, 23(1), 43–49.
Wollensak, G., Wilsch, M., Spoerl, E., & Seiler, T. (2004). Collagen fiber
diameter in the rabbit cornea after collagen crosslinking by
riboflavin/UVA. Cornea, 23(5), 503–507.
How to cite this article: Subasinghe SK, Ogbuehi KC,
Mitchell L, Dias GJ. Morphological alterations of the cornea
following crosslinking treatment (CXL). Clinical Anatomy. 2021;
1–8. https://doi.org/10.1002/ca.23728
8 SUBASINGHE ET AL.
255
Ethical review of research projects using cadaveric material 
4.Report to the University of Otago Human Ethics Committee (Health)
Anatomy Body Ethics Review Committee 
Report to the University of Otago Human Ethics Committee (Health) 
Date 26 February 2018 
Research Title "Biological characterisation of the wound repair and collagen fibre alterations 
in cornea following collagen cross-linking (CXL) by Riboflavin/ Ultraviolet-A (UVA) in vitro"
Co-coordinating Investigator 
George Dias 
Kelechi C. Ogbuehi 
Sandeepani Kanchana Subasinghe 
REVIEW GUIDELINE PROMPTS COMMENTS 
GUIDELINE 
Department of • Confirmation that only cadaveric Can be confirmed 
Anatomy material obtained under the
bequest Department of Anatomy's
bequest of bodies conditions and
restrictions are being used for this
study
Relative merit • Important, worthwhile and This request forms part of an important research question 
of the justifiable - addresses a on extracellular matrix distribution at human cornea with 
research significant question focus and emphasis on keratoconus. 
• Methods are likely to produce
valid results
Human • Complies with the Human Yes 
Tissues Act Tissues Act
. 
Consistent with the original Bequest • Yes 
consent of the bequest 
Student • Confirmation of appropriate level Yes 
projects of supervision if the material is
being used for a student project
Priority for • Will the material also be used for Not according to the application ' 
use another research project?
The Anatomy Body Ethics Review Committee recommends to the Department of Anatomy 
Body Committee the approval of this human cadaver research proposal 








fL _g g:;��,� 
CHRISTCHURCH 
University of Otago, Christchurch 
Animal Ethics Committee 
4 July 2017 
Associate Professor George Dias 
Department of Anatomy 
University of Otago, Christchurch 
Dear Associate Professor Dias, 
APPLICATION NO: CG4/17 
Thank you for your Form G Tissue Retrieval request received by this office on 12 June 2017. 
The Animal Ethics Committee has given its full approval, for you to use tissue as per Dr Scott Loeffler's 
protocol C8/15 "Polyclonal Antibody Production in Sheep and Rabbits". 
The approval is for the use of rabbit heads to study corneal topographic curvature and thickness. 
Thank you for your compliance with the policies of the Animal Ethics Committee. 
Yours sincerely 
Jacqui Birchall 
Secretary, On behalf of the Animal Ethics Committee 
University of Otago, Christchurch 
CC Animal Welfare Office, Dunedin 
Veterinary Head, CARA 
Research and Development Christchurch 
University of Otago, Christchurch 
PO Box 4345, Christchurch 8140. New Zealand 
Tel +64 3 364 0237 • Email research.uoc@ocago.ac.nz 




Staining protocol for Haematoxylin-Eosin (H&E) staining 
Solution preparation 
Eosin solution (ready to use Leica Biosystems Eosin) 
Gill II Haematoxylin (ready to use Leica Biosystems Surgipath Gill II 
Haematoxylin 
Scott’s tap water; 
Potassium bicarbonate 2g 
Magnesium sulphate 20g 
Distilled water 1000ml 
Method 
1. Dewax slides to water
2. Stain in Gill II haematoxylin for 4 minutes
3. Wash in Scott’s tap water for 2 minutes
4. Place in Scott’s tap water for 2 minutes
5. Stain in eosin for 30 seconds
8. Dehydrate in different concentrations of alcohol
9. Place the slides in the 100% Xylene
10. Coverslip the histological section and air dry it before examining through the
light microscopy.
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Staining protocol for  Masson Trichrome (MT) staining 
Solution preparation 
Acetic acid 1% 
Glacial acetic acid 10ml 
Distilled water 1000ml 
Acid fuchsin 0.5% 
Acid fuchsin  0.5g 
Glacial acetic acid 0.5ml 
Distilled water 100ml 
Methyl Blue 
Methyl blue  2g 
Glacial acetic acid 2.5ml 
Distilled water 100ml 
Phosphomolybdic acid 1% 
Phosphomolybdic acid 10g 
Distilled water 1000ml 
Method 
1. Dewax slides to water
2. Stain in celestine blue for 5 minutes
3. Rinse in distilled water for 30 seconds
4. Stain in Gill II haematoxylin for 4 minutes
5. Wash in running tap water for 2 minutes
6. Place in Scott’s tap water for 2 minutes
7. Wash in running tap water
8. Stain in 0.5% acid fuchsin for 5 minutes
9. Rinse slides in distilled water until most of the colour is out
10. Place in 1% phosphomolybdic acid for 4 minutes
11.Drain slides
12. Stain in 2% methyl blue for 3.5 minutes
13. Rinse slides in distilled water until most of the colour is out
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14. Place in 1% acetic acid for 2 minutes
15. Place in 100% alcohol for 30 seconds
16. Dehydrate rapidly with different concentrations of ethanol
17. Place the slides in the 100% Xylene




Processing and TEM sample preparation 
Preparation of Primary fixative 
Fixative is 4% paraformaldehyde + 2.0% glutaraldehyde in 0.15M Cacodylate 
buffer with 2mM CaCl2 
Buffer stock solution – 0.3M Cacodylate buffer, pH 7.4; 
To make 500ml, 
1. Weigh out 32.1g sodium cacodylate powder (trihydrate)
2. Dissolve in 450ml of distilled water. Use a 500ml beaker or flask.
3. Place the buffer on the stirrer and set up the pH electrode to measure.
4. Slowly add 1N HCL while stirring and measuring until the pH is 7.4 (this will
take approximately 7ml) 
5. Make up to 500ml with distilled water
6. Check the osmolality.  It should be in the range 600 - 610 mosmol/kg.
(The actual values were 605, 618, 614)
Note: The pH is around 8.16 before the 1N HCL is added. 
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To make up the fixative - 4% paraformaldehyde + 2.0% 
glutaraldehyde in 0.15M Cacodylate buffer with 2mM CaCl2) 
• Solution One, 8% paraformaldehyde, to make up 200ml;
1. 16mg Paraformaldehyde
2. Dissolve in 160ml distilled water heating to 60oC
3. When at 60oC start adding 1-10 drops of 1 M NaOH (4 drops at a time) till clear
(while stirring) 
4. Make up to 200mls with distilled water and allow to cool.
5. Filter if necessary to remove flocculence, use wet strength filter paper.
• Solution Two, 4.0% glutaraldehyde in 0.3M Cacodylate buffer,  to make up
200mls.
1. Measure out 32mls of 25% glutaraldehyde stock solution
2. Make up to 200mls with 0.3M Cacodylate buffer pH = 7.2
Note: we are using double strength buffer as we are going to dilute this 1:1 to 
give a final concentration of 0.15M buffer) 
To make up the working strength fixative solution 
1. Mix solution one (8% paraformaldehyde) and solution two (4%
glutaraldehyde) together to give a final volume of 400ml.  
Final concentrations should be 4% Paraformaldehyde, 2% Glutaraldehyde in 
0.15M Cacodylate buffer.  
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2. Add 200mg CaC12 or 414mg CaC12.6H20
3. Record osmolality, the values were 828, 807, 795
4. Record the pH, the value was 7.38
Processing of primary fixative fixed  corneal samples 
Once the samples were fixed in the primary fixative solution, the samples were 
stored in an refrigerator at 4 ºC until the processing which was performed 
within the following week. One the day of the processing the samples were 
taken out of the refrigerator and following procedure was performed; 
1. Washed x3 with 0.15M cacodylate buffer for 10 mintues each on rotator.
2. Osmicated for 1.5hrs in 1% OsO4  + 1.5% potassium ferrocyanide in 0.1M
cacodylate buffer.
3. Washed x3 with DDH2O, 10 minutes each.
4. 1% Uranyl Acetate in DDH2O for 1 hr.
5. Washed x3 with DDH2O and left in fridge until further processing.
The samples were then further process in the following manner;
50% ethanol for 10 mins on rotator.
6. 70% ethanol for 10 mins on rotator.
7. 95% ethanol       “       “ “ 
8. 100% ethanol     “       “ “ 
9. 100% ethanol for 15 mins         “ 
10. 100% ethanol for 20 mins         “ 
11. Propylene oxide 20 mins each x2
12. 1:1 propylene oxide / resin for 2hrs.
13. Resin for 2 hrs.
14. Resin overnight.
15. Transfer the samples to fresh resin in the morning for 4 hrs.
16. Embedded in silicone moulds and polymerised for 48 hrs @ 60oC.
(Resin used was EmBed DER 736 low viscosity resin.) 
Samples were the cut on a Leica UC7 ultramicrotme using a Diatome diamond 
knife and mounted on formvar coated copper slot grids before being 
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stained with 1% uranyl acetate and 3% lead citrate using the LKB 
ultrostainer. 
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INTRODUCTION
1. BACKGROUND
TUNEL Assay Kit - HRP-DAB (ab206386) allows the recognition of 
apoptotic nuclei in paraffin-embedded tissue sections, frozen tissue 
sections, or in preparations of single cell suspensions fixed on slides. 
In this assay, Terminal deoxynucleotidyl Transferase (TdT) binds to 
exposed 3’-OH ends of DNA fragments, which are generated in 
response to apoptotic signals, and catalyzes the addition of biotin-
labeled deoxynucleotides. Biotinylated nucleotides are detected using 
a streptavidin-horseradish peroxidase (HRP) conjugate. 
Diaminobenzidine (DAB) reacts with the HRP-labeled sample to 
generate an insoluble brown substrate at the site of DNA 
fragmentation. Counterstaining with methyl green aids in the 
morphological evaluation and characterization of normal and apoptotic 
cells.
Apoptosis is the result of a cascade of molecular and biochemical 
events involving endogenous endonucleases that cleave DNA into the 
prototypical ‘ladder of DNA fragments’ that may be visualized in 
agarose gels. This apoptosis detection assay exploits the fact that, 
when the apoptotic endonucleases produce the classical DNA ladder, 
they generate free 3’-OH groups at the ends of these DNA fragments. 
These free 3’-OH groups are end-labelled by TUNEL Assay Kit - HRP-
DAB, allowing for the detection of apoptotic cells using a molecular 
biology-based end labelling technique.
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Permeabilize samples using Proteinase K 23
Inactivate endogenous peroxidases with 3% H2O2 5
Label  with TdT Enzyme 125
Block samples with Blocking Buffer 10
Incubate with Conjugate 35
Prepare and incubate with DAB Solution 20
Counterstain with Methyl Green Counterstain 1-3
Dehydrate mount with coverslip 15
Note that this assay summary represents the use of ab206386 with 
paraffin-embedded tissue sections. A modified protocol should be 
followed for end-labelling of tissue cryosections and cell preparations 
fixed on slides (see Pages 10-16 for further details). 
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3. PRECAUTIONS
Please read these instructions carefully prior to beginning the 
assay.
All kit components have been formulated and quality control tested 
to function successfully as a kit. Modifications to the kit components 
or procedures may result in loss of performance.
4. STORAGE AND STABILITY
Store kit at -20ºC in the dark immediately upon receipt. 
Refer to list of materials supplied for storage conditions of individual 
components. Observe the storage conditions for individual prepared 
components in section 5.
Aliquot components in working volumes before storing at the 
recommended temperature.
5. LIMITATIONS
 Assay kit intended for research use only. Not for use in
diagnostic procedures.
 Do not use kit or components if it has exceeded the expiration
date on the kit labels.
 Do not mix or substitute reagents or materials from other kit lots
or vendors. Kits are QC tested as a set of components and
performance cannot be guaranteed if utilized separately or
substituted.
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Proteinase K 50 µL 100 µL -20°C -20°C
TdT Equilibration Buffer 4 mL 8 mL -20°C 4°C
TdT Labeling Reaction Mix 1 x 1.3 mL 2 x 1.3 mL -20°C -20°C
TdT Enzyme 40 µL 70 µL -20°C -20°C
Stop Buffer 4 mL 8 mL -20°C -20°C
Blocking Buffer 12 mL 24 mL -20°C -20°C
25X Conjugate 150 µL 300 µL -20°C -20°C
DAB Solution 1 150 µL 300 µL -20°C -20°C
DAB Solution 2 4 mL 8 mL -20°C -20°C
Methyl Green Counterstain 1 x 3.5 mL 2 x 3.5 mL -20°C -20°C
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7. MATERIALS REQUIRED, NOT SUPPLIED
These materials are not included in the kit, but will be required to 
successfully perform this assay:
 Xylene
 Ethanol, 100, 90, 80 and 70%
 Methanol
 30% hydrogen peroxide
 Tris-buffered saline (1X TBS, 20 mM Tris pH 7.6, 140mM NaCl)
 DNase I (optional, for use in generating positive control)
 Distilled de-ionized water (dH2O)
 Coplin jars, glass or plastic with slide holders
 Humidified chamber (see Technical Hints section)
 Glass or plastic coverslips
 Mounting media (ab64230)
 Microscope
 1-20 μL, 20-200 μL, and 200-1000 μL precision pipettes
 Sterile DNase/RNase free disposable pipette tips
 Microcentrifuge tubes
 Absorbent wipes
 Cold block or ice bath
 PAP pen (ab2601)
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8. TECHNICAL HINTS
 Review the protocol completely to confirm this kit meets
your requirements. Please contact our Technical Support
staff with any questions.
 Read through the protocol before running the assay as modified
sample preparation protocols are required for suspension cell
lines, fixed cell preparations and tissue cryosections.
 Please refer to Section 11 for suitable positive and negative
controls.
 Incubation times for Proteinase K, DNase I and labeling may
need to be optimized for your cell type and slide preparation
using this protocol as a starting point.
 Keep enzymes, heat labile components and samples on ice
during the assay. The TdT Enzyme should be placed in a -20°C
storage device during use.
 Make sure all buffers and solutions are kept on ice before
starting the experiment.
 Avoid foaming or bubbles when mixing or reconstituting
components.
 Avoid cross-contamination of samples or reagents by changing
tips between sample, standard and reagent additions.
 A humidified chamber should be used where indicated to
prevent reagent loss through evaporation. To construct a simple
humidified chamber, place a moist paper towel at the bottom of a
plastic box with a lid (ensure that the paper towel is not too wet).
Either place slides carefully directly onto the moist surface or
onto a support made by placing plastic pipettes onto the moist
surface. Place lid on box.
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9. REAGENT PREPARATION
 Briefly centrifuge small vials at low speed prior to opening to avoid
reagent loss in tube caps.
9.1 Proteinase K:
Ready to use as supplied. 30 minutes prior to use, thaw 
component and keep on ice. Return to -20°C immediately 
after use. 
9.2 TdT Equilibration Buffer:
Ready to use as supplied. 30 minutes prior to use, thaw 
component and keep on ice. Return to -20°C immediately 
after use. 
9.3 TdT Labelling Reaction Mix:
Ready to use as supplied. 30 minutes prior to use, thaw 
component and keep on ice. Special care should be taken to 
keep cold. Return to -20°C immediately after use. 
9.4 TdT Enzyme:
Ready to use as supplied. Contains glycerol and will not 
freeze solid at -20°C. Do not remove from -20°C freezer until 
immediately before use. Place in a -20°C storage device for 
use, special care should be taken to keep cold. Return to -
20°C immediately after use.
9.5 Stop Buffer:
Ready to use as supplied. Thaw component 30 minutes prior 
to use. Return to -20°C after use. 
9.6 Blocking Buffer:
Ready to use as supplied. Thaw component 30 minutes prior 
to use. Return to -20°C after use.  
9.7 25X Conjugate:
Ready to use as supplied. 30 minutes prior to use, thaw 
component and keep on ice. Special care should be taken to 
keep cold. Return to -20°C immediately after use. 
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9.8 DAB Solution 1:
Ready to use as supplied. 30 minutes prior to use, thaw 
component and keep on ice. Return to-20°C immediately 
after use. 
9.9 DAB Solution 2:
Ready to use as supplied. 30 minutes prior to use, thaw 
component and keep on ice. Return to -20°C immediately 
after use. 
9.10 Methyl Green Counterstain:
Ready to use as supplied. 30 minutes prior to use, thaw 
component. Return to -20°C after use. 
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10.ASSAY PROCEDURE and DETECTION
Paraffin embedded tissue sections 
 DO NOT LET THE SPECIMEN DRY OUT DURING OR
BETWEEN ANY STEPS! If necessary, cover or immerse the
specimen in 1X TBS to keep hydrated.
10.1. Rehydration:
10.1.1 Immerse slides in xylene for 5 minutes at room 
temperature. Repeat (total two 5 minute incubations). 
Xylene should be changed frequently.
10.1.2 Immerse slides in 100% ethanol for 5 minutes at room 
temperature. Repeat (total two 5 minute incubations).
10.1.3 Immerse slides in 90% ethanol for 3 minutes at room 
temperature.
10.1.4 Immerse slides in 80% ethanol for 3 minutes at room 
temperature.
10.1.5 Immerse slides in 70% ethanol for 3 minutes at room 
temperature.
10.1.6 Rinse slides briefly with 1X TBS for 5 minutes and carefully 
dry the glass slide around the specimen.
To help contain small reaction volumes around the specimen, it may 
be helpful at this point to encircle the specimen using a waxed pen or a 
hydrophobic slide marker (PAP pen, ab2601).
10.2. Permeabilization of specimen:
10.2.1 Dilute Proteinase K 1:100 in dH2O (mix 1 μL of Proteinase 
K plus 99 μL dH2O per specimen).
10.2.2 Cover the entire specimen with 100 μL of Proteinase K 
solution prepared above and incubate at room temperature 
for 20 minutes.
10.2.3 Rinse slide with 1X TBS for 5 minutes. 
10.2.4 Gently tap off excess liquid and carefully dry the glass 
slide around the specimen using an adsorbent wipe. Care 
should be taken to not touch the specimen.
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10.3. Quenching: inactivation of endogenous peroxidases:
10.3.1 Dilute 30% H2O2 1:10 in methanol (mix 10 μL 30% H2O2 
with 90 μL methanol per specimen).
10.3.2 Cover the entire specimen with 100 µL of 3% H2O2. 
Incubate at room temperature for 5 minutes.
10.3.3 Rinse slide with 1X TBS for 5 minutes.
10.3.4 Gently tap off excess liquid and carefully dry the glass 
slide around the specimen.
10.4. Equilibration:
10.4.1 Cover the entire specimen with 100 μL of TdT Equilibration 
Buffer provided. Incubate at room temperature for 30 
minutes. During the last five minutes of this incubation 
prepare the Labeling Reaction Mixture.
10.5. Labeling Reaction:
10.5.1 Prepare the working TdT Labeling Reaction Mixture as 
follows: pulse-spin the TdT Enzyme tube in a 
microcentrifuge prior to opening. Prepare only enough TdT 
Labeling Reaction Mix for the number of samples/ slides to 
be labeled. For each sample to be labeled, add 1 μL TdT 
Enzyme to 39 μL TdT Labeling Reaction Mix in a clean 
microfuge tube, mix gently and keep on ice or a cold block 
until use.
10.5.2 Carefully blot the TdT Equilibration Buffer from the 
specimen, taking care not to touch the Specimen.
10.5.3 Immediately apply 40 μL of TdT Labeling Reaction Mix 
(prepared above) onto each specimen and cover the 
specimen with a coverslip to assure even distribution of 
the reaction mixture and prevent loss due to evaporation 
during incubation.
10.5.4 Place slides in a humidified chamber and incubate at room 
temperature (at least 22ºC) for 1.5 hours. NOTE: If room 
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10.6. Termination of labeling reaction:
10.6.1 Inspect the Stop Buffer. If a precipitate is present, warm 
the Stop Buffer to 37ºC for five minutes or until precipitate 
is no longer evident.
10.6.2 Remove coverslip* and rinse slide with 1X TBS for 5 
minutes.
Cover slip is best removed by sub-merging the slide in 
TBS solution in a Coplin jar or beaker and allowing cover 
slip to gently slide off specimen. A glass cover slip is 
recommended but a plastic cover slip may be used.
10.6.3 Cover the entire specimen with 100 μL of Stop Buffer. 
Incubate at room temperature for 5 minutes.
10.6.4 Rinse slide with 1X TBS for 5 minutes.
10.6.5 Gently tap off excess liquid and carefully dry the glass 
slide around the specimen.
10.7. Blocking
10.7.1 Cover the entire specimen with 100 μL of Blocking Buffer. 
Incubate at room temperature for 10 minutes. During the 
last 5 minutes of blocking, prepare the Conjugate solution.
10.8. Detection
10.8.1 Dilute the 25X Conjugate 1:25 in Blocking Buffer (mix 4 μL 
25X Conjugate with 96 μL Blocking Buffer per specimen). 
Prepare only enough working solution for the number of 
slides/specimens being processed. Keep on ice or a cold 
block until ready to use.
10.8.2 Carefully blot the Blocking Buffer from the specimen, 
taking care not to touch the specimen. Immediately apply 
100 μL of diluted 1X Conjugate to the specimen.
10.8.3 Place slides in a humidified chamber and incubate at room 
temperature for 30 minutes.
10.8.4 Rinse slides with 1X TBS for 5 minutes.
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10.9. Development
10.9.1 Gently tap off excess liquid and carefully dry the glass 
slide around the specimen.
10.9.2 Prepare working DAB solution by adding 4 µL DAB 
Solution 1 to 116 µl DAB Solution 2 (1:30 dilution). 
Prepare only enough working DAB solution for specimens 
to be processed. Do not store diluted DAB solution. 
Prepare fresh on each occasion.
10.9.3 Cover the entire specimen with 100 μL of DAB solution 
prepared in section 10.9.2 above. Incubate at room 
temperature for 15 minutes.
10.9.4 Rinse slides gently with dH2O.
10.10. Counterstain and Storage
10.10.1 Immediately cover the entire specimen with 100 μL of 
Methyl Green Counterstain solution provided.
10.10.2 Incubate at room temperature for 1-3 minutes.
10.10.3 Press an edge of the slide against an absorbent towel to 
draw off most of the counterstain and place in a Coplin jar 
slide holder.
10.10.4 Dip slides 2-4 times into 100% ethanol.
10.10.5 Blot slides briefly on an absorbent towel.
10.10.6 Repeat step 4 using fresh 100% ethanol. Blot slides 
briefly on an absorbent towel.
10.10.7 Dip slides 2-4 times into 100% xylene.
10.10.8 Wipe excess xylene from back of slide and around 
specimen.
10.10.9 Mount a glass coverslip using mounting media (such as 
ab64230) over the specimen.
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Tissue cryosections 
This protocol is similar to that for paraffin-embedded tissue sections 
except that a short hydration step is used instead of the 
deparaffinization step and permeabilization with Proteinase K is only 
performed for 10 minutes. Fixation of cryopreserved tissue prior to 
performing the assay is required. 
To avoid loss of tissue from glass slides during washing steps, gently 
dip the slides 2-3 times in a beaker of 1X TBS instead of rinsing with a 
wash bottle.   
 DO NOT LET THE SPECIMEN DRY OUT DURING OR
BETWEEN ANY STEPS. If necessary, cover or immerse the
specimen in 1X TBS to keep hydrated.
10.11. Tissue fixation and hydration 
10.11.1 Immerse slides in 4% formaldehyde (prepared in 1X 
PBS) for 15 minutes at room temperature.
10.11.2 Gently drain off excess liquid and carefully dry the glass 
slide around the specimen.
10.11.3 Immerse slides in 1X TBS for 15 minutes at room 
temperature.
10.11.4 Carefully dry the glass slide around the specimen*.
* To help contain small reaction volumes around the specimen, it may
be helpful at this point to encircle the specimen using a waxed pen
(PAP pen, ab2601) or a hydrophobic slide marker.
10.12. Permeabilization of specimen
10.12.1 Dilute Proteinase K 1:100 in dH2O (mix 1 μL of 
Proteinase K plus 99 μL dH2O per specimen).
10.12.2 Cover the entire specimen with 100 μL of Proteinase K 
solution prepared above and incubate at room temperature 
for exactly 10 minutes. Do not incubate for longer than 10 
minutes. 
10.12.3 Rinse slide with 1X TBS for 5 minutes.
10.12.4 Gently tap off excess liquid and carefully dry the glass 
slide around the specimen using an adsorbent wipe. Care 
should be taken to not touch the specimen. All remaining 
steps are identical to those steps outlined for paraffin-
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embedded tissue sections. Proceed from Section 10.3 
(Quenching: inactivation of endogenous peroxidases) and 
complete procedure. Care should be taken during wash 
steps to avoid losing tissue sections. Washing by gentle 
emersion is recommended.
Cell suspensions or fixed cells
Cells grown in suspension (suspension cultures etc.) can be fixed and 
attached to slides. The protocol differs from that used for paraffin-
embedded tissue sections as the deparaffinization step is replaced 
with a rehydration step and permeabilization with Proteinase K is 
performed only for 5 minutes. 
10.13. Fixing cell preparations 
10.13.1 Pelleted cells by gentle centrifugation for 5 minutes at 
4°C. Wash cells twice with cold (4°C) PBS.
10.13.2 Re-suspend cells in 4% formaldehyde (in PBS) at a cell 
density of 1x106/mL and incubate at room temperature for 
10 minutes.
10.13.3 Pellet cells by gentle centrifugation for 5 minutes at room 
temperature and re-suspended, at the same concentration, 
in 80% ethanol.
10.13.4 Store fixed cells at 4°C. Fixed cells (100-300 μL) can be 
immobilized onto glass slides by directly placing the cell 
suspension onto the slide and allowing to air dry. The use 
of a cytospin may also be used – follow manufacturer’s 
recommendation for slide preparation.
NOTE: Pre-coating slides with poly-L-lysine may enhance cell 
adherence. Store cytospun samples at -20°C.
NOTE: To avoid loss of cells from glass slides during washing 
steps, dip slides 2-3 times into a beaker of 1X TBS instead 
of rinsing with a wash bottle.
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10.14. Rehydration 
10.14.1 Immerse slides in 1X TBS for 15 minutes at room 
temperature.
10.14.2 Carefully dry the glass slide around the specimen. To 
help contain small reaction volumes around the specimen, 
it may be helpful at this point to encircle the specimen 
using a waxed pen or a hydrophobic slide marker (PAP 
pen, ab2601).
10.15. Permeabilization of specimen
10.15.1 Dilute 2 mg/ml Proteinase K 1:100 in 10 mM Tris pH 8 
(mix 1 μL of 2 mg/ml Proteinase K with 99 μL 10 mM Tris 
per specimen).
10.15.2 Cover the entire specimen with 50 -100 μL of 20 g/ml 
Proteinase K. Incubate at room temperature for exactly 5 
minutes. Do not incubate for longer than 5 minutes. 
10.15.3 Dip slide 2-3 times into a beaker of 1X TBS. 
10.15.4 Gently tap off excess liquid and carefully dry the glass 
slide around the specimen.
10.15.5  Please follow protocol for paraffin embedded sections 
from section 10.2 (Quenching: inactivation of endogenous 
peroxidases).
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11. ANALYSIS
An apoptosis end point, indicative of positive staining in the apoptosis 
detection assay, is represented by a dark brown (DAB) signal. Lighter 
shades of brown and/or shades of blue-green to green—brown 
indicate a nonreactive/negative cell. 
To generate a positive control, treat one or more slides with 1 µg/µL 
DNase I in TBS/1 mM MgSO4 for 20 minutes at room temperature 
immediately following the Proteinase K treatment step in the protocol 
booklet (perform all other steps as described). Slides of 10 µm 
thickness are preferred. The DNase I treatment will fragment DNA in 
normal cells to generate free 3’OH groups identical to those generated 
during apoptosis. 
To add a negative control, substitute the TdT Enzyme with dH2O in the 
reaction mix or keep the specimen in reaction buffer (with cover slip to 
prevent drying out) during the labeling stage.  Perform all other steps 
as described. This is a suitable control for endogenous peroxidases 
and non-specific conjugate binding or background in the assay. A non-
apoptotic control is also a useful control. A delay in fixation or routine 
mechanical manipulation may result in unwanted DNA breakage that 
could be read as apoptosis.
Since 3’-OH ends of DNA fragments, generated during apoptosis, are 
concentrated within the nuclei and apoptotic bodies, morphology as 
well as DAB staining can and should be used to interpret kit results. 
Characteristic morphological changes during apoptosis are well 
characterized and should be used as verification of programmed cell 
death. Non-apoptotic cells do not incorporate significant amounts of 
biotin labelled nucleotide since they lack free 3’-OH ends (indicative of 
apoptosis). 
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After performing the TUNEL Assay Kit - HRP-DAB detection test, 
careful evaluation of the slides should be performed using a light 
microscope. 
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12.TYPICAL DATA
Figure 1. Using paraffin fixed human tonsil tissue, 10 μm sections (1000X).
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Figure 2. Using paraffin fixed human tonsil tissue, 10 μm sections (1000X). A] 
Section processed and counter-stained with methyl green according to the 
manual. B] Counter-stain step was eliminated to more clearly illustrate the 
level of positive staining in the germinal centres of tonsil tissue. C] Section 
treated with DNase I in order to generate a positive control slide. Note all 
nuclei stain positive. The use of DNase I generates free 3’-OH groups on 
cellular DNA, these free 3’-OH groups are then labelled with biotin-nucleotide 
by the TdT in the kit. D] Negative control, the TdT Enzyme step was 
eliminated thereby generating a negative slide.
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13.QUICK ASSAY PROCEDURE
NOTE: This procedure, which starts at the permeabilization step for
paraffin-embedded tissue sections, is provided as a quick reference
for experienced users. Follow the detailed procedure when
performing the assay for the first time. This procedure should be
modified for frozen sections and fixed cells.
 Cover specimen with 100 µL Proteinase K solution for 20 minutes.
 Rinse with TBS for 5 minutes.
 Cover specimen with 100 µL of 3% H202 for 5 minutes.
 Rinse with TBS for 5 minutes.
 Cover specimen with 100 µL TdT Equilibration buffer for 30
minutes.
 Add 40 µL of TdT labeling Reaction Mix to each sample, place
cover slip over the top and incubate at 37°C for 90 minutes.
 Remove coverslip and rinse with TBS for 5 minutes.
 Cover specimen with 100 µL Stop Buffer and incubate at room
temperate for 5 minutes.
 Rinse with TBS for 5 minutes.
 Add 100 µL Blocking Buffer to the specimen and incubate at room
temperature for 10 minutes.
 Carefully blot the Blocking Buffer from the specimen.
 Immediately apply 100 μL of 1X Conjugate to the specimen and
incubate for 30 minutes.
 Rinse with TBS for 5 minutes.
 Cover specimen with 100 µL DAB solution and incubate for 15
minutes.
 Rinse with dH2O.
 Cover specimen with 100 µL Methyl green for 3 minutes.
 Dehydrate slides by repeated immersion in 100% ethanol followed
by xylene before adding a glass coverslip.
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 Study 1 - The effect of corneal swelling on corneal collagen 
fibrillar diameter and interfibrillar distance 
1.1 Purpose: 
The corneal samples used in the present study were stored in culture media for less 
than 24 hours prior to crosslinking treatment, a process that led to significant swelling 
of the cornea. This prompted us to investigate the effects of corneal swelling on 
corneal CF diameter and the interfibrillar distance.  
1.2 Materials 
The study was conducted on 5 sets of porcine corneas obtained from the abattoir 
(“South Kill”, New Zealand). The post-mortem time until the retrieval of the corneas 
was less than 2 hours.  Once the corneas were removed, the thickness of the central 
cornea was measured using a Digital Vernier Calliper and transported in culture 
media and stored at 34 °C in an incubator until the crosslinking treatment, was 
performed within the next 24 hours. (Detailed description of corneal retrieval, 
preparation of media and other solutions is discussed  Chapter 4) 
1.3 Methods 
Prior to crosslinking treatment, the corneas were taken out of the culture media and 
examined with a dissection microscope to exclude any signs of corneal pathology such 
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as corneal scarring.  Only healthy corneas were used in this study. Two corneas were 
discarded due to signs of corneal scarring. 
Before starting the crosslinking process, central CCT was again measured using a 
Digital Vernier Calliper. One cornea from each pig was directly crosslinked after 
storing in culture media for 6 hours, while the other was transferred to culture media 
with 4% Dextran T-500 (de-swelling solution) and stored for 6 hours at 30°C in an 
incubator prior to crosslinking. In previous studies, the use of de-swelling agents to 
reduce the swelling of the cornea prior to corneal transplant has been described 
[Builles, 2006 #1501][Lisbeth, 1997 #1471]. Therefore, in this preliminary study, a de-
swelling agent was used to reduce the effects of swelling on the corneal stroma. 
Corneal buttons were bisected soon after CXL treatment, and one half was used for 
histology to visualise the general arrangement of collagen fibres. Half of the cornea 
used for histology was embedded in paraffin.  Six consecutive sections were prepared 
from each paraffin block, and out of these six sections three sections were stained in 
Haematoxylin-eosin (H&E), and remaining three were stained in Manson Trichrome 
(MT) (Appendix 3). The other half of the cornea was used to analyse the changes of 
diameter and nearest neighbouring distance (interfibrillar distance) using a 
transmission electron microscope (TEM) (CM100 BioTWIN Philips Transmission 
Electron Microscope) (preparation of corneal samples for TEM is described in detail 
in Appendix 4).  The effect of swelling on these parameters was compared between 
anterior, intermediate and posterior regions of the crosslinked corneas (the steps 
followed in analysing the TEM sections in each of these regions will be described later 
in Chapter 4). 
1.4 Statistical Analysis 
The corneas which underwent CXL treatment directly after taking from the culture 
media and the corneas stored in 4% Dextran prior to CXL treatment were compared 
using student t-test for each region of the corneal stroma (anterior, intermediate and 
posterior). P=0.05 was considered statistically significant. Statistical analysis was 
performed under the guidance of Dr Ari Samaranayaka (Senior research fellow, 
Centre for Biostatistics, University of Otago) using GraphPad Prism (Version 8.4.3, 
©1994- 2020 GraphPad Software, LLC). 
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1.5 Results 
A. Central corneal thickness (CCT)
There were statistically significant increases in the corneal thickness after storing the 
cornea in culture media prior to CXL treatment (P=0.007). Mean corneal thickness at 
the time of retrieval was 1.00mm (SD±0.05) while after less than 24 hours of storage in 
culture media, it was increased to 0.16mm (SD±0.16).  
B. Histology
 Distribution of collagen fibres within the corneal stroma was visualised clearly in 
samples stained in Manson Trichrome (MT) and Haematoxylin-eosin (H&E) staining. 
Collagen fibres were more closely packed in the anterior region while in the posterior 
region it gradually became loosely packed. The collagen fibre arrangement was 
similar in corneas stored in de-swelling solution and culture media. No observable 
pathological changes were seen with the standard light microscopy in all sections. No 
demarcation line was evident. No notable differences in the general arrangement of 
the collagen fibre and keratocytes distribution were evident between the corneas 
stored in only culture media and corneas stored in 4% Dextran prior to CXL treatment 
(Figure 4.1).  
c) Transmission electron microscopy
No statistically significant difference was observed in corneal CF diameter (anterior 
region p=0.378, intermediate region p=0.774, posterior region p=0.377) (Figure 4.2) 
and interfibrillar distance (anterior region p=0.243, intermediate region p=0.435, 
posterior region p=0.700) (Figure 4.3) between both groups (corneas kept in culture 
media  and corneas kept in de-swelling agents). 
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Figure 1.1 – Histology of corneas with and without de swelling agents 
A – Corneal stroma with direct CXL treatment (H&E staining) 
B – Corneal stroma of corneas that was stored in Dextran solution prior to CXL treatment (H&E staining) 
C – Corneal stroma with direct CXL treatment (MT staining) 
D – Corneal stroma  which was stored in Dextran solution prior to CXL treatment (MT staining) 
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Figure 1.2 – Effects of corneal swelling on collagen fibrillar diameter 
WITH DEXT _ Corneas stored in 4% Dextran for 6 hours prior to CXL treatment 
WO\DEXT – Corneas directly crosslinked after storing in culture medium 
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Figure 1.3- Effect of corneal swelling on corneal interfibrillar distance 
WITH DEXT _ Corneas stored in 4% Dextran for 6 hours prior to CXL treatment 
WO\DEXT – Corneas directly crosslinked after storing in culture medium 
1.6 Conclusion 
Corneal oedema/swelling due to storage in the culture media has a minimal effect on 
the corneal collagen diameter and on the interfibrillar distance following CXL 
treatment when compared to corneas stored in de-swelling solutions.  
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Study 2 - The hydration effects by the iso-osmolar riboflavin 
solution on collagen fibrillar diameter and interfibrillar 
distance  
2.1 Purpose 
 Hydration properties of the cornea can have an influence on the CF diameter and 
interfibrillar distance [Hayes, 2013 #471]. The conventional crosslinking treatment 
used in the present main study uses iso-osmolar riboflavin solution for the CXL 
treatment (detailed description of the CXL treatment was described in Chapter 4).   
In the main study described in Chapter 4, corneas undergo de-epithelialisation after 
removal from the culture media and are immediately taken into processing, while the 
treatment corneas, following de-epithelialisation are exposed to the photosensitiser, 
riboflavin 0.1% solution (10 mg riboflavin-5-phosphate in 10 ml dextran T-500 20% 
solution in PBS) for 30 minutes before exposing them to the UVA irradiation for 
another 30 minutes. Therefore, in our main study (Chapter 4), all the treated corneas 
have been exposed to riboflavin for 60 minutes more than the control corneas.    
Consequently, when comparing control samples with treated samples, we wanted to 
find out if there is a significant effect on the treated samples which have been exposed 
to riboflavin solution for 60 minutes more than the control samples. Therefore, the 
present preliminary study was performed to investigate the effects of iso-osmolar 
riboflavin solution on CF diameter and interfibrillar distance by comparing the 
corneas which have been exposed to riboflavin for 60 minutes and corneas which have 
been taken directly for processing following de-epithelialisation.   
2.2 Materials 
The study was conducted on 5 sets of porcine corneas obtained from the abattoir 
(“South Kill”, New Zealand). The post-mortem time until the retrieval of the corneas 
was less than 2 hours.  Once the corneas were removed, they were transported in 
culture media and stored at 34 °C in an incubator until the crosslinking treatment, 
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which was performed within the next 24 hours. (Detailed description of corneal 
retrieval, preparation of media and other solutions will be discussed in Chapter 4 ). 
2.3 Methods 
As soon as the corneas were taken out of the culture media,  they were examined with 
a dissection microscope to exclude any signs of corneal pathology such as corneal 
scarring.  Only healthy corneas were used in this study.  
Initially, both corneas (left and right) underwent de-epithelialisation and following 
de-epithelialisation one cornea (Sample 1) was directly taken for further processing 
for histology and TEM analysis, while the remaining corneal flap (Sample 2) was 
exposed to the photosensitiser, riboflavin 0.1% solution (10 mg riboflavin-5-phosphate 
in 10 ml dextran T-500 20% solution in PBS) for 60 minutes. During the initial 30 
minutes, riboflavin was instilled every 1 minute, and during the next 30 minutes 
riboflavin was instilled every 5 minutes (similar to the CXL treatment used in the main 
study) 
Both Sample 1 and Sample 2 corneal buttons were bisected, and one half was used for 
histology to visualise the general arrangement of collagen fibres. Half of the cornea 
used for histology was embedded in paraffin.  Six consecutive sections were prepared 
from each paraffin block and of these six sections, three sections were stained in H&E, 
and the remaining three were stained in MT. The other half of the cornea was used to 
analyse the changes of CF diameter and interfibrillar distance using TEM (the detailed 
process is described in Chapter 4). The effect of hydration on CF diameter and 
interfibrillar distance caused by riboflavin solution were compared in the anterior, 
intermediate and posterior regions of Sample 1 and Sample 2.  
2.4 Statistical Analysis 
The corneas with only epithelial debridement (Sample 1) and corneas exposed to 
riboflavin solution (Sample 2) were compared with student t-test to find out if there 
was a significant change in CF diameter and interfibrillar distance between different 
regions of the cornea ( anterior, intermediate and posterior regions). P=0.05 was 
considered significant. Statistical analysis was performed under the guidance of Dr 
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Ari Samaranayaka (Senior research fellow, Centre for Biostatistics, University of 
Otago) using GraphPad Prism (Version 8.4.3, ©1994- 2020 GraphPad Software, LLC). 
2.5 Results 
A. Histology
The distribution of collagen fibres within the corneal stroma was visualised clearly 
with samples stained in MT and H&E staining. The collagen fibre arrangement was 
similar in both sample 1 and sample 2 corneas.  No observable pathological changes 
were seen with the standard light microscopy in all sections. No notable difference in 
the general arrangement of the collagen fibres and keratocyte distribution was evident 
between corneas, only with epithelial debridement and corneas which had been 
exposed to riboflavin solution for 60 minutes (Figure 2.1). 
B. Transmission electron microscopy
No statistically significant difference was observed in  the corneal CF diameter 
(anterior region p=0.389, intermediate region p=0.778, posterior region p=0.584) 
(Figure 2.2) and interfibrillar distance (anterior region p=0.401, intermediate region 
p=0.323 , posterior region p=0.599)  (Figure 2.3) in both groups (corneas with only de-
epithelialisation and corneas with epithelial debridement with 60 minutes riboflavin 
exposure)  
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Figure 2.1– Light micrograph of a cornea with  only epithelial debridement and cornea exposed to riboflavin for 30 minutes 
A&B- Anterior region of the cornea with only epithelial debridement (A- H&E staining, B- MT staining) 
C&D – Anterior regions of the corneal stroma which has been exposed to riboflavin solution (A- H&E staining, B- MT staining) 
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Figure 2.2- The hydration effects of iso-osmolar riboflavin solution on collagen 
fibrillar diameter 
Sample 1 – Corneas with only epithelial debridement 
Sample 2– Corneas with epithelial debridement and 30 minutes exposure to 
riboflavin solution 
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Figure 2.3 - The hydration effects of  iso-osmolar riboflavin solution on 
interfibrillar distance 
Sample 1 – Corneas with only epithelial debridement 
Sample 2 – Corneas with epithelial debridement and 30 minutes exposure to 
riboflavin solution 
2.6 Conclusion 
The application of iso-osmolar riboflavin for 60 minutes had no statistically 
significant effect on the corneal CF diameter and interfibrillar distance of a cornea 
compared to corneas which were not exposed to riboflavin solution. Therefore, in 
our main study, (described in Chapter 4)  the control samples had epithelial 
debridement only before processing (without application of riboflavin). The 
treatment samples underwent epithelial debridement followed by 30 minutes 
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riboflavin application and finally another 30 minutes of application of riboflavin 
and exposure to UVA irradiation. 
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